WO2018071809A1 - Inducible t-cell system and uses thereof - Google Patents
Inducible t-cell system and uses thereof Download PDFInfo
- Publication number
- WO2018071809A1 WO2018071809A1 PCT/US2017/056576 US2017056576W WO2018071809A1 WO 2018071809 A1 WO2018071809 A1 WO 2018071809A1 US 2017056576 W US2017056576 W US 2017056576W WO 2018071809 A1 WO2018071809 A1 WO 2018071809A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- inducible
- antibody
- ligand
- checkpoint
- Prior art date
Links
- 230000001939 inductive effect Effects 0.000 title claims abstract description 206
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 564
- 108091008028 Immune checkpoint receptors Proteins 0.000 claims abstract description 268
- 102000037978 Immune checkpoint receptors Human genes 0.000 claims abstract description 268
- 210000004027 cell Anatomy 0.000 claims abstract description 236
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 178
- 239000003446 ligand Substances 0.000 claims abstract description 171
- -1 small molecule compounds Chemical class 0.000 claims abstract description 163
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 85
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 85
- 230000011664 signaling Effects 0.000 claims abstract description 41
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 33
- 230000003993 interaction Effects 0.000 claims abstract description 17
- 239000003596 drug target Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims description 199
- 239000008177 pharmaceutical agent Substances 0.000 claims description 172
- 230000014509 gene expression Effects 0.000 claims description 124
- 238000003197 gene knockdown Methods 0.000 claims description 109
- 108010002350 Interleukin-2 Proteins 0.000 claims description 99
- 102000000588 Interleukin-2 Human genes 0.000 claims description 99
- 238000003209 gene knockout Methods 0.000 claims description 98
- 230000000139 costimulatory effect Effects 0.000 claims description 96
- 238000013518 transcription Methods 0.000 claims description 88
- 230000035897 transcription Effects 0.000 claims description 88
- 239000000411 inducer Substances 0.000 claims description 83
- 150000002605 large molecules Chemical class 0.000 claims description 82
- 229920002521 macromolecule Polymers 0.000 claims description 82
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 71
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 65
- 230000006044 T cell activation Effects 0.000 claims description 55
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 49
- 229960003130 interferon gamma Drugs 0.000 claims description 46
- 229960003722 doxycycline Drugs 0.000 claims description 45
- 239000000090 biomarker Substances 0.000 claims description 43
- 239000011324 bead Substances 0.000 claims description 42
- 108010074328 Interferon-gamma Proteins 0.000 claims description 41
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 40
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 40
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 40
- 102000008070 Interferon-gamma Human genes 0.000 claims description 39
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 39
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 37
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 35
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 34
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 34
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 32
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 32
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108091033409 CRISPR Proteins 0.000 claims description 27
- 229960005386 ipilimumab Drugs 0.000 claims description 27
- 229960003301 nivolumab Drugs 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 23
- 108091008034 costimulatory receptors Proteins 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 19
- 230000001404 mediated effect Effects 0.000 claims description 17
- 150000003384 small molecules Chemical class 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 14
- 238000010354 CRISPR gene editing Methods 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 210000005260 human cell Anatomy 0.000 claims description 13
- 229960002621 pembrolizumab Drugs 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- 238000002965 ELISA Methods 0.000 claims description 12
- 102000043131 MHC class II family Human genes 0.000 claims description 10
- 108091054438 MHC class II family Proteins 0.000 claims description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 9
- 230000001064 anti-interferon Effects 0.000 claims description 9
- 229940043355 kinase inhibitor Drugs 0.000 claims description 9
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 9
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 8
- 102100034980 ICOS ligand Human genes 0.000 claims description 8
- 230000009437 off-target effect Effects 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 7
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 7
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 7
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- 102000020233 phosphotransferase Human genes 0.000 claims description 7
- 239000003104 tissue culture media Substances 0.000 claims description 7
- 229950007217 tremelimumab Drugs 0.000 claims description 7
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 6
- 229940126530 T cell activator Drugs 0.000 claims description 6
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 6
- 229950010773 pidilizumab Drugs 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 102100035990 Adenosine receptor A2a Human genes 0.000 claims description 5
- 102100031351 Galectin-9 Human genes 0.000 claims description 5
- 101710121810 Galectin-9 Proteins 0.000 claims description 5
- 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 claims description 5
- 101710093458 ICOS ligand Proteins 0.000 claims description 5
- 102000004551 Interleukin-10 Receptors Human genes 0.000 claims description 5
- 108010017550 Interleukin-10 Receptors Proteins 0.000 claims description 5
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 229960003852 atezolizumab Drugs 0.000 claims description 5
- 229950002916 avelumab Drugs 0.000 claims description 5
- 229950009791 durvalumab Drugs 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 101150030213 Lag3 gene Proteins 0.000 claims description 4
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 4
- 108010048507 poliovirus receptor Proteins 0.000 claims description 4
- 102100024263 CD160 antigen Human genes 0.000 claims description 3
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 claims description 3
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 3
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 claims description 3
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 2
- 238000012360 testing method Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 3
- 238000010200 validation analysis Methods 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 43
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 43
- 239000002773 nucleotide Substances 0.000 description 38
- 125000003729 nucleotide group Chemical group 0.000 description 38
- 238000002474 experimental method Methods 0.000 description 23
- 229940125904 compound 1 Drugs 0.000 description 17
- 229940125782 compound 2 Drugs 0.000 description 17
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 16
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 16
- 230000027455 binding Effects 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 13
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 13
- 102000013691 Interleukin-17 Human genes 0.000 description 13
- 108050003558 Interleukin-17 Proteins 0.000 description 13
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 13
- 230000000996 additive effect Effects 0.000 description 13
- 102100032937 CD40 ligand Human genes 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 9
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 8
- 102000003816 Interleukin-13 Human genes 0.000 description 8
- 108090000176 Interleukin-13 Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 108010029697 CD40 Ligand Proteins 0.000 description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
- 108010065805 Interleukin-12 Proteins 0.000 description 7
- 102000013462 Interleukin-12 Human genes 0.000 description 7
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012239 gene modification Methods 0.000 description 7
- 230000005017 genetic modification Effects 0.000 description 7
- 235000013617 genetically modified food Nutrition 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 6
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 6
- 102100027207 CD27 antigen Human genes 0.000 description 6
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 6
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 6
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 108010065637 Interleukin-23 Proteins 0.000 description 6
- 102000013264 Interleukin-23 Human genes 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 6
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 229940117681 interleukin-12 Drugs 0.000 description 6
- 229940124829 interleukin-23 Drugs 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 108091006024 signal transducing proteins Proteins 0.000 description 6
- 102000034285 signal transducing proteins Human genes 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 5
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 5
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 102100039897 Interleukin-5 Human genes 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 5
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 102000050862 Transmembrane Activator and CAML Interactor Human genes 0.000 description 5
- 101710178302 Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000005746 immune checkpoint blockade Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 229940100602 interleukin-5 Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000003990 molecular pathway Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 102100023688 Eotaxin Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 4
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 4
- 102100022339 Integrin alpha-L Human genes 0.000 description 4
- 108010002335 Interleukin-9 Proteins 0.000 description 4
- 102000000585 Interleukin-9 Human genes 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 4
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 4
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 4
- 102000008108 Osteoprotegerin Human genes 0.000 description 4
- 108010035042 Osteoprotegerin Proteins 0.000 description 4
- 102100023472 P-selectin Human genes 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 4
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 102000004114 interleukin 20 Human genes 0.000 description 4
- 108090000681 interleukin 20 Proteins 0.000 description 4
- 229940118526 interleukin-9 Drugs 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 description 4
- RYSMHWILUNYBFW-GRIPGOBMSA-N 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](N)[C@H]1O RYSMHWILUNYBFW-GRIPGOBMSA-N 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 3
- 108010065524 CD52 Antigen Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100021592 Interleukin-7 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102100026236 Interleukin-8 Human genes 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 108010034396 Streptogramins Proteins 0.000 description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
- 229940126575 aminoglycoside Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229960003008 blinatumomab Drugs 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000004073 interleukin-2 production Effects 0.000 description 3
- 229940100994 interleukin-7 Drugs 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229940056360 penicillin g Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 2
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100031168 CCN family member 2 Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 108010055204 Chemokine CCL8 Proteins 0.000 description 2
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 2
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 101710205775 Inducible T-cell costimulator Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 108060004872 MIF Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 2
- 101710103494 Platelet-derived growth factor subunit B Chemical class 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229940101815 blincyto Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 229950001237 lilotomab Drugs 0.000 description 2
- 229950011263 lirilumab Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229940126611 FBTA05 Drugs 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 102100025594 Guided entry of tail-anchored proteins factor CAMLG Human genes 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000775498 Homo sapiens Adenylate cyclase type 10 Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000932902 Homo sapiens Guided entry of tail-anchored proteins factor CAMLG Proteins 0.000 description 1
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001057159 Homo sapiens Melanoma-associated antigen C3 Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 1
- 108010023610 IL13-PE38 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 102100039898 Interleukin-18 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229940123917 Lipid kinase inhibitor Drugs 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 102000034655 MIF Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 101100058191 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) bcp-1 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229950001146 adargileukin alfa Drugs 0.000 description 1
- 229950008714 afasevikumab Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229950005794 anrukinzumab Drugs 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- 229950002882 aselizumab Drugs 0.000 description 1
- 229950006637 atexakin alfa Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229950003269 bectumomab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229950002853 bimekizumab Drugs 0.000 description 1
- 229960000810 binetrakin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229950002903 bivatuzumab Drugs 0.000 description 1
- 229950000009 bleselumab Drugs 0.000 description 1
- 229950007686 blontuvetmab Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229950009342 brazikumab Drugs 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229950000771 carlumab Drugs 0.000 description 1
- 229950006754 cedelizumab Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 229950001357 celmoleukin Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229950010810 cintredekin besudotox Drugs 0.000 description 1
- 229950002334 clenoliximab Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229950001607 daniplestim Drugs 0.000 description 1
- 108010017136 daniplestim Proteins 0.000 description 1
- 229950005026 dapirolizumab pegol Drugs 0.000 description 1
- 108010048522 dapirolizumab pegol Proteins 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229950008135 dectrekumab Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 229960005350 edodekin alfa Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229950002507 elsilimomab Drugs 0.000 description 1
- 229950008963 emoctakin Drugs 0.000 description 1
- 229950007313 enokizumab Drugs 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229950010512 fezakinumab Drugs 0.000 description 1
- 229950010043 fletikumab Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 229950004356 foralumab Drugs 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229950003717 gevokizumab Drugs 0.000 description 1
- 229940126613 gomiliximab Drugs 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 102000049849 human CD86 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229950010245 ibalizumab Drugs 0.000 description 1
- 229950005013 iboctadekin Drugs 0.000 description 1
- 229950001392 ilodecakin Drugs 0.000 description 1
- 229950003680 imalumab Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229950005015 inebilizumab Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229950007937 inolimomab Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229950000038 interferon alfa Drugs 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 229950003818 itolizumab Drugs 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 229950010828 keliximab Drugs 0.000 description 1
- 229950002183 lebrikizumab Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229950007439 lenzilumab Drugs 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229950008140 lulizumab pegol Drugs 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229950008083 maslimomab Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229950005555 metelimumab Drugs 0.000 description 1
- 229950008119 mobenakin Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229950011628 muplestim Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229950007708 namilumab Drugs 0.000 description 1
- 229950002138 naratuximab Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229950010465 odulimomab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950010006 olokizumab Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 229950000121 otlertuzumab Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229950003709 oxelumab Drugs 0.000 description 1
- 229950003481 pamrevlumab Drugs 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 229950009674 pegaldesleukin Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229950005079 perakizumab Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229950002247 pifonakin Drugs 0.000 description 1
- 229940126621 pogalizumab Drugs 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940126623 prezalizumab Drugs 0.000 description 1
- 229950003700 priliximab Drugs 0.000 description 1
- 229940040939 repurposed drug Drugs 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950010316 rontalizumab Drugs 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229950010077 sifalimumab Drugs 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 229950006094 sirukumab Drugs 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229950010265 tabalumab Drugs 0.000 description 1
- 229950009696 tamtuvetmab Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229950001699 teceleukin Drugs 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- 229950000301 teneliximab Drugs 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229950008998 tezepelumab Drugs 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229950005515 tildrakizumab Drugs 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229950010086 tregalizumab Drugs 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 229950010095 ulocuplumab Drugs 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229950006959 vorsetuzumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1107—B cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- an inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors.
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor.
- the inducible T-cell system may comprise a ligand-presenting cell (e.g. , a B-cell) engineered to constitutively express one or more checkpoint receptor ligands.
- the ligand-presenting cell may express a costimulatory ligand.
- the inducible T-cell system may comprise an anti-CD3 antibody, e.g. , to stimulate TCR signaling.
- the T-cell may be a Jurkat cell.
- the ligand-presenting cell may be a B-cell or an antigen-presenting cell.
- the ligand-presenting cell may be a Raji cell.
- the T-cell and/or B- cell may be derived from a human cell line.
- the ligand-presenting cell may be derived from a human or non-human cell, and the one or more checkpoint receptor ligands may be human checkpoint receptor ligands.
- the ligand-presenting cell may be derived from a human or non-human cell, and the
- costimulatory ligand may be a human costimulatory ligand.
- the two or more checkpoint receptors may comprise PD-1 and CTLA-4.
- the one or more checkpoint receptor ligands may comprise PD-L1 and/or PD-L2.
- the two or more checkpoint receptors may comprise PD-1, CTLA-4, PD-1H, LAG- 3, BTLA, KIR2D, TIM-3, ADORA2A, CD 160, 2B4, TIGIT, and/or interleukin-10 receptor.
- the one or more checkpoint receptor ligands may comprise PD-L1, PD-L2, B7.1, B7.2, B7-H4, B7-H2, B7- H7, MHC class II, HVEM, CD155, galectin-9, and/or TIM-3 ligand.
- the costimulatory receptor may be CD28.
- the costimulatory ligand expressed by the ligand-presenting cell may be B7.1 or B7.2.
- the expression of the two or more checkpoint receptors may be controlled by a promoter inducible by doxycycline (dox).
- dox doxycycline
- the anti-CD3 antibody may be associated with a bead.
- the inducible T-cell system may further comprise reagents to determine the expression of interleukin-2 or interferon ⁇ by the T-cell.
- the reagents may be selected from a primary antibody, an anti-interleukin-2 antibody, an anti-interferon ⁇ antibody, a secondary antibody, an anti-IgG antibody, an antibody-fluorophore conjugate, an antibody-biotin conjugate, an antibody-enzyme conjugate, a colorimetric substrate for horseradish peroxidase, and a colorimetric substrate for alkaline phosphatase.
- the T-cell may further comprise a gene knockout or knockdown.
- the gene knockout or knockdown may be a lymphoid lineage gene knockout or knockdown.
- a lymphoid lineage gene may be a T-cell gene.
- a knockout may be a CRISPR/Cas9-mediated knockout.
- the inducible T-cell system may further comprise one or more pharmaceutical agents.
- the one or more pharmaceutical agents may comprise a small molecule compound and/or a large molecule (e.g. , an antibody).
- the invention relates to a method of identifying small molecule T-cell activators.
- the method may comprise providing an inducible T-cell system comprising a T- cell engineered to inducibly express two or more checkpoint receptors.
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor.
- the method may comprise providing a B-cell engineered to constitutively express one or more checkpoint receptor ligands.
- the B-cell may express a costimulatory ligand to provide a costimulatory signal.
- the method may comprise providing an anti-CD3 antibody to stimulate TCR signaling.
- the TCR signaling may be measurable by IL-2 expression of the T-cell (or interferon ⁇ expression).
- the method may comprise inducing the expression of the two or more checkpoint receptors in the T-cell.
- the method may comprise contacting the T-cell of the inducible T- cell system with one or more candidate compounds.
- the method may comprise determining the level of IL-2 expression (or interferon ⁇ expression) of the T-cell as compared to a control level of IL-2 expression (or interferon ⁇ expression) of a non-induced control T-cell, thereby identifying if the one or more candidate compounds are T-cell activators.
- the invention relates to a method of assessing interactions between T-cell activators and checkpoint inhibitory antibodies.
- the method may comprise providing an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors.
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor.
- the method may comprise providing a B-cell engineered to constitutively express one or more checkpoint receptor ligands.
- the B-cell may express a costimulatory ligand to provide a costimulatory signal.
- the method may comprise providing an anti-CD3 antibody to stimulate TCR signaling.
- the TCR signaling may be measurable by IL-2 expression of the T-cell (or interferon ⁇ expression).
- the method may comprise inducing the expression of the two or more checkpoint receptors in the T-cell.
- the method may further comprise contacting the T-cell of the inducible T-cell system with one or more candidate compounds.
- the method may further comprise contacting the T-cell of the inducible T-cell system with one, two, or more checkpoint inhibitory antibodies.
- the method may further comprise determining the level of IL-2 expression (or interferon ⁇ expression) of the T-cell as compared to the level of IL-2 expression (or interferon ⁇ expression) of an otherwise identical inducible T-cell system but contacted with only one or more candidate compounds, thereby assessing the interaction between one or more candidate compounds and the one, two, or more checkpoint inhibitory antibodies.
- the one, two, or more checkpoint inhibitory antibodies may comprise an FDA approved checkpoint inhibitory drug.
- the FDA approved checkpoint inhibitory drug may be a monoclonal antibody.
- the one or more candidate compounds may comprise a small molecule compound.
- the invention relates to a method of validating a T-cell target gene.
- the method may comprise providing an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors.
- the T-cell may further comprise a candidate T-cell gene knockout.
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor.
- the method may comprise providing a B-cell engineered to constitutively express one or more checkpoint receptor ligands.
- the B-cell may express a costimulatory ligand to provide a costimulatory signal.
- the method may comprise providing an anti-CD3 antibody to stimulate TCR signaling.
- the TCR signaling may be measurable by IL-2 expression of the T-cell (or interferon ⁇ expression).
- the method may comprise inducing the expression of the two or more checkpoint receptors in the T-cell.
- the method may comprise determining the level of IL-2 expression (or interferon ⁇ expression) of the T-cell as compared to a control level of IL-2 expression (or interferon ⁇ expression) of a non-induced control T-cell, thereby determining if the candidate T-cell gene is a T-cell checkpoint-independent target gene.
- the invention relates to a method of interrogating ON or OFF target activity of a small molecule compound.
- the method may comprise providing an inducible T- cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors.
- the T-cell may further comprise a candidate T-cell gene knockout.
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor.
- the method may comprise providing a B-cell engineered to constitutively express one or more checkpoint receptor ligands.
- the B-cell may express a costimulatory ligand to provide a costimulatory signal.
- the method may comprise providing an anti-CD3 antibody to stimulate TCR signaling.
- the TCR signaling may be measurable by IL-2 expression of the T-cell (or interferon ⁇ expression).
- the method may comprise inducing the expression of the two or more checkpoint receptors in the T-cell.
- the method may comprise contacting the T-cell of the inducible T- cell system with a small molecule compound.
- the method may comprise determining the level of IL-2 expression (or interferon ⁇ expression) of the T-cell with the T-cell target gene knockout as compared to a control level of IL-2 expression (or interferon ⁇ expression) of a control wild-type T-cell under otherwise identical conditions, thereby interrogating ON vs. OFF target activity of the small molecule compound.
- the T-cell may be a Jurkat cell line
- the B-cell may be a Raji cell line
- the T-cell and/or the B-cell may be derived from a human cell line.
- the two or more checkpoint receptors may comprise PD-1 and CTLA-4.
- the one or more checkpoint receptor ligands may comprise PD-L1 and/or PD-L2.
- the expression of the two or more checkpoint receptors may be controlled by a promoter inducible by doxycycline (dox).
- the inducing step may comprise introducing the dox to the T-cell.
- the costimulatory receptor may be CD28.
- the costimulatory ligand expressed by the B-cell may be B7.1 or B7.2.
- the anti-CD3 antibody may be associated with a bead.
- the invention relates to a plurality of inducible T-cell systems.
- Each system may comprise a T-cell (e.g. , a Jurkat cell) engineered to inducibly express two or more checkpoint receptors (e.g. , PD-1 and CTLA-4).
- Each system may comprise a ligand- presenting cell (e.g. , a B cell such as a Raji cell) that expresses at least one checkpoint receptor ligand (e.g. , PD-L1 , PD-L2, B7.1, and/or B7.2).
- Each system may comprise a costimulatory ligand (e.g. , an anti-CD3 antibody associated with a solid support).
- At least one system of a plurality of systems may comprise a transcription inducer (e.g. , doxycycline) that induces the transcription of the two or more checkpoint inhibitors. At least one system of a plurality of systems may lack the transcription inducer.
- a transcription inducer e.g. , doxycycline
- At least one system of a plurality of systems may comprise a pharmaceutical agent
- At least one system of a plurality of systems may lack the pharmaceutical agent.
- the T-cell of at least one system of the plurality may comprise a gene knockout or gene knockdown (e.g. , a random knockout or a knockout/knockdown of a T-cell signaling protein).
- the T-cell of at least one system of the plurality may lack the gene knockout or gene knockdown.
- the plurality of systems may comprise a system that comprises a transcription inducer, comprises a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown.
- the plurality of systems may comprise a system that lacks a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown.
- the plurality of systems may comprise a system that comprises a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown.
- the plurality of systems may comprise a system that lacks a transcription inducer, comprises a pharmaceutical agent, and lacks a T- cell comprising a gene knockout or gene knockdown.
- the plurality of systems may comprise a system that lacks a transcription inducer, lacks a pharmaceutical agent, and comprises a T- cell comprising a gene knockout or gene knockdown.
- the plurality of systems may comprise a system that comprises a transcription inducer, comprises a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown.
- the plurality of systems may comprise a system that comprises a transcription inducer, lacks a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown.
- the plurality of systems may comprise a system that lacks a transcription inducer, comprises a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown.
- the plurality of systems may comprise a system that comprises one small molecule compound and at least two large molecules.
- the plurality of systems may comprise a system that lacks a small molecule compound and lacks a large molecule.
- the plurality of systems may comprise a system that comprises one small molecule compound and lacks a large molecule.
- the plurality of systems may comprise a system that comprises both one small molecule compound and one large molecule.
- the plurality of systems may comprise a system that comprises at least two small molecule compounds and lacks a large molecule.
- the plurality of systems may comprise a system that comprises at least two small molecule compounds and one large molecule.
- the plurality of systems may comprise a system that lacks a small molecule compound and comprises at least two large molecules.
- the at least one large molecule may comprise an antibody such as an anti-CTLA-4 antibody and/or an anti-PD- 1 antibody.
- the at least one large molecule may comprise avelumab, atezolizumab, durvalumab, ipilimumab, lambrolizumab, nivolumab,
- the at least one large molecule may comprise
- ipilimumab ipilimumab and/or nivolumab.
- the invention relates to a multi-well plate comprising a plurality of inducible T-cell systems as described herein.
- the multi-well plate may be a 6 well, 12 well, 24 well, 96 well, 384 well, 1536 well, or 3,456 well plate.
- the invention relates to a method of preparing the multi-well plate, comprising adding a T-cell to each well of a plurality of wells of the multi-well plate.
- the T- cell may be engineered to inducibly express the two or more checkpoint receptors.
- the method may comprise adding a transcription inducer to a first group of wells of the plurality of wells.
- the method may comprise adding a costimulatory ligand to the plurality of wells.
- the method may comprise adding a ligand-presenting cell to the plurality of wells, wherein the ligand-presenting cell expresses a checkpoint receptor ligand.
- Adding a T-cell to each well of a plurality of wells may comprise adding a knockout or knockdown T-cell to a first group of wells of a plurality of wells and adding a wild type T- cell to a second group of wells of the plurality of wells.
- the knockout or knockdown T-cell may be engineered to inducibly express two or more checkpoint receptors, and the knockout or knockdown T-cell may comprise a gene knockout or knockdown.
- the wild type T-cell may be engineered to inducibly express the two or more checkpoint receptors, and the wild type T-cell may lack the gene knockout or knockdown.
- the plurality of wells may consist of the first group of wells and the second group of wells.
- no well of the plurality of wells is included in both the first group of wells and the second group of wells.
- the group of wells to which the transcription inducer is added may include both wells of the first group of wells and wells of the second group of wells.
- the costimulatory ligand may be added to the plurality of wells at least 24 hours after adding the transcription inducer to a group of wells.
- the method may further comprise washing the cells of each well of the plurality prior to adding the costimulatory ligand, e.g., to reduce the concentration of the transcription inducer in each well.
- the ligand-presenting cell may be added to the plurality of wells at least 5 minutes after adding the costimulatory ligand to the plurality of wells.
- the method may further comprise adding a first antibody to each well of a fourth group of wells of the plurality of wells.
- the method may further comprise adding a second antibody to each well of a fifth group of wells of the plurality of wells, wherein the fifth group of wells includes at least one well of the fourth group of wells.
- the first antibody and second antibody may be selected from antibodies that bind checkpoint receptors and antibodies that bind checkpoint receptor ligands such as anti-CTLA-4 antibodies and anti- PD-1 antibodies.
- the method may further comprise adding a first small molecule compound to each well of a sixth group of wells of the plurality of wells.
- the first small molecule compound may be, for example, a kinase inhibitor.
- the method may further comprise adding a second small molecule compound to each well of a seventh group of wells of the plurality of wells, wherein the seventh group of wells includes at least one well of the sixth group of wells.
- the invention relates to a method of discovering or validating a drug target.
- the method may comprise providing a plurality of inducible T-cell systems as described herein.
- the method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising a T-cell having a knockout or knockdown of a gene encoding the drug target.
- the invention relates to a method of determining whether a small molecule compound affects T-cell activation.
- the method may comprise providing a plurality of inducible T-cell systems as described herein.
- the method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include both a system comprising the small molecule compound and a system lacking the small molecule compound.
- the invention relates to a method of assessing an interaction between a small molecule compound and an antibody that binds a checkpoint receptor.
- the method may comprise providing a plurality of inducible T-cell systems as described herein.
- the method may further comprise measuring the concentration of a biomarker associated with T- cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the small molecule compound and the antibody.
- the invention relates to a method of assessing an interaction between a first small molecule compound and a second small molecule compound.
- the method may comprise providing a plurality of inducible T-cell systems as described herein.
- the method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the first small molecule compound and the second small molecule compound.
- the invention relates to a method of assessing whether a protein (e.g. , a signaling protein such as a kinase or phosphatase) affects T-cell activation through a signaling pathway mediated by a checkpoint receptor.
- the method may comprise providing a plurality of inducible T-cell systems as described herein.
- the method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both an antibody that specifically binds the checkpoint receptor and a T-cell comprising a knockout or knockdown of a gene encoding the protein.
- the invention relates to a method of assessing whether a
- the method may comprise providing a plurality of inducible T-cell systems as described herein.
- the method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the pharmaceutical agent and a T-cell comprising a knockout or knockdown of a gene encoding the target.
- the pharmaceutical agent may be a small molecule compound or a large molecule (e.g. , antibody).
- Various embodiments of the foregoing methods may further comprise comparing the relative concentration of the biomarker in at least one system of the plurality of systems to the relative concentration of the biomarker in at least one other system of the plurality of systems.
- FIG. 1 depicts an exemplary embodiment of an inducible T-cell system.
- the drawing depicts a T-cell that inducibly expresses checkpoint receptors PD-1 and CTLA-4.
- the T-cell also expresses CD28 and the T-cell receptor (TCR).
- the drawing depicts a B-cell that expresses either PD-Ll, PD-L2, or both and either B7.1, B7.2, or both.
- the drawing also depicts beads coated with anti-CD3 antibodies.
- Figures 2A-2B depict exemplary embodiments of an inducible T-cell system, similar to the embodiment depicted in Figure 1.
- Figure 2A shows two states of the inducible T-cell system. In a first state (2A, left), the transcription inducer doxycycline (dox) is not present, and thus, the T-cell does not express the PD-1 or CTLA-4 constructs.
- the T-cell may receive costimulatory signals from B7.1 or B7.2, which interact with CD28, and anti-CD3 antibodies, which interact with the T-cell receptor.
- the costimulatory signals result in interleukin-2 (IL2) production by the T-cell.
- IL2 interleukin-2
- the transcription inducer doxycycline (dox) is added, and thus, the T-cell may express PD-1 and CTLA-4.
- the T-cell may receive costimulatory signals from B7.1 or B7.2 and the anti-CD3 antibodies.
- the T- cell may also receive inhibitory signals from PD-Ll or PD-L2, which interact with PD-1, and B7.1 or B7.2, which interact with CTLA-4.
- the inhibitory signals result in decreased interleukin-2 (IL2) production by the T-cell relative to the first state (2B).
- IL2 interleukin-2
- Figures 3A-3B depict exemplary embodiments of an inducible T-cell system that demonstrate how the system may be utilized to analyze combinations of therapeutic antibodies targeting immune checkpoint receptors.
- Experiments "1" and “2" of Figures 3A and 3B are identical to Figures 2A and 2B.
- Experiment "3” depicts the addition of the anti- PD-1 antibody nivolumab (Nivo; N) to the system in addition to doxycycline.
- Experiment "4" depicts the addition of the anti-CTLA-4 antibody ipilimumab (Ipi; I) to the system in addition to doxycycline.
- Experiment "5" depicts the addition of nivolumab, ipilimumab, and doxycycline to the system.
- Nivolumab and ipilimumab both increased interleukin-2 (IL2) production relative to an IgG control, and the combination of nivolumab and ipilimumab displayed an additive effect (3B).
- Figures 4A-4B depict exemplary embodiments of an inducible T-cell system that demonstrate how the system may be utilized to probe molecular pathways and identify drug targets related to checkpoint receptors.
- the figures depict a T-cell system that is similar to Figures 1 and 2A-2B except that the T-cell of the system comprises a knockout of a gene encoding an intracellular protein.
- the gene knockout resulted in elevated interleukin-2 (IL2) production in the presence of doxycycline thereby suggesting that the gene product inhibits T-cell activation.
- the protein product of the knockout gene may therefore be a viable drug target, e.g. , small molecule inhibitors of the protein product may increase T-cell activation.
- Figures 5A-5B depict exemplary embodiments of an inducible T-cell system that demonstrate how the system may be utilized to analyze combination therapies that affect immune checkpoint receptors and the molecular pathways that the therapies might act upon.
- Experiments "1," “2,” and “3” are described above (e.g. , in Figures 3A-3B).
- Experiment "4" is described in Figures 4A-4B.
- Experiment "5" shows that a knockout may be used in combination with a drug or drug cocktail, for example, to assess whether the drug or drug cocktail acts on a molecular pathway associated with the knockout gene.
- nivolumab (Nivo; N) and ipilimumab (Ipi; I) increase the activation of knockout T-cells, which suggests that a drug that inhibits the product of the knockout gene will display an additive effect when used in combination with nivolumab and/or ipilimumab.
- Experiments “6” and “7” show that the inducible T-cell system may be used to probe the effect of small molecule therapeutics either alone (Experiment “6") or in combination with other therapies (Experiment “7”).
- Experiment “6” shows that the small molecule compounds “compound 1" and “compound 2” activate T-cells despite checkpoint receptor-mediated T-cell inhibition (5B).
- Experiment "7” shows that the combination of nivolumab (Nivo; N), ipilimumab (Ipi; I), and either small molecule compound 1 or compound 2 displays a synergistic effect (5B).
- Figures 6A-6C depict exemplary embodiments of an inducible T-cell system that demonstrate how the system may be utilized to analyze whether a small molecule compound affects T-cell signaling through a target protein.
- Figure 6A is identical to experiment "6" of Figure 5A, and it depicts an inducible T-cell system that is contacted with a small molecule compound.
- Figure 6B is similar to Figure 6A except that the T-cell of figure 6B comprises a gene knockout.
- FIG. 6C depicts experiments with T-cells comprising or lacking a gene knockout that were incubated with Raji cells, anti-CD3 beads, doxycycline, and either small molecule "compound 1" or small molecule “compound 2.”
- Control experiments were performed with either compound 1, compound 2, or vehicle (DMSO) and T-cells that did not include the knockout.
- the dashed line indicates the level of T-cell activation in DMSO control samples either comprising (KO) or lacking (WT) the gene knockout (set at 100%).
- Both compound 1 and compound 2 increased T-cell activation relative to the vehicle control in T-cells that did not include the knockout.
- Neither compound 1 nor compound 2 increased T-cell activation relative to the vehicle control in T-cells that included the knockout.
- the present invention relates to a system comprising a T-cell engineered to inducibly express two or more checkpoint receptors, a B-cell engineered to constitutively express one or more checkpoint receptor ligands, and an anti-CD3 antibody (e.g. , anti-CD3 coated beads).
- This system allows for the analysis of pharmaceutical agents that target checkpoint receptors to determine whether the agents display an additive or synergistic effect.
- the system also allows for the analysis of molecular pathways related to checkpoint inhibition, e.g. , by selectively knocking out T-cell genes. Knockouts may provide insights into whether pharmaceutical agents that target checkpoint receptors target the same or different molecular pathways.
- Knockouts may also provide insights into whether a pharmaceutical agent displays an ON target or OFF target effect, e.g. , wherein the gene encoding the target is knocked out of a T-cell. Knockouts may also identify proteins that may be suitable drug targets that modulate T-cell activation.
- the inducible T-cell system provides a useful control because baseline readouts (e.g. interleukin-2 expression) may be obtained for the system by simply performing an experiment in the absence of conditions that allow for expression of the checkpoint receptors.
- the expression of two or more checkpoint receptors allows for the analysis of additive or synergistic effects among combinations of pharmaceutical agents that target different checkpoint receptor pathways.
- the T-cell may be a mammalian T-cell, such as a human T-cell.
- the T-cell may be immortalized.
- the T-cell may be immortalized because the T-cell has been transformed with an Epstein-Barr virus.
- the T-cell may be derived from a T-cell leukemia or lymphoma.
- the T-cell may be derived from a cell line, such as a human cell line.
- the T-cell may be a Jurkat, HuT-78, CEM, Molt- 4, DND-41, T-ALL1, or HPB-ALL cell.
- the T-cell may be a ARR, CCRF-CEM, CML-T1, DEL, DND-41, DU.528, H-SB2, HUT 102, JB6, Karpas 299, Karpas 45, KE-37/SKW-3, K- Tl, Loucy, MOLT 13, MOLT 16/17, MOLT 3/4, MT-1, P12-Ichikawa, Peer/Bel3, PF-382, RPMI 8402, SU-DHL-1, SUP-T1, SUP-T3, or TALL-104 cell.
- the T-cell may be derived from a Jurkat cell line.
- the T-cell may be a Jurkat cell.
- the T-cell may express one or more of CD3, TCRa, TCR , TCRy, TCR5, CD4, CD8, CD28, CTLA-4, CD40L, CD2, and LFA-1.
- the T-cell may be a suspension cell or an adherent cell.
- T-cells express the T-cell receptor (TCR).
- TCR may transduce a costimulatory signal upon binding to an antigen presented by a B-cell or an antigen presenting cell (APC).
- a TCR may transduce a costimulatory signal upon binding an anti-CD3 antibody.
- An anti-CD3 antibody may be associated with a bead, multi-well plate, or tissue culture plate, or an anti-CD3 antibody may be crosslinked as an oligomer, such as a tetramer.
- An anti-CD3 antibody may be a bi-specific antibody, such as a bi-specific T-cell engager (BiTE®).
- An example of an anti-CD3 bi-specific antibody that may bind CD3 and thereby transduce a costimulatory signal is blinatumomab (BLINCYTO®), which is bi-specific for CD3 and CD19 (present on B-cells).
- a T-cell may express a costimulatory receptor such as CD28.
- CD28 is a cell surface receptor protein capable of transducing a costimulatory signal that enables T-cell activation and survival.
- CD28 may transduce an intracellular signal upon binding B7.1 (CD80) or B7.2 (CD86), which may be present on a B-cell.
- CD28 may transduce a costimulatory signal upon binding an anti-CD28 antibody.
- An anti-CD28 antibody may be associated with a bead, multi-well plate, or tissue culture plate, or an anti-CD28 antibody may be crosslinked as an oligomer, such as a tetramer.
- a T-cell may express 4-1BB (CD137), CD27, OX40 (CD134; TNFRSF4), B-cell activating factor receptor (BAFFR), transmembrane activator and CAML interactor (TACI), B-cell Maturation Antigen (BMCA), CD40 ligand (CD40L; CD154), CD28, inducible T-cell costimulator (ICOS; CD278), and/or glucocorticoid-induced TNFR-related protein (GITR; AITR; TNFRSF18).
- 4- IBB, CD27, OX40, BAFFR, CAML, BMCA, CD40L, or GITR may transduce a costimulatory signal that enables T-cell activation and survival independent of CD28.
- a T-cell may be engineered to express two or more checkpoint receptors.
- a T-cell may comprise a recombinant gene encoding a checkpoint receptor.
- a T-cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene encodes a different checkpoint receptor.
- Each checkpoint receptor may be selected from cytotoxic T- lymphocyte antigen 4 (CTLA-4; CD152), programmed cell death 1 (PD-1; CD279), programmed death- 1 homolog (PD-1H), lymphocyte-activation gene 3 (LAG-3; CD223), B- and T-lymphocyte attenuator (BTLA; CD272), a killer-cell immunoglobulin-like receptor (KIR), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), adenosine A2a receptor (A2aR; ADORA2A), CD 160, 2B4 (CD244), T cell immunoreceptor with Ig and ITIM domains (TIGIT), and interleukin-10 receptor.
- the two or more checkpoint receptors may be inhibitory checkpoint receptors. Nevertheless, a checkpoint receptor may be selected from stimulatory checkpoint receptors, such as 4-1BB (CD137), CD27, OX40 (CD134;
- TNFRSF4 B-cell activating factor receptor (BAFFR), transmembrane activator and CAML interactor (TACI), B-cell Maturation Antigen (BMCA), CD40 ligand (CD40L; CD154), CD28, inducible T-cell costimulator (ICOS; CD278), and glucocorticoid-induced TNFR- related protein (GITR; AITR; TNFRSF18).
- a T-cell may be engineered to express two or more checkpoint receptors wherein the two or more checkpoint receptors comprise PD- 1 and CTLA-4.
- a checkpoint receptor may be a human checkpoint receptor, e.g., the checkpoint receptor may have a human amino acid sequence.
- a checkpoint receptor may be encoded by a human nucleotide sequence. Nevertheless, the amino acid sequence of a checkpoint receptor or the nucleotide sequence encoding the checkpoint receptor may have slight variations from human sequences, which may be introduced, for example, to assist with the cloning or expression of a recombinant gene. For example, tyrosine 165 of CTLA-4 may be replaced with phenylalanine (Tyrl65Phe) to increase surface localization of CTLA-4.
- a nucleotide sequence encoding a checkpoint receptor may contain introns or lack introns.
- a nucleotide sequence encoding a checkpoint receptor may be a cDNA nucleotide sequence or a reverse complement thereof.
- Each checkpoint receptor may be the target of an agent that specifically binds a checkpoint receptor, such as a therapeutic antibody.
- a therapeutic antibody such as a therapeutic antibody.
- lambrolizumab, nivolumab, pembrolizumab, and pidilizumab are therapeutic antibodies that specifically bind the checkpoint receptor PD-1.
- Ipilimumab, ticilimumab, and tremelimumab are therapeutic antibodies that specifically bind the checkpoint receptor CTLA-4.
- Lirilumab is a therapeutic antibody that specifically binds the checkpoint receptor KIR2D.
- one or more checkpoint receptors are not targets of a therapeutic antibody or an agent that specifically binds a checkpoint receptor.
- a T-cell may comprise a first recombinant gene and a second recombinant gene, e.g. , wherein the two or more checkpoint receptors are encoded by the first recombinant gene and the second recombinant gene.
- the first recombinant gene may encode the checkpoint receptor PD-1 and the second recombinant gene may encode the checkpoint receptor CTLA- 4.
- a gene may be recombinant because the mRNA-encoding nucleotide sequence of the gene may be operably-linked to an inducible promoter, such as a promoter that is inducible by doxycycline.
- a gene may be recombinant because the gene was introduced into a T-cell by transfection and then integrated into the genome of the cell.
- the nucleotide sequence encoding a checkpoint receptor may be operably-linked to a promoter, such as an inducible promoter.
- a recombinant gene may therefore comprise a nucleotide sequence encoding a checkpoint receptor and a promoter (e.g. , inducible promoter) operably-linked to the nucleotide sequence.
- Each nucleotide sequence encoding a checkpoint receptor may be operably-linked to a promoter (e.g. , an inducible promoter).
- a T-cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene comprises both a nucleotide sequence encoding a checkpoint receptor and a promoter (e.g.
- a T- cell may comprise a first recombinant gene encoding the checkpoint receptor PD- 1 and a first inducible promoter, wherein the nucleotide sequence encoding PD- 1 is operably-linked to the first inducible promoter.
- the T-cell may comprise a second recombinant gene encoding the checkpoint receptor CTLA-4 and a second inducible promoter, wherein the nucleotide sequence encoding CTLA-4 is operably-linked to the second inducible promoter.
- the first inducible promoter and the second inducible promoter may comprise the same nucleotide sequence.
- Each recombinant gene encoding a checkpoint receptor may comprise a promoter with the same nucleotide sequence, or each recombinant gene may have at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with one another.
- Each recombinant gene encoding a checkpoint receptor may comprise a promoter that is subject to control by the same stimulus.
- the T-cell may be engineered to inducibly express two or more checkpoint receptors, wherein the two or more checkpoint receptors are controlled by an inducible promoter.
- the expression of a checkpoint receptor may be controlled by a promoter inducible by a transcription inducer such as doxycycline, tetracycline, a streptogramin, or a macrolide.
- the expression of a checkpoint receptor may be controlled by a promoter inducible by a dimerization (e.g. , ARGENT® or iDIMERIZE®).
- the expression of a checkpoint receptor may be controlled by a promoter inducible by a transcription inducer such as AP20187, AP21967, AP21998, or AP1510 (e.g., which induce dimerization of a transcription factor).
- a transcription inducer such as AP20187, AP21967, AP21998, or AP1510 (e.g., which induce dimerization of a transcription factor).
- the expression of a checkpoint receptor may be controlled by a hormone response element, such as an estrogen response element.
- the expression of a checkpoint receptor may be controlled by a promoter inducible by a transcription inducer such as estrogen.
- the two or more checkpoint receptors may be controlled by a promoter inducible by doxycycline (dox).
- dox doxycycline
- a checkpoint receptor may be controlled by a promoter inducible by doxycycline.
- Each nucleotide sequence encoding a checkpoint receptor may be operably- linked to a promoter that is inducible by doxycycline.
- a T-cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene comprises a promoter that is inducible by doxycycline and operably-linked to a nucleotide sequence encoding a checkpoint receptor (e.g. , PD-1 and/or CTLA-4).
- a T-cell may comprise one or more genetic modifications in addition to a
- a genetic modification may be a gene knockout, gene knockdown, expression cassette, or the modification of a regulatory element of a gene.
- a T-cell may comprise a T-cell gene knockout or an antigen presenting cell gene knockout. Any gene may be knocked or knocked down, such as genes of the lymphoid lineage or T-cell specific genes.
- Gene knockouts may be useful to determine whether the knockout gene affects a signaling pathway that is mediated by a checkpoint receptor.
- PD- 1 may transduce signals through multiple different signaling pathways that implicate myriad signaling proteins, which may include SHP2, phosphoinositide 3-kinase (PI3K), protein kinase B (PKB; AKT), p27kip, and/or ZAP70.
- a T-cell may comprise a gene knockout of SHP2, PI3K, AKT, p27kip, and/or ZAP70.
- a knockout of an individual signaling protein may enable the elucidation of whether a checkpoint receptor signals through the protein.
- a knockout may be introduced into the T-cell of an inducible T-cell system as described herein, T-cell receptor signaling may be assessed in the absence of the checkpoint receptor (e.g. , IL2 production may be assessed in the absence of doxycycline-induced PD-l/CTLA-4 expression), and T-cell receptor signaling may be assessed in the presence of the checkpoint receptor (e.g. , IL2 production may be assessed in the presence of doxycycline-induced PD- l/CTLA-4 expression).
- T-cell receptor signaling is similar in the absence and presence of the checkpoint receptor, then the knockout gene might be critical for downstream signaling through the checkpoint receptor.
- Such systems may be further probed, for example, by adding an antibody to the system that blocks T-cell receptor signaling (e.g. , nivolumab or pembrolizumab for PD-1; ipilimumab or tremelimumab for CTLA-4).
- T-cell receptor signaling is similar in the presence of the checkpoint receptor, regardless of whether an antibody is present that blocks the checkpoint receptor, then the knockout gene is likely critical for signaling downstream of the checkpoint receptor.
- Polypeptides encoded by genes that are determined to be critical for T-cell receptor signaling may be viable drug targets, particularly if the polypeptide exists on the cell membrane or if the protein is secreted.
- Intracellular polypeptides may also be viable drug targets (e.g. , for small molecule drugs).
- a genetic knockout identified using the above strategy might also be introduced into a lymphocyte used in an adoptive cell transfer therapy, for example, to suppress checkpoint inhibition of the lymphocyte.
- Methods for knocking out a gene in a T-cell include homologous recombination and CRISPR/Cas9-mediated knockout. Other methods of generating specific knockouts include TALEN (transcription activator-like effector nucleases) and zinc finger nuclease strategies.
- a T-cell gene may thus be knocked out by CRISPR/Cas9, a zinc finger nuclease, or a TALEN.
- a T-cell may comprise a T-cell gene knockout, wherein the T-cell gene is knocked out by CRISPR/Cas9.
- a knockout may or may not replace the coding regions of the knockout gene with the coding regions of a reporter gene, e.g. , a T-cell may comprise a reporter gene. Additionally, a knockout may replace the promoter of a knockout gene with a different promoter, e.g. , a promoter that is operably-linked to a reporter gene.
- a T-cell may comprise a gene for luciferase.
- a T-cell may comprise two gene fragments of ⁇ -galactosidase which may encode polypeptide products that may combine in the T-cell to form a protein with ⁇ -galactosidase activity.
- a T-cell may comprise a luciferase protein or a ⁇ -galactosidase protein.
- a T-cell may be homozygous for a knockout (e.g. , wherein both copies of a gene are knocked out) or heterozygous for a knockout (e.g. , wherein a single copy of a gene is knocked out).
- a T-cell may comprise a random gene knockout. Random knockouts may be generated by insertion mutagenesis such as by transfecting a T-cell with a retrovirus or transposable element (transposon). Random knockouts may be useful to identify genes or other genetic features that may be involved in checkpoint inhibition or T-cell activation.
- a T-cell may comprise a gene knockdown.
- a gene knockdown may be a transient knockdown (e.g. , wherein a T-cell is transfected with antisense RNA, short hairpin RNA, microRNA, or small interfering RNA) or a knockdown may be a stable knockdown (e.g.
- a gene knockdown may be a conditional knockdown (e.g. , wherein the expression of an antisense RNA, microRNA, or small interfering RNA is controlled by an inducible promoter).
- a T-cell may comprise a genetic modification that increases the expression of a gene, e.g. , in addition to the two or more checkpoint receptors.
- a T-cell may comprise a recombinant gene that does not encode a checkpoint receptor.
- a recombinant gene that does not encode a checkpoint receptor may instead encode a signaling protein, for example, such as a kinase or phosphatase.
- a recombinant gene that does not encode a checkpoint receptor may encode a human protein, such as a protein expressed by T-cells. The protein encoded by a recombinant gene may contain one or more mutations relative to the wild type protein.
- the one or more mutations may affect the expression, cellular localization, function, and/or activity of the protein.
- the one or more mutations may or may not be naturally-occurring mutations or mutations that are associated with disease, such as cancer or an autoimmune disease.
- the one or more mutations may or may not be associated with the efficacy of a drug that targets the protein, e.g. , a mutation may be associated with drug resistance or sensitivity.
- a genetic modification that increases the expression of a gene may be introduced into a T-cell, for example, as an expression cassette comprising a promoter operably-linked to an open reading frame encoding a protein product.
- a T-cell may comprise a recombinant gene encoding a protein other than a checkpoint receptor, such as a signaling protein (e.g. , kinase or phosphatase).
- a nucleotide sequence encoding a protein other than a checkpoint receptor may be operably-linked to a promoter, such as a constitutive or inducible promoter.
- a genetic modification may increase the expression of an endogenous gene of a T- cell.
- the regulatory region of an endogenous gene of a T-cell may be modified to increase the expression of a gene.
- Modifications that increase expression include the replacement of an endogenous promoter with a strong promoter (or a promoter that is stronger than the endogenous promoter).
- An endogenous promoter may be replaced with an inducible promoter (e.g. , a doxycycline-inducible promoter) or a constitutive promoter (e.g. , cytomegalovirus promoter or SV40 promoter).
- Other modifications that increase gene expression include the mutation or deletion of a silencer nucleotide sequence.
- the modification of an endogenous gene may be accomplished using known techniques, such as homologous recombination, CRISPR/Cas9-mediated gene editing, TALEN strategies, and zinc-finger strategies.
- Various aspects of the invention relate to a checkpoint receptor ligand-presenting cell
- a checkpoint receptor ligand-presenting cell may be a B-cell.
- a B-cell may be a mammalian B-cell, such as a human B-cell.
- a B-cell may be immortalized. For example, a B-cell may be immortalized because the B-cell has been transformed with an Epstein-Barr virus.
- a B-cell may be derived from a B-cell leukemia or lymphoma.
- a B-cell may be derived from a cell line, such as a human cell line.
- a B-cell may be derived from a Raji cell line.
- a B-cell may be a Raji cell or a BLCL cell.
- a B-cell may be an Epstein-Barr virus-immortalized lymphoblast.
- a B-cell may endogenously express B7.1 and/or B7.2.
- B7.1 and/or B7.2 may bind to CD28 present on a T-cell thereby transducing a costimulatory signal.
- B7.1 and/or B7.2 may bind to CTLA-4 present on a T-cell thereby suppressing the activation and proliferation of the T-cell.
- a B-cell may endogenously express PD-L1.
- PD-L1 may bind PD-1 present on a T- cell thereby suppressing the activation and proliferation of the T-cell.
- a B-cell may endogenously express major histocompatibility complex class II (MHC class II).
- MHC class II may bind LAG-3 present on a T-cell thereby suppressing the activation and proliferation of the T-cell.
- a checkpoint receptor ligand-presenting cell may be a human or non-human cell.
- the ligand-presenting cell is not a B-cell.
- a ligand- presenting cell may be a HEK293 cell or a Chinese hamster ovary (CHO) cell.
- a ligand- presenting cell may be a 3T3-L1, 4T1, 9L, A172, A20, A253, A2780, A2780ADR, A2780cis, A431, A549, AHL-1, ALC, B16, B35, BCP-1, BEAS-2B, bEnd.3, BHK-21, BOSC23, BT- 20, BxPC3, C2C12, C3H-10T1/2, C6, Caco-2, Cal-27, CGR8, CHO, CML Tl, CMT12, COR-L23, COS-7, COV-434, CT26, D17, DH82, DU145, DuCaP, E14Tg2a, EL4, EM-2, EM-3, EMT6/AR1, FM3, GL261, H1299, HaCaT, HCA2, HEK293, HeLa, Hep G2, Hepalclc7, HL-60, HT-1080, HT-29, J558L, Jurkat,
- a checkpoint receptor ligand-presenting cell may be derived from a human or non- human cell, and the ligand-presenting cell may be engineered to express a human checkpoint receptor ligand, such as B7.1, B7.2, PD-L1, or PD-L2.
- a ligand-presenting cell may be derived from a human or non-human cell, and the ligand-presenting cell may be engineered to express a human costimulatory ligand such as B7.1 or B7.2.
- A. Checkpoint receptor ligands such as B7.1, B7.2, PD-L1, or PD-L2.
- a checkpoint receptor ligand-presenting cell may be engineered to constitutively express one or more checkpoint receptor ligands.
- a ligand-presenting cell may comprise a recombinant gene encoding a checkpoint receptor ligand.
- a ligand-presenting cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene encodes a different checkpoint receptor ligand.
- Each checkpoint receptor ligand may be selected from B7.1 (CD80), B7.2 (CD86), V-set domain-containing T-cell activation inhibitor 1 (VTCN1; B7-H4), programmed cell death-ligand 1 (PD-L1; B7-H1; CD274), B7-H2 (ICOS ligand; CD275), B7-H7, programmed cell death-ligand 2 (PD-L2; B7-DC; CD273), major histocompatibility complex class II (MHC class II), herpesvirus entry mediator (HVEM; TNFRSF14), CD155, galectin-9, and T-cell immunoglobulin and mucin-domain containing-3 ligand (TIM-3 ligand).
- the one or more checkpoint receptor ligands may comprise PD-L1 and/or PD-L2.
- a checkpoint receptor ligand may be a human checkpoint receptor ligand, e.g. , the checkpoint receptor ligand may have a human amino acid sequence.
- a checkpoint receptor ligand may be encoded by a human nucleotide sequence. Nevertheless, the amino acid sequence of a checkpoint receptor ligand or the nucleotide sequence encoding the checkpoint receptor ligand may have slight variations from human sequences, which may be introduced, for example, to assist with the cloning or expression of a recombinant gene.
- a nucleotide sequence encoding a checkpoint receptor ligand may contain introns or lack introns.
- a nucleotide sequence encoding a checkpoint receptor ligand may be a cDNA nucleotide sequence or a reverse complement thereof.
- a checkpoint receptor ligand-presenting cell may comprise 1, 2, 3, 4, or more recombinant genes, wherein each recombinant gene encodes a checkpoint receptor ligand.
- a checkpoint receptor ligand may be selected from PD-L1, PD-L2, B7.1, and B7.2.
- a ligand- presenting cell may comprise a first recombinant gene wherein the first recombinant gene encodes the checkpoint receptor ligand PD-L1 or PD-L2.
- a ligand-presenting cell may comprise a second recombinant gene, wherein the second recombinant gene encodes the checkpoint receptor ligand B7.1 or B7.2.
- a gene may be recombinant because the mRNA- encoding nucleotide sequence of the gene is operably-linked to an inducible promoter, such as a promoter that is inducible by doxycycline.
- a gene may be recombinant because the gene was introduced into a ligand-presenting cell by transfection and then integrated into the genome of the cell.
- the nucleotide sequence encoding a checkpoint receptor ligand may be operably- linked to a promoter such as a constitutive promoter.
- a recombinant gene may therefore comprise a nucleotide sequence encoding a checkpoint receptor ligand and a promoter (e.g. , constitutive promoter) operably-linked to the nucleotide sequence.
- Each nucleotide sequence encoding a checkpoint receptor ligand may be operably-linked to a promoter (e.g. , a constitutive promoter).
- a checkpoint receptor ligand-presenting cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene comprises both a nucleotide sequence encoding a checkpoint receptor ligand and a promoter (e.g. , a constitutive promoter) operably-linked to the nucleotide sequence.
- a ligand-presenting cell may comprise a recombinant gene encoding the checkpoint receptor ligand PD-L1 or PD-L2 and a constitutive promoter, e.g. , wherein the nucleotide sequence encoding PD-L1 or PD-L2 is operably-linked to the constitutive promoter.
- a ligand-presenting cell may comprise a recombinant gene encoding the checkpoint receptor ligand B7.1 or B7.2 and a constitutive promoter, e.g. , wherein the nucleotide sequence encoding B7.1 or B7.2 is operably-linked to the constitutive promoter.
- a checkpoint receptor ligand-presenting cell may comprise a first recombinant gene encoding the checkpoint receptor ligand PD-L1 or PD-L2 and a first constitutive promoter, e.g. , wherein the nucleotide sequence encoding PD-L1 or PD-L2 is operably-linked to the first constitutive promoter.
- the ligand-presenting cell may comprise a second recombinant gene encoding the checkpoint receptor ligand B7.1 or B7.2 and a second constitutive promoter, e.g. , wherein the nucleotide sequence encoding B7.1 or B7.2 is operably-linked to the second constitutive promoter.
- the first constitutive promoter and the second constitutive promoter may comprise the same nucleotide sequence.
- Each recombinant gene encoding a checkpoint receptor ligand may comprise a promoter with the same nucleotide sequence or with at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity.
- a checkpoint receptor ligand-presenting cell is not engineered to constitutively express one or more checkpoint receptor ligands.
- a ligand- presenting cell may endogenously express one or more of the checkpoint receptor ligands, e.g. , wherein the checkpoint receptor ligands are selected from B7.1, PD-L1, and MHC class II.
- a checkpoint receptor ligand-presenting cell may express a costimulatory ligand.
- a ligand-presenting cell may express B7.1 and/or B7.2, which are costimulatory ligands for CD28.
- a B-cell may endogenously express a costimulatory ligand, such as B7.1.
- a ligand-presenting cell may be engineered to constitutively or inducibly express a costimulatory ligand.
- the ligand-presenting cell may be a HEK293 cell or a CHO cell, and the ligand-presenting cell may be engineered to express human B7.1 and/or human B7.2.
- a ligand-presenting cell e.g.
- either a B-cell or non-B-cell may be engineered to express an anti-CD28 antibody (e.g. , an anti-CD28 scFv antibody), which may optionally comprise a transmembrane domain that anchors the antibody to the ligand- presenting cell.
- an anti-CD28 antibody e.g. , an anti-CD28 scFv antibody
- an anti-CD28 scFv antibody may optionally comprise a transmembrane domain that anchors the antibody to the ligand- presenting cell.
- the checkpoint receptor ligand-presenting cell does not comprise a costimulatory ligand or the inducible T-cell system does not comprise a ligand- presenting cell or B-cell.
- a costimulatory ligand may instead be provided as a reagent optionally associated with a solid support, such as a bead.
- a costimulatory ligand may be an anti-human CD28 antibody, which may optionally be associated with a bead.
- a system may be an inducible T cell system, e.g. , the system may comprise a T cell engineered to inducibly express two or more checkpoint receptors.
- a system may further comprise a checkpoint receptor ligand-presenting cell as described in section II, supra.
- a ligand-presenting cell may or may not be a B-cell.
- the system may comprise an antigen presenting cell (APC) instead of a B-cell, e.g. , wherein the T-cell receptor costimulatory signal is provided by a MHC-peptide complex on the surface of the APC.
- APC antigen presenting cell
- a system may further comprise a second costimulatory ligand that is different from the costimulatory ligand expressed by a ligand-presenting cell, which may simulate T-cell receptor signaling.
- a second costimulatory ligand may be associated with a bead, multi-well plate, or tissue culture plate, or the second costimulatory ligand antibody may be crosslinked as an oligomer, such as a tetramer.
- a second costimulatory ligand may be, for example, an anti-CD3 antibody.
- An anti-CD3 antibody may be associated with a bead, e.g. , a system may further comprise an anti-CD3 antibody coated bead.
- An anti-CD3 antibody may be a bi-specific antibody, such as a bi-specific T-cell engager (BiTE®).
- a bi-specific T-cell engager BiTE®
- An example of an anti-CD3 bi-specific antibody that may bind CD3 and thereby transduce a costimulatory signal is blinatumomab (BLINCYTO®), which is bi-specific for CD3 and CD19.
- C19 may be present on a B-cell, such as a B-cell of an inducible T-cell system.
- a system may further comprise a transcription inducer.
- a transcription inducer may control the transcription of an inducible gene of a T-cell of a system.
- the transcription inducer may be doxycycline, tetracycline, a streptogramin, or a macrolide.
- the transcription inducer may be AP20187, AP21967, AP21998, or AP1510, which may mediate FKBP F36 v- dimer mediated transcription (e.g. , in ARGENT® or iDIMERIZE®).
- the transcription inducer may be an estrogen, e.g. , which binds to a hormone response element.
- a system may further comprise media, such as Roswell Park Memorial Institute (RPMI) media.
- a system may further comprise serum, such as fetal bovine serum (FBS).
- FBS fetal bovine serum
- a system may further comprise an antibiotic such as a penicillin (e.g. , penicillin G), an aminoglycoside (e.g. , streptomycin, gentamicin), and/or an aminonucleoside (e.g. , puromycin).
- a system may further comprise reagents to determine the expression level of a biomarker that is associated with T-cell activation.
- a system may comprise an antibody that specifically binds the biomarker.
- the biomarker may be, for example, interleukin-2 or interferon ⁇ .
- a system may further comprise reagents to determine the expression of interleukin-2 by the T-cell.
- a system may comprise an anti- interleukin-2 antibody and/or a secondary antibody, such as an anti-IgG antibody.
- a system may further comprise reagents to determine the expression of interferon ⁇ by the T-cell.
- a system may comprise an anti-interferon ⁇ antibody and/or a secondary antibody, such as an anti-IgG antibody.
- An anti-interleukin-2 antibody, anti-interferon ⁇ antibody, or a secondary antibody may be conjugated to an enzyme (e.g. , alkaline phosphatase or horseradish peroxidase), a fluorophore (e.g. , fluorescein or Texas red), or a crosslinker (e.g. , biotin).
- an enzyme e.g. , alkaline phosphatase or horseradish peroxidase
- a fluorophore e.g. , fluorescein or Texas red
- a crosslinker e.g. , biotin
- a system may comprise a colorimetric alkaline phosphatase substrate or a colorimetric horseradish peroxidase substrate.
- a system may comprise a luciferase substrate such as BIO-GLO®.
- a system may comprise one or more pharmaceutical agents such as two or more pharmaceutical agents.
- a pharmaceutical agent may or may not be an FDA approved pharmaceutical agent.
- a pharmaceutical agent may be a small molecule compound or a large molecule.
- the one or more pharmaceutical agents may be selected from small molecule compounds and large molecules.
- a pharmaceutical agent may be a candidate compound.
- Candidate compounds are typically small molecule compounds that are drug-like, including compounds of a drug screen (such as compounds used in high-throughput screening), rationally designed compounds, pre-lead compounds, lead compounds, clinical candidates, and repurposed drugs.
- a small molecule compound may have a molecular weight of less than about 900 amu, such as less than about 800, 700, or 600 amu.
- a small molecule compound may have a molecular weight of about 3 amu to about 899.9 amu, such as about 100 to 800, 100 to 700, 100 to 600, 100 to 500, 200 to 800, 200 to 700, 200 to 600, 200 to 500, 300 to 800, 300 to 700, 300 to 600, 300 to 500, 400 to 800, 400 to 700, 400 to 600, 500 to 800, 500 to 700, or 600 to 800 amu.
- the small molecule compound has a molecular weight of about 400 amu to about 700 amu.
- a small molecule compound may be an immunomodulatory imide drug (IMiD).
- IMD immunomodulatory imide drug
- a small molecule compound may be thalidomide, lenalidomide, pomalidomide, or apremilast.
- a small molecule compound may be a kinase inhibitor such as a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, or a lipid kinase inhibitor.
- a kinase inhibitor such as a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, or a lipid kinase inhibitor.
- a large molecule may have a molecular weight of at least about 900 amu, such as at least about 1 kDa, 10 kDa, 50 kDa, 100 kDa, or 150 kDa.
- a large molecule may have a molecular weight of about 900 amu to 5 kDa, 1 kDa to 50 kDa, 1 kDa to 30 kDa, 1 kDa to 25 kDa, 1 kDa to 20 kDa, 1 kDa to 10 kDa, 5 kDa to 30 kDa, 5 kDa to 25 kDa, 5 kDa to 20 kDa, 5 kDa to 15 kDa, 10 kDa to 30 kDa, 10 kDa to 25 kDa, 10 kDa to 20 kDa, 20 kDa to 80 kDa, 20 kDa to 40 kDa, 40
- a cytokine for example, may have a molecular weight of about 5 kDa to about 20 kDa.
- An antibody may have a molecular weight of about 120 kDa to about 180 kDa, such as about 140 kDa to about 160 kDa.
- a fragment antigen-binding (Fab) fragment of an antibody may have a molecular weight of about 20 kDa to about 80 kDa, such as about 40 kDa to about 60 kDa.
- a large molecule may be a hormone, cytokine, chemokine, lymphokine, interferon, or interleukin.
- a large molecule may be selected from interferon alfa, interferon alfacon-1, pegylated interferon alpfa-2a, pegylated interferon alfa- 2b, interferon ⁇ , interferon jib, interleukin-2, interleukin-7, interleukin- 12, pifonakin, mobenakin, adargileukin alfa, aldesleukin, celmoleukin, denileukin diftitox, pegaldesleukin, teceleukin, tucotuzumab celmoleukin, daniplestim, muplestim, binetrakin, atexakin alfa, emoctakin, ilodecakin, oprelvekin, edodekin alfa, cintredekin besudotox, and iboctadekin.
- a T-cell and/or ligand-presenting cell may produce a molecule with the same chemical structure as a large molecule or pharmaceutical agent, and the terms
- a pharmaceutical agent e.g. , large molecule
- a pharmaceutical agent may be interleukin-2 or interferon ⁇ , in which case the interleukin-2 or interferon ⁇ pharmaceutical agent refers to interleukin-2 or interferon ⁇ that is added to a T-cell system rather than interleukin-2 or interferon ⁇ that is produced by a cell of the system.
- the pharmaceutical agent does not have the same chemical structure as any molecule produced by a cell of a T-cell system, e.g. in some embodiments the pharmaceutical agent does not have the same chemical structure as interleukin-2, interferon ⁇ , or any other molecule produced by a cell of an inducible T-cell system.
- a large molecule may be interleukin-2 or interferon ⁇ .
- a large molecule may be selected from brain-derived neurotrophic factor (BDNF),
- CCL11 Eotaxin
- CCL3 MIP-1 alpha
- CCL4 MIP-1 beta
- CCL5 RANTES
- CD31 PECAM-1
- CD62P P-selectin
- CXCL1 GRO alpha
- CXCL10 IP-10
- GM-CSF granulocyte- macrophage colony- stimulating factor
- HGF hepatocyte growth factor
- IFNa interferon a
- LIF le
- a large molecule may be an antibody such as a therapeutic antibody.
- a therapeutic antibody is typically a monoclonal antibody, or an antigen-binding fragment thereof, which is either chimeric (e.g. , comprising human sequences), humanized, or fully human.
- An antibody may be a checkpoint inhibitory antibody.
- One or more pharmaceutical agents may comprise a small molecule compound, an antibody, and/or an FDA approved checkpoint inhibitory antibody.
- Two or more pharmaceutical agents may comprise a small molecule compound, an antibody, and/or an FDA approved checkpoint inhibitory antibody.
- antibody encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. , bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen- binding activity.
- An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments are well known in the art (see, e.g.
- the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. , the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variants, e.g. , containing naturally occurring mutations or that may arise during production of the monoclonal antibody, such variants generally being present in minor amounts.
- polyclonal antibody preparations typically include different antibodies directed against different determinants (epitopes)
- each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on the antigen.
- the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method (see, e.g. , Kohler et al, Nature, 256:495 (1975)), recombinant DNA methods (see, e.g. , U.S. Patent No. 4,816,567), phage-display methods (e.g.
- Two or more checkpoint inhibitory drugs may comprise an FDA approved checkpoint inhibitory drug wherein the FDA approved checkpoint inhibitory drug is a monoclonal antibody.
- a "bi-specific antibody” is a multispecific antibody comprising an antigen-binding domain that is capable of specifically binding to two different epitopes on one biological molecule or is capable of specifically binding to epitopes on two different biological molecules.
- a large molecule may be an antibody that specifically binds 2B4, 4- IBB, BAFF,
- a large molecule may be an antibody that specifically binds brain-derived
- BDNF neurotrophic factor
- CCL11 Eotaxin
- CCL3 MIP-1 alpha
- CCL4 MIP-1 beta
- CCL5 RANTES
- CD31 PECAM-1
- CD62P P-selectin
- CXCL1 GRO alpha
- CXCL10 IP- 10
- GM-CSF granulocyte-macrophage colony-stimulating factor
- HGF hepatocyte growth factor
- IFNa interferon a
- interleukin-2 interleukin-4
- interleukin-5 interleukin-6, interleukin-7
- interleukin-8 interleukin-8
- interleukin-9 interleukin-10, interleukin-12, interleukin-13, interleukin-15, interleukin-16, interleukin-17a, interleukin-20, interleukin-21, interleukin-1 receptor antagonist, leukemia
- a large molecule may be selected from Afasevikumab (which binds interleukin-17 A and interleukin-17F), Afutuzumab (which binds CD20), ALD518 (which binds interleukin- 6), Alemtuzumab (which binds CD52), Anrukinzumab (which binds interleukin-13), Aselizumab (which binds L-selectin), Atezolizumab (which binds CD274), Avelumab (which binds CD274), Basiliximab (which binds CD23), Bectumomab (which binds CD22), Belimumab (which binds BAFF), Bimekizumab (which binds interleukin-17A and interleukin-17F), Bivatuzumab (which binds CD44), Bleselumab (which binds CD40), Blinatumomab (which
- Denintuzumab (which binds CD19), Denosumab (which binds RANKL), Dupilumab (which binds interleukin-4), Durvalumab (which binds CD274), Efalizumab (which binds LFA-1), Elsilimomab (which binds interleukin-6), Enokizumab (which binds interleukin-9),
- Epratuzumab (which binds CD22), FBTA05 (which binds CD20), Fezakinumab (which binds interleukin-22), Fletikumab (which binds interleukin-20), Fontolizumab (which binds IFN- ⁇ ), Foralumab (which binds CD3), Fresolimumab (which binds TGF- ⁇ ), Galiximab (which binds CD80), Gevokizumab (which binds interleukin- ⁇ ), Gomiliximab (which binds CD23), GSK3174998 (which binds OX40), Guselkumab (which binds interleukin-23), Ibalizumab (which binds CD4), Ibritumomab (which binds CD20), Imalumab (which binds MIF), Inebilizumab (which binds CD 19), Inolimomab (which binds CD
- Isatuximab which binds CD38
- Itolizumab which binds CD6
- Ixekizumab which binds interleukin-17 A
- Keliximab which binds CD4
- Lambrolizumab which binds PD-1
- Lebrikizumab which binds interleukin-13
- Lenzilumab which binds CSF2
- Lerdelimumab which binds TGF- 2
- Lilotomab which binds CD37
- Lirilumab which binds KIR2D
- Lucatumumab which binds CD40
- Lulizumab pegol which binds CD28
- Lumiliximab which binds CD23
- Maslimomab which binds T-cell receptor
- MEDI6383 which binds OX40
- Mepolizumab which binds interleukin-5
- Metelimumab which binds T
- Prezalizumab (which binds ICOSL), Priliximab (which binds CD4), PRO 140 (which binds CCR5), Reslizumab (which binds interleukin-5), Risankizumab (which binds interleukin- 23A), Rituximab (which binds CD20), Rontalizumab (which binds IFN-a), Ruplizumab (which binds CD 154), Sarilumab (which binds interleukin-6), Secukinumab (which binds interleukin-17A), SGN-CD19A (which binds CD19), Sifalimumab (which binds IFN-a), Siltuximab (which binds interleukin-6), Siplizumab (which binds CD2), Sirukumab (which binds interleukin-6), Tabalumab (which binds BAFF), Tamtuvetmab (which
- Zanolimumab which binds CD4
- Zolimomab which binds CD5
- an antigen-binding fragment of any one of the foregoing may be selected from
- a system may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more pharmaceutical agents as described herein.
- a system may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
- a system of the plurality may comprise an inducible T-cell, a checkpoint receptor ligand-presenting cell (e.g. , a B-cell), and second costimulatory ligand.
- a system may or may not further comprise a transcription inducer such as doxycycline.
- a system may further comprise 0, 1, 2, 3, or 4 of a first large molecule, a second large molecule, a first small molecule compound, and a second small molecule compound.
- a system may comprise an inducible T-cell, modified inducible T-cell, transcription inducer, checkpoint receptor ligand-presenting cell (e.g. , a B-cell), second costimulatory ligand, first large molecule, second large molecule, first small molecule compound, and second small molecule.
- a plurality of systems may be arranged, for example, in a plate configured for high- throughput screening, e.g. , a multi-well plate, such as a 6 well, 12 well, 24 well, 96 well, 384 well, 1536 well, or 3,456 well plate.
- a plurality of systems may comprise 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 or more systems.
- Each system of a plurality of systems may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a ligand-presenting cell that expresses at least one checkpoint receptor ligand; and a costimulatory ligand.
- the T-cell may be any T-cell described herein, such as a human T-cell (e.g. , a Jurkat cell).
- the ligand-presenting cell may be any ligand-presenting cell described herein, such as a human B-cell (e.g. , a Raji cell).
- the costimulatory ligand may be an anti-CD3 antibody or other ligand that specifically binds the T-cell receptor thereby activating T-cell receptor mediated signaling.
- An anti-CD3 antibody may be associated with a solid support, such as a bead.
- At least one system of a plurality of systems may comprise a transcription inducer that induces the transcription of the two or more checkpoint inhibitors. At least one system of a plurality of systems may lack the transcription inducer.
- the transcription inducer may be a small molecule such as doxycycline, tetracycline, a streptogramin, a macrolide, a steroid (e.g. , an estrogen), AP20187, AP21967, AP21998, or AP1510.
- At least one system of a plurality of systems may comprise a pharmaceutical agent. At least one system of a plurality of systems may lack the pharmaceutical agent. For example, at least one system may lack both a transcription inducer and a pharmaceutical agent; at least one system may comprise the transcription inducer and lack the pharmaceutical agent; at least one system may lack the transcription inducer and comprise the pharmaceutical agent; and/or at least one system may comprise both the transcription inducer and the pharmaceutical agent.
- At least one system of a plurality of systems may comprise a T-cell comprising a gene knockout or gene knockdown (i.e. , wherein a T-cell comprising the gene knockout or gene knockdown is a T-cell engineered to inducibly express two or more checkpoint inhibitors).
- At least one system of a plurality of systems may comprise a T-cell lacking the gene knockout or gene knockdown (i.e. , wherein the T-cell lacking the gene knockout or gene knockdown is a T-cell engineered to inducibly express two or more checkpoint inhibitors).
- At least one system may lack a transcription inducer and comprise a T-cell lacking the gene knockout or gene knockdown; at least one system may comprise the transcription inducer and comprise a T-cell lacking the gene knockout or gene knockdown; at least one system may lack the transcription inducer and comprise a T-cell comprising the gene knockout or gene knockdown; and/or at least one system may comprise the transcription inducer and comprise a T-cell comprising the gene knockout or gene knockdown.
- At least one system may lack a pharmaceutical agent and comprise a T-cell lacking the gene knockout or gene knockdown; at least one system may comprise the pharmaceutical agent and comprise a T-cell lacking the gene knockout or gene knockdown; at least one system may lack the pharmaceutical agent and comprise a T-cell comprising the gene knockout or gene knockdown; and/or at least one system may comprise the pharmaceutical agent and comprise a T-cell comprising the gene knockout or gene knockdown
- At least one system of a plurality of systems may comprise a T-cell engineered to express a recombinant gene in addition to the two or more checkpoint receptors. At least one system of a plurality of systems may comprise a T-cell lacking the recombinant gene.
- at least one system may lack a transcription inducer and comprise a T-cell engineered to express the recombinant gene; at least one system may comprise the transcription inducer and comprise a T-cell engineered to express the recombinant gene; at least one system may lack the transcription inducer and comprise a T-cell lacking the recombinant gene; and/or at least one system may comprise the transcription inducer and comprise a T-cell lacking the recombinant gene.
- At least one system may lack a pharmaceutical agent and comprise a T-cell engineered to express the recombinant gene; at least one system may comprise the pharmaceutical agent and comprise a T-cell engineered to express the recombinant gene; at least one system may lack the pharmaceutical agent and comprise a T-cell lacking the recombinant gene; and/or at least one system may comprise the pharmaceutical agent and comprise a T-cell lacking the recombinant gene.
- a T-cell may be engineered to inducibly express two or more checkpoint receptors as described herein, such as two or more checkpoint receptors are selected from PD-1, CTLA-4, PD-1H, LAG-3, BTLA, KIR2D, TIM-3, ADORA2A, CD160, 2B4, TIGIT, and interleukin- 10 receptor.
- a T-cell may be engineered to inducibly express two or more checkpoint receptors selected from PD-1 and CTLA-4.
- a ligand-presenting cell may express at least one checkpoint receptor ligand that is a ligand of the two or more checkpoint receptors of the T-cell.
- the ligand-presenting cell may endogenously express the at least one checkpoint receptor ligand or the ligand-presenting cell may be engineered to express the at least one checkpoint receptor ligand.
- the at least one checkpoint receptor ligand(s) may be selected from PD-L1, PD-L2, B7.1, B7.2, B7-H4, B7- H2, B7-H7, MHC class II, HVEM, CD 155, galectin-9, and TIM-3 ligand.
- a ligand-presenting cell may express either PD-L1 or PD-L2 and either B7.1 or B7.2.
- a ligand-presenting cell may express a second costimulatory ligand in addition to the costimulatory ligand of a system.
- the second costimulatory ligand may be a ligand of a costimulatory receptor, e.g. , wherein the costimulatory receptor is expressed by the T-cell of a system.
- the second costimulatory ligand may be a ligand of 4- IBB, CD27, OX40, BAFFR, TACI, BMCA, CD40L, CD28, ICOS, or GITR.
- a ligand-presenting cell may express B7.1 and/or B7.2, which are ligands of CD28.
- the costimulatory ligand may be, for example, an anti-CD3 antibody as described herein, which may be associated with a solid support, such as a bead, the surface of a tissue culture plate, or the surface of a multi-well plate.
- a plurality of systems may be useful to determine whether a protein may be a suitable drug target or whether a pharmaceutical agent has an ON target or OFF target affect.
- a plurality of systems may comprise an inducible T-cell system comprising a gene knockout or knockdown to determine whether a protein encoded by the gene is a suitable drug target.
- a plurality of systems may comprise (1) a system comprising a pharmaceutical agent and a T-cell comprising a gene knockout or knockdown, (2) a system comprising the pharmaceutical agent and a T-cell lacking the gene knockout or knockdown, (3) a system lacking the pharmaceutical agent and a T-cell lacking the gene knockout or knockdown, and/or (4) a system lacking the pharmaceutical agent and a T-cell comprising the gene knockout or knockdown, which may be useful to determine whether the pharmaceutical agent affects T-cell activation through a pathway mediated by the protein product of the gene.
- Each system of a plurality of systems may be selected from: a system that lacks a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown; a system that comprises a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown; a system that lacks a transcription inducer, comprises a pharmaceutical agent, and lacks a T- cell comprising a gene knockout or gene knockdown; a system that comprises a transcription inducer, comprises a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown; a system that lacks a transcription inducer, lacks a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown; a system that comprises a transcription inducer, lacks a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown; a system that comprises a transcription inducer, lacks
- a plurality of systems may comprise a system comprising two pharmaceutical agents.
- the two pharmaceutical agents may be selected from at least one small molecule compound and at least one large molecule.
- the two pharmaceutical agents may be two small molecule compounds, two large molecules (e.g. , two antibodies), or a small molecule compound (e.g. , a kinase inhibitor) and a large molecule (e.g. , an antibody).
- Each system of a plurality of systems may be selected from: a system that lacks a small molecule compound and lacks a large molecule; a system that comprises one small molecule compound and lacks a large molecule; a system that comprises one small molecule compound and one large molecule; a system that comprises at least two small molecule compounds and lacks a large molecule; a system that comprises at least two small molecule compounds and one large molecule; a system that lacks a small molecule compound and comprises at least two large molecules; and/or a system that comprises one small molecule compound and at least two large molecules.
- the at least one large molecule may comprise an antibody such as an anti-CTLA-4 antibody and an anti-PD- 1 antibody.
- the plurality of systems may comprise a system comprising two pharmaceutical agents wherein the two pharmaceutical agents are an anti- CTLA-4 antibody and an anti-PD- 1 antibody.
- the at least one large molecule may comprise 1 or 2 of avelumab, atezolizumab, durvalumab, ipilimumab, lambrolizumab, nivolumab, pembrolizumab, pidilizumab, tremelimumab, and ticilimumab.
- the plurality of systems may comprise a system comprising two pharmaceutical agents wherein the two pharmaceutical agents are selected from avelumab, atezolizumab, durvalumab, ipilimumab, lambrolizumab, nivolumab, pembrolizumab, pidilizumab, tremelimumab, and ticilimumab.
- the at least one large molecule may comprise ipilimumab and/or nivolumab.
- the plurality of systems may comprise a system comprising two pharmaceutical agents wherein the two pharmaceutical agents are ipilimumab and nivolumab.
- Each system of a plurality of inducible T-cell systems may comprise tissue culture media, such as RPMI media.
- a system may further comprise blood serum (e.g. , FBS), which may be present at a concentration of about 1% to about 20% serum, such as about 5% to about 15%, such as about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15%.
- FBS blood serum
- Each system may further comprise an antibiotic such as a penicillin (e.g. , penicillin G), an aminoglycoside (e.g. , streptomycin, gentamicin), and/or an aminonucleoside (e.g. , puromycin).
- a plurality of samples may comprise the supernatants of each system of a plurality of systems.
- a plurality of samples may or may not comprise the cells of an inducible T-cell system.
- a plurality of samples may be substantially free of the cells of a plurality of inducible T-cell systems (i.e. , T-cells and ligand-presenting cells).
- a plurality of samples may comprise the supernatant of a plurality of inducible T-cell systems as described herein and reagents for an enzyme-linked immunosorbent assay (ELISA) or other colorimetric immunoassay.
- Each sample of a plurality of samples may consist essentially of the supernatant of an inducible T-cell system (e.g. , of a plurality of systems) as described herein and reagents for an (ELISA) or other colorimetric immunoassay.
- Reagents for an ELISA or other colorimetric immunoassay may include one or more a primary antibody (e.g. , an anti-interleukin-2 antibody or an anti-interferon ⁇ antibody), a secondary antibody (e.g. , an anti-IgG antibody, anti-IgA antibody, anti-IgY antibody, anti- IgM antibody, anti-IgE antibody, anti-IgD antibody, an anti-Rabbit IgG antibody, an anti-Rat IgG antibody, an anti-Mouse IgG antibody, an anti-Human IgG antibody), an antibody- fluorophore conjugate (e.g.
- a primary antibody e.g. , an anti-interleukin-2 antibody or an anti-interferon ⁇ antibody
- a secondary antibody e.g. , an anti-IgG antibody, anti-IgA antibody, anti-IgY antibody, anti- IgM antibody, anti-IgE antibody, anti-IgD antibody, an
- an antibody- Alexa Fluor 488 conjugate an antibody-Texas Red conjugate, an antibody-fluorescein conjugate
- an antibody-biotin conjugate an antibody- enzyme conjugate (e.g. , an antibody- horseradish peroxidase conjugate or an antibody- alkaline phosphatase conjugate)
- a colorimetric substrate for horseradish peroxidase e.g. , ABTS, OPD, AmplexRed, DAB, AEC, TMB, homovanillic acid, luminol
- a colorimetric substrate for alkaline phosphatase e.g. , nitroblue tetrazolium, 5-bromo-4-chloro-3-indolyl phosphate
- a plurality of systems or plurality of samples may be arranged in a multi-well plate such as a 6 well, 12 well, 24 well, 96 well, 384 well, 1536 well, or 3,456 well plate.
- a multi- well plate may comprise, for example, U-bottom wells.
- a method may utilize a multi-well plate, although a method may be adapted to other formats including individual tissue culture plates, tissue culture flasks, test tubes, microfluidics platforms, or lab-on-chip platforms.
- a method may be a method of preparing a multi-well plate.
- compositions e.g. , cell, bead, transcription inducer, pharmaceutical agent
- system may comprise the addition of the composition to a well of a multi-well plate.
- a plurality of systems may be arranged, for example, in a plurality of wells of a multi-well plate (or a plurality of wells on multiple multi-well plates).
- a group of systems may correspond to a group of wells of a plurality of wells.
- a method may comprise adding a T-cell as described herein to each well of a plurality of wells of a multi-well plate.
- a method may comprise adding a T-cell as described herein to each system of a plurality of systems.
- the cells may be added in tissue culture media such as RPMI media, which may comprise serum (e.g. FBS).
- the tissue culture media may optionally comprise L-glutamine.
- the tissue culture media may optionally comprise an antibiotic, such as a penicillin (e.g. , penicillin G), an aminoglycoside (e.g. , streptomycin, gentamicin), and/or an aminonucleoside (e.g. , puromycin).
- a T-cell may or may not comprise a genetic modification such as a gene knockout, gene knockdown, or a recombinant gene (i.e. , in addition to the two or more recombinant genes encoding checkpoint receptors).
- Each T-cell added to a system may be from the same species or cell line.
- each T-cell may be a Jurkat cell.
- Each T-cell added to a system of a plurality of systems may comprise recombinant gene(s) encoding the same checkpoint receptors, e.g. , each T-cell may be descendant from the same parent cell, wherein the cell lineage defined by the parent cell is engineered to inducibly express two or more checkpoint receptors.
- T-cells of individual systems may nevertheless vary.
- a T-cell may further comprise a gene knockout, gene knockdown, or additional recombinant gene that has been engineered into the T-cell on top of the genes encoding the two or more checkpoint receptors.
- a method may comprise adding a knockout T-cell to a first group of systems of a plurality of systems.
- the knockout T-cell may be engineered to inducibly express two or more checkpoint receptors and the knockout T-cell may comprise a gene knockout.
- the method may further comprise adding a wild type T-cell to a second group of systems of the plurality of systems.
- the wild type T-cell may be engineered to inducibly express the two or more checkpoint receptors and the wild type T-cell may lack the gene knockout.
- a wild type T-cell and knockout T-cell may be descendent from the same parent cell, e.g. , wherein the parent cell comprised genes encoding the two or more checkpoint receptors and wherein the parent cell lacked the gene knockout.
- a plurality of systems may consist of the first group of systems and the second group of systems. In some embodiments, the first group and second group do not overlap.
- a method may further comprise adding a transcription inducer to a group of systems (e.g. , a third group of systems).
- the transcription inducer may be doxycycline, which may be added at a concentration of about 50 ng/mL to about 1000 ng/mL, such as about 100 ng/mL to about 500 ng/mL or about 200 ng/mL to about 300 ng/mL.
- the group of systems may be a subset of a plurality of systems. Systems that do not comprise the transcription inducer may serve as relevant controls.
- a method may further comprise incubating the T-cells of a plurality of systems (e.g. , after adding the T-cells to a plurality of systems and after adding the transcription inducer to a group of systems).
- the T-cells may be incubated at about 37°C.
- the T-cells may be incubated for about 6 hours to about 7 days, such as about 12 hours to about 96 hours, about 24 hours to about 72 hours, or about 36 hours to about 50 hours.
- the T-cells may be incubated for at least about 6 hours, 12 hours, 24 hours, 30 hours, 36 hours, 42 hours, or 48 hours.
- a method may further comprise washing the T-cells of a plurality of systems (e.g. , after adding a transcription inducer to a group of systems and/or prior to adding a costimulatory ligand).
- the T-cells may be washed in tissue culture media. Washing the T- cells may reduce the concentration of a transcription inducer in the tissue culture media.
- a method may further comprise adding a costimulatory ligand as described herein (e.g. , anti-CD3 antibody-coated beads) to each system of a plurality of systems.
- the costimulatory ligand may be added to each system of a plurality of systems about 6 hours to about 7 days after adding the transcription inducer, such as about 12 hours to about 96 hours, about 24 hours to about 72 hours, or about 36 hours to about 50 hours.
- the costimulatory ligand may be added to each system of a plurality of systems at least about 6 hours, 12 hours, 24 hours, 30 hours, 36 hours, 42 hours, or 48 hours after adding the transcription inducer to a group of systems.
- the costimulatory ligand may be added to each system of a plurality of systems after washing the T-cells of a plurality of systems to reduce the concentration of a transcription inducer.
- a method may comprise adding one or more pharmaceutical agents to systems of the plurality.
- a method may comprise adding a first pharmaceutical agent to each system of a group of systems (e.g. , a fourth group of systems).
- a first pharmaceutical agent may be a large molecule (e.g. , antibody, such as an anti-PD-1 or anti-CTLA-4 antibody) or a small molecule compound (e.g. , kinase inhibitor).
- a first pharmaceutical agent may be added to a system that was contacted with a transcription inducer, e.g. , to determine whether the first pharmaceutical agent can increase the activation state of a T-cell expressing two or more checkpoint receptors in the presence of checkpoint receptor ligands.
- a first pharmaceutical agent may be added to a system that was not contacted with a transcription inducer, e.g. , as a control.
- a first pharmaceutical agent may be added to a system comprising a knockout T- cell, e.g. , to determine whether the first pharmaceutical agent increases T-cell activation through a signaling pathway mediated by the knockout gene.
- a first pharmaceutical agent may be added to a system comprising a wild type T-cell, e.g. , as a control.
- a method may comprise adding a second pharmaceutical agent to a group of systems (e.g. , a fifth group of systems).
- a second pharmaceutical agent may be a large molecule or a small molecule compound.
- the first pharmaceutical agent and the second pharmaceutical agent may be antibodies, e.g. , the first pharmaceutical agent may be an anti- PD- 1 antibody and the second pharmaceutical agent may be an anti-CTLA-4 antibody.
- the first pharmaceutical agent and the second pharmaceutical agent may both be small molecule compounds, or the first pharmaceutical agent may be a large molecule and the second pharmaceutical agent may be a small molecule compound.
- the first pharmaceutical agent and the second pharmaceutical agent may both be added to at least one discrete system, e.g. , to assess whether the two pharmaceutical agents display an additive or synergistic effect.
- the at least one system may comprise a system that was contacted with the transcription inducer.
- the at least one system may comprise a system that was not contacted with the transcription inducer, e.g. , to serve as a control.
- the first pharmaceutical agent may be added to at least one system to which the second pharmaceutical agent is not added, e.g. to serve as a control.
- the second pharmaceutical agent may be added to at least one system to which the first pharmaceutical agent is not added, e.g. to serve as a control.
- a plurality of systems may comprise a system to which neither the first pharmaceutical agent nor the second
- pharmaceutical agent is added, e.g. , to serve as a control.
- a method may comprise adding a third pharmaceutical agent to a group of systems
- a third pharmaceutical agent may be a large molecule or a small molecule compound.
- the first pharmaceutical agent and the second pharmaceutical agent may be antibodies (e.g. , anti-PD-1 and anti-CTLA-4 antibodies, respectively), and the third pharmaceutical agent may be a small molecule compound (e.g. , a kinase inhibitor).
- the first pharmaceutical agent, second pharmaceutical agent, and third pharmaceutical agent may each be added to at least one discrete system, e.g. , to assess whether the three pharmaceutical agents display an additive or synergistic effect.
- the at least one system may comprise a system that was contacted with the transcription inducer.
- the at least one system may comprise a system that was not contacted with the transcription inducer, e.g. , to serve as a control.
- the first pharmaceutical agent may be added to at least one system to which the second pharmaceutical agent and third pharmaceutical agent are not added, e.g. to serve as a control.
- the second pharmaceutical agent may be added to at least one system to which the first pharmaceutical agent and third pharmaceutical agent are not added, e.g. to serve as a control.
- the third pharmaceutical agent may be added to at least one system to which the second pharmaceutical agent and first pharmaceutical agent are not added, e.g. to serve as a control.
- a plurality of systems may comprise a system to which neither the first pharmaceutical agent, second pharmaceutical agent, nor third pharmaceutical agent is added, e.g. , to serve as a control.
- Each permutation of the three pharmaceutical agents may be added to systems that were contacted with the transcription inducer.
- Various permutations of the three pharmaceutical agents may be added to systems that were not contacted with the transcription inducer,
- a method may comprise adding a fourth pharmaceutical agent to a group of systems (e.g. , a seventh group of systems).
- a fourth pharmaceutical agent may be a large molecule or a small molecule compound.
- the third pharmaceutical agent may be a small molecule compound and the fourth pharmaceutical agent may be a small molecule compound.
- a pharmaceutical agent may be added at a concentration of about 0.1 ⁇ g/mL to about 100 ⁇ g/mL, such as about 1 ⁇ g/mL to about 50 ⁇ g/mL, about 0.1 ⁇ g/mL to about 10 ⁇ g/mL, about 0.1 ⁇ g/mL to about 1 ⁇ g/mL, about 1 ⁇ g/mL to about 10 ⁇ g/mL, about 5 ⁇ g/mL to about 20 ⁇ g/mL, about 10 ⁇ g/mL to about 30 ⁇ g/mL, or about 20 ⁇ g/mL to about 50 ⁇ g/mL (e.g. , wherein the pharmaceutical agent is a large molecule, such as an antibody).
- a pharmaceutical agent may be added at a concentration of about 100 pM to about 10 ⁇ , such as about 100 pM to about 10 nM, about 500 pM to about 50 nM, about 1 nM to about 100 nM, about 5 nM to about 500 nM, about 10 nM to about 1 ⁇ , about 50 nM to about 5 ⁇ , about 100 pM to about 10 nM, about 500 pM to about 100 nM, about 1 nM to about 500 nM, about 1 nM to about 1 ⁇ , or about 1 nM to about 5 ⁇ (e.g. , for small molecule compounds).
- a method may further comprise adding a ligand-presenting cell to each system of a plurality of systems.
- the same ligand-presenting cell (e.g., different cells from the same cell line) may be added to each system.
- the ligand-presenting cell may be a B-cell, such as a Raji cell.
- the ligand-presenting cell may be a cell that is engineered to express a ligand of a checkpoint receptor (e.g. , PD-L1, PD-L2, B7.1, B7.2).
- the ligand-presenting cell may be added at a ratio of about 1: 10 to 10: 1 relative to the T-cell, such as about 1 :5 to about 5: 1, about 1 :4 to about 4: 1, about 1 :3 to about 3: 1, or about 1 :2 to about 2: 1.
- the ligand- presenting cell may be added after adding the costimulatory ligand.
- the ligand-presenting cell may be added after adding the one or more pharmaceutical agents.
- a method may comprise measuring a concentration of a biomarker.
- Measuring the concentration of the biomarker may comprise measuring the concentration of the biomarker in the supernatant of a system. Measuring may comprise performing an enzyme-linked immunosorbent assay (ELISA) or other colorimetric immunoassay.
- the biomarker may be interleukin-2 or interferon ⁇ .
- a method may comprise contacting a system or supernatant thereof with one or more of a primary antibody, an anti-interleukin-2 antibody, an anti- interferon ⁇ antibody, a secondary antibody, an anti-IgG antibody, an antibody-fluorophore conjugate, an antibody-biotin conjugate, an antibody-enzyme conjugate, a colorimetric substrate for horseradish peroxidase, and a colorimetric substrate for alkaline phosphatase.
- a method may comprise contacting each system of a plurality of systems (or the supernatants thereof) with one or more of a primary antibody, an anti-interleukin-2 antibody, an anti- interferon ⁇ antibody, a secondary antibody, an anti-IgG antibody, an antibody-fluorophore conjugate, an antibody-biotin conjugate, an antibody-enzyme conjugate, a colorimetric substrate for horseradish peroxidase, and a colorimetric substrate for alkaline phosphatase.
- a method may further comprise comparing the relative concentration of the biomarker in at least one system of the plurality of systems to the relative concentration of the biomarker in at least one other system of the plurality of systems.
- a method may comprise providing an inducible T-cell system as described herein.
- the inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a checkpoint receptor ligand-presenting cell engineered to
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor such as CD28.
- TCR T-cell receptor
- the T-cell may be a Jurkat cell.
- the ligand-presenting cell may express a costimulatory ligand (e.g. , B7.1 and/or B7.2).
- the costimulatory ligand may be useful to provide a costimulatory signal.
- the ligand-presenting cell may be a B-cell, such as a Raji cell.
- the T-cell may comprise a gene knockout or knockdown, as described herein, supra.
- a gene knockout may be made, for example, using a CRISPR/Cas9 strategy.
- the T-cell engineered to inducibly express two or more checkpoint receptors may therefore be a T-cell comprising a gene knockout or knockdown, such as a gene knockout generated using a CRISPR/Cas9 strategy.
- a method may comprise providing a CRISPR/Cas9 system to knockout a candidate T-cell gene.
- a method may further comprise inducing the expression of the two or more checkpoint receptors in the T-cell.
- the two or more checkpoint receptors may be operably-linked to a promoter that is inducible by doxycycline, and inducing the expression of two or more checkpoint receptors may comprise contacting the T-cell (or the inducible T-cell system) with doxycycline.
- TCR signaling (e.g. , T-cell activation) is measurable by monitoring the interleukin-2 (IL2) expression of a T-cell.
- IL2 interleukin-2
- a method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in a non-induced control T-cell.
- a method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in an induced control T-cell that does not comprise the gene knockout or gene knockdown.
- a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in a non-induced control T-cell.
- a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in an induced control T-cell that does not comprise the gene knockout or gene knockdown.
- a method may thereby identify if the candidate T-cell gene is a T-cell checkpoint target gene.
- a method of discovering or validating a drug target comprising providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon ⁇ ) in at least two systems of the plurality.
- a biomarker associated with T-cell activation e.g. , interleukin-2 or interferon ⁇
- a plurality of inducible T-cell systems may include a system comprising a T-cell having a knockout or knockdown of a gene encoding the drug target.
- the plurality may further include a system comprising a T-cell lacking the knockout or knockdown of the gene.
- the method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising the knockout or knockdown and the T-cell system lacking the knockout or knockdown.
- the drug target is validated if the system comprising the T-cell having the knockout or knockdown displays increased T-cell activation relative to the system
- a method may comprise providing an inducible T-cell system as described herein.
- the inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a checkpoint receptor ligand-presenting cell engineered to constitutively express one or more checkpoint receptor ligands; and/or an anti-CD3 antibody to stimulate TCR signaling.
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor such as CD28.
- the T-cell may be a Jurkat cell.
- the ligand-presenting cell may express a costimulatory ligand (e.g. , B7.1 and/or B7.2). The costimulatory ligand may be useful to provide a costimulatory signal.
- the ligand-presenting cell may be a B-cell, such as a Raji cell.
- a method may further comprise inducing the expression of the two or more checkpoint receptors in the T-cell.
- the two or more checkpoint receptors may be operably-linked to a promoter that is inducible by doxycycline, and inducing the expression of two or more checkpoint receptors may comprise contacting the T-cell (or the inducible T-cell system) with doxycycline.
- a method may further comprise contacting the T-cell (or inducible T-cell system) with one or more candidate compounds.
- a candidate compound may be, for example, a pharmaceutical agent, such as a small molecule compound or a large molecule as described herein, supra.
- TCR signaling (e.g. , T-cell activation) is measurable by monitoring the interleukin-2 (IL2) expression of a T-cell.
- IL2 interleukin-2
- a method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in a non-induced control T-cell.
- a method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in an induced control T-cell that is not contacted with the one or more candidate compounds.
- TCR signaling is measurable by monitoring other molecules, such as interferon ⁇ (INFy), and thus, a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in a non-induced control T-cell. A method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in an induced control T-cell that is not contacted with the one or more candidate compounds.
- INFy interferon ⁇
- a method may thereby identify if the one or more candidate compounds are checkpoint inhibitors.
- a method of determining whether a small molecule compound affects T-cell activation comprising providing a plurality of inducible T- cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon ⁇ ) in at least two systems of the plurality.
- a biomarker associated with T-cell activation e.g. , interleukin-2 or interferon ⁇
- a plurality of inducible T-cell systems may include a system comprising the small molecule compound.
- the plurality may further include a system lacking the small molecule compound.
- the method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising the small molecule compound and the T-cell system lacking the small molecule compound.
- the small molecule compound affects T-cell activation if the system comprising the small molecule compound displays different T-cell activation relative to the system lacking small molecule compound.
- a small molecule compound may be a viable drug candidate for use in treating cancer or infection, for example, if the system comprising the small molecule compound displays increased T-cell activation relative to the system lacking small molecule compound.
- a small molecule compound may be a viable drug candidate for use in autoimmune disease, for example, if the system comprising the small molecule compound displays attenuated T-cell activation relative to the system lacking small molecule compound.
- a method may comprise providing an inducible T-cell system as described herein.
- the inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a checkpoint receptor ligand-presenting cell engineered to constitutively express one or more checkpoint receptor ligands; and/or an anti- CD3 antibody to stimulate TCR signaling.
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor such as CD28.
- the T-cell may be a Jurkat cell.
- the ligand- presenting cell may express a costimulatory ligand (e.g. , B7.1 and/or B7.2).
- the costimulatory ligand may be useful to provide a costimulatory signal.
- the ligand-presenting cell may be a B-cell, such as a Raji cell.
- a method may further comprise inducing the expression of the two or more checkpoint receptors in the T-cell.
- the two or more checkpoint receptors may be operably-linked to a promoter that is inducible by doxycycline, and inducing the expression of two or more checkpoint receptors may comprise contacting the T-cell (or the inducible T-cell system) with doxycycline.
- a method may further comprise contacting the T-cell (or inducible T-cell system) with two or more checkpoint inhibitors.
- a checkpoint inhibitory drug may be, for example, an FDA-approved checkpoint inhibitory drug.
- a checkpoint inhibitory drug may be a monoclonal antibody, such as an anti-CTLA or anti-PD-1 antibody.
- the two or more checkpoint inhibitors may comprise a small molecule compound as described herein, supra.
- TCR signaling (e.g. , T-cell activation) is measurable by monitoring the interleukin-2 (IL2) expression of a T-cell.
- a method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in a non-induced control T-cell.
- a method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in an induced control T-cell that is contacted with less than two or more checkpoint inhibitors, such as a single individual checkpoint inhibitor.
- TCR signaling is also measurable by monitoring other molecules, such as interferon ⁇ (INFy), and thus, a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in a non-induced control T-cell.
- a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in an induced control T-cell that is contacted with less than two or more checkpoint inhibitors, such as a single individual checkpoint inhibitor.
- a method may thereby assess the interaction between the one or more checkpoint inhibitors.
- a method of assessing an interaction between a small molecule compound and an antibody that binds a checkpoint receptor may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon ⁇ ) in at least two systems of the plurality.
- a biomarker associated with T-cell activation e.g. , interleukin-2 or interferon ⁇
- a plurality of inducible T-cell systems may include a system comprising both the small molecule compound and the antibody.
- the plurality may further include a system comprising the small molecule compound and lacking the antibody, a system lacking the small molecule compound and comprising the antibody, and/or a system lacking the small molecule compound and lacking the antibody.
- a method of assessing an interaction between a first small molecule compound and a second small molecule compound may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon ⁇ ) in at least two systems of the plurality.
- a biomarker associated with T-cell activation e.g. , interleukin-2 or interferon ⁇
- a plurality of inducible T-cell systems may include a system comprising the first small molecule compound and the second small molecule compound.
- the plurality may further include a system comprising the first small molecule compound and lacking the second small molecule compound, a system lacking the first small molecule compound and comprising the second small molecule compound, and/or a system lacking both the first small molecule compound and the second small molecule compound.
- Various aspects of the invention relate to a method of assessing an interaction between a first large molecule and a second large molecule.
- the method may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon ⁇ ) in at least two systems of the plurality.
- a biomarker associated with T-cell activation e.g. , interleukin-2 or interferon ⁇
- a plurality of inducible T- cell systems may include a system comprising both the first large molecule and the second large molecule.
- the plurality may further include a system comprising the first large molecule and lacking the second large molecule, a system lacking the first large molecule and comprising the second large molecule, and/or a system lacking both the first large molecule and the second large molecule.
- a method may comprise providing an inducible T- cell system as described herein.
- the inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a checkpoint receptor ligand-presenting cell engineered to constitutively express one or more checkpoint receptor ligands; and/or an anti-CD3 antibody to stimulate TCR signaling.
- the T-cell may express the T-cell receptor (TCR) and a costimulatory receptor such as CD28.
- the T-cell may be a Jurkat cell.
- the ligand-presenting cell may express a costimulatory ligand (e.g. , B7.1 and/or B7.2). The costimulatory ligand may be useful to provide a costimulatory signal.
- the ligand-presenting cell may be a B-cell, such as a Raji cell.
- the T-cell may comprise a gene knockout or knockdown, as described herein, supra.
- a gene knockout may be made, for example, using a CRISPR/Cas9 strategy.
- the T-cell engineered to inducibly express two or more checkpoint receptors may therefore be a T-cell comprising a gene knockout or knockdown, such as a gene knockout generated using a CRISPR/Cas9 strategy.
- a method may comprise providing a CRISPR/Cas9 system to knockout a candidate T-cell gene.
- a method may further comprise inducing the expression of the two or more checkpoint receptors in the T-cell.
- the two or more checkpoint receptors may be operably-linked to a promoter that is inducible by doxycycline, and inducing the expression of two or more checkpoint receptors may comprise contacting the T-cell (or the inducible T-cell system) with doxycycline.
- a method may further comprise contacting the T-cell (or the inducible T-cell system) with a pharmaceutical agent, such as a small molecule compound.
- a pharmaceutical agent such as a small molecule compound.
- the pharmaceutical agent may specifically bind and/or inhibit the product encoded by the knockout gene or knockdown gene, or the pharmaceutical agent may specifically bind and/or inhibit a molecule upstream or downstream of the product in a signaling pathway that includes the product.
- the gene knockout or gene knockdown may be a kinase and the pharmaceutical agent may be a kinase inhibitor.
- the gene knockout or gene knockdown may be a substrate of a kinase and the pharmaceutical agent may be a kinase inhibitor.
- TCR signaling (e.g. , T-cell activation) is measurable by monitoring the interleukin-2 (IL2) expression of a T-cell.
- IL2 interleukin-2
- a method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in a non-induced control T-cell.
- a method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in an induced control T-cell that does not comprise the gene knockout or gene knockdown.
- a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in a non-induced control T-cell.
- a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in an induced control T-cell that does not comprise the gene knockout or gene knockdown.
- a method may thereby identify if the candidate T-cell gene is a T-cell checkpoint target gene.
- a protein affects T-cell activation through a signaling pathway mediated by a checkpoint receptor.
- the protein may be, for example, a kinase or phosphatase.
- the method may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g., interleukin-2 or interferon ⁇ ) in at least two systems of the plurality.
- a plurality of inducible T- cell systems may include a system comprising a checkpoint inhibitory antibody and a T-cell having a knockout or knockdown of a gene encoding the protein.
- the plurality may further include a system comprising the checkpoint inhibitory antibody and comprising a T-cell lacking the knockout or knockdown of the gene, a system lacking the checkpoint inhibitory antibody and comprising a T-cell having the knockout or knockdown of the gene, and/or a system lacking the checkpoint inhibitory antibody and comprising a T-cell lacking the knockout or knockdown of the gene.
- the method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising the checkpoint inhibitor antibody and T-cell comprising the knockout or knockdown with a T-cell system lacking either the checkpoint inhibitor antibody, the knockout/knockdown, or both.
- a protein affects T-cell activation through a signaling pathway mediated by the checkpoint receptor targeted by the checkpoint inhibitory antibody if T-cell activation in the system comprising the checkpoint inhibitory antibody and knockout/knockdown is different from the system comprising the checkpoint inhibitory antibody and lacking the knockout/knockdown.
- a method of assessing whether a pharmaceutical agent displays an ON target or OFF target effect may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon ⁇ ) in at least two systems of the plurality.
- a biomarker associated with T-cell activation e.g. , interleukin-2 or interferon ⁇
- a plurality of inducible T- cell systems may include a system comprising both a pharmaceutical agent and a T-cell having a knockout or knockdown of a gene encoding the target.
- the plurality may further include a system comprising the pharmaceutical agent and a T-cell lacking the knockout or knockdown of the gene, a system lacking the pharmaceutical agent and comprising a T-cell having the knockout or knockdown of the gene, and/or a system lacking the pharmaceutical agent and comprising a T-cell lacking the knockout or knockdown of the gene.
- the method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising both the pharmaceutical agent and the T-cell comprising the knockout or knockdown with a T-cell system lacking either the pharmaceutical agent, the
- the pharmaceutical agent may display an ON target effect, for example, if the system comprising the pharmaceutical agent and knockout/knockdown displays similar T-cell activation as the system comprising the pharmaceutical agent and lacking the knockout/knockdown and/or similar T-cell activation as the system lacking the pharmaceutical agent and comprising the knockout/knockdown.
- Example 1 T-cells expressing doxy cycline -inducible PD-1 and CTLA-4
- Jurkat cells which are immortalized human T-cells, were transfected with a gene for checkpoint receptor PD- 1 operably-linked to a doxycycline-inducible promoter and a gene for checkpoint receptor CTLA-4 operably-linked to a doxycycline-inducible promoter.
- human checkpoint receptor cDNAs for PD- 1 and CTLA-4 were cloned into a pLVX- TetOne vector (Clontech) under the control of the doxycycline inducible TRE3G promoter.
- Jurkat cells were infected with lenti viral vectors pLVX-TetOne-PD-1 and pLVX-TetOne- CTLA-4 thereby generating a T-cell line configured to inducibly express PD-1 and CTLA-4.
- FIG. 1 includes a drawing of a T-cell expressing PD-1 and CTLA-4 transgenes as well as CD28 and the T-cell receptor (TCR).
- CD28 is a costimulatory receptor required for T-cell activation and survival.
- T-cell stimulation through CD28 in addition to the T-cell receptor can provide a potent signal for the production of various cytokines including interleukin-2 (IL2).
- IL2 interleukin-2
- CD28 may be activated by ligands B7.1 (CD80) and B7.2 (CD86) as well as certain anti-CD28 antibodies.
- the T-cell receptor may be activated by engaging an antigen bound to a major histocompatibility complex (MHC) molecule or by engaging an anti-TCR antibody such as an anti-CD3 antibody.
- MHC major histocompatibility complex
- Example 2 B-cells constitutively expressing PD-L1 or PD-L2
- Raji cells which are immortalized human B-cells, were transfected with a gene for either PD-L1 or PD-L2. Briefly, human checkpoint ligand cDNAs for PD-L1 and PD-L2 were each cloned into a pLVX-IRES-Puro vector (Clontech) under expression of a constitutive CMV promoter. Raji cells were infected with a lentiviral vector pLVX-IRES- Puro-PD-Ll or pLVX-IRES-Puro-PD-L2, thereby generating B-cells that constitutively express either PD-L1 or PD-L2.
- PD-L1 and PD-L2 are checkpoint receptor ligands, which bind to checkpoint receptor PD-1, thereby inhibiting T-cell activation.
- Raji cells also endogenously express checkpoint receptor ligands B7.1 (CD80) and B7.2 (CD86), which bind to checkpoint receptor CTLA-4.
- B7.1 and B7.2 may also activate T-cells by binding CD28.
- Figure 1 includes a drawing of a B-cell expressing either a PD-L1 transgene or a PD-L2 transgene (PD-L1/PD-L2) as well as B7.1 and B7.2 (B-7.1/B-7.2).
- Example 3 Expression of PD-1 and CTLA-4 checkpoint receptors in the presence of a PD-1 checkpoint ligand (PD-L1 or PD-L2) and a CTLA-4 checkpoint ligand (B7.1 or B7.2) decreases ⁇ -cell-mediated interleukin-2 production
- the Jurkat cells expressing inducible PD-1 and CTLA-4 transgenes described in Example 1 were combined with (a) the Raji cells constitutively expressing either a PD-L1 or PD-L2 transgene as well as B7.1 and B7.2 as described in Example 2 and (b) anti-CD3 beads (CD3 Ab).
- the anti-CD3 beads were prepared by coating anti-human CD3 antibodies from eBioscience to Dynabeads M-450 Epoxy beads from Invitrogen using Invitrogen' s coating protocol. Briefly, 700 of Dynabeads M-450 Epoxy beads were separated from
- the beads were resuspended in 1120 ⁇ , of 0.1% BSA in PBS (pH 7.4) resulting in a lOx stock solution of 200,000 beads per 10 ⁇ ,. Prior to adding the beads to cells, the PBS is removed and the beads were diluted with RPMI media containing 10% fetal bovine serum (FBS).
- FBS fetal bovine serum
- the inducible Jurkat cells described in Example 1 were induced with 250 ng/niL doxycycline for 2 days. Control samples without doxycycline were cultured in parallel. After the 2 days, the cell media was changed to wash out the doxycycline, and the cells were diluted to 1,000,000 cells in 900 ⁇ , of RPMI media containing 10% fetal bovine serum (FBS). Raji cells constitutively expressing either PD-Ll or PD-L2 as described in Example 2 were diluted to 1,000,000 cells in 1000 ⁇ , of RPMI media containing 10% FBS. 2,000,000 anti-CD3 beads in 50 ⁇ , were added to 450 ⁇ , of the Jurkat cells (500,000 cells), i.e.
- FBS fetal bovine serum
- the 96-well plates were centrifuged at 1000 rpm for 5 minutes. 150 ⁇ ⁇ of supernatant was transferred into a new 96-well U-bottomed plate. The new 96-well plate was optionally frozen. 100 ⁇ , of supernatant was then used in an interleukin-2 (IL2) ELISA to determine the concentration of IL2 secreted by the Jurkat cells.
- IL2 interleukin-2
- the anti-PD-1 antibody nivolumab (Nivo; N) and/or the anti-CTLA-4 antibody ipilimumab (Ipi; I) were added to the Jurkat/Raji/anti-CD3 bead system described in Example 3. Briefly, 5-25 ⁇ g of nivolumab and/or ipilimumab was added to Jurkat cells in a protocol similar to that described in Example 3. The antibodies were added to the system after adding the anti-CD3 beads to the Jurkat cells and before incubating the Jurkat cells for 30 minutes at room temperature. A control IgG antibody (IgG) was added to a different sample as a negative control.
- IgG IgG
- Example 5 T-cells expressing inducible PD-1 and CTLA-4 and comprising a gene knockout display increased interleukin-2 expression
- a gene involved in the negative regulation of T-cells was knocked out of the Jurkat cells described in Example 1 using a CRISPR/Cas9 knockout strategy. Briefly, single guide RNAs (sgRNAs) and Cas9 were co-delivered to the Jurkat cells described in Example 1 using a single lentiviral vector. The knockout cells were incubated with Raji cells, anti-CD3 beads, and doxycycline as described in Example 3. The knockout cells displayed high interleukin-2 (IL2) secretion, suggesting that the knockout gene could be targeted to activate T-cells in the context of immune checkpoint inhibition (Figure 4).
- sgRNAs single guide RNAs
- Cas9 single guide RNAs
- the knockout cells were incubated with Raji cells, anti-CD3 beads, and doxycycline as described in Example 3.
- the knockout cells displayed high interleukin-2 (IL2) secretion, suggesting that the knockout gene could be targeted to activate T-cells in the context of immune check
- the knockout cells were incubated with Raji cells, anti-CD3 beads, doxycycline, anti- PD-1 antibody nivolumab (Nivo; N), and anti-CTLA-4 antibody ipilimumab (Ipi; I) as described in Example 4.
- the gene knockout and the anti-PD- 1 and anti-CTLA-4 antibodies displayed an additive effect on interleukin-2 (IL2) secretion ( Figure 5, experiments "3,” “4,” and “5"). This finding suggests that a drug that inhibits the product of the knockout gene will display an additive effect when used in combination with nivolumab and/or ipilimumab.
- IL2 interleukin-2
- Jurkat cells, Raji cells, and anti-CD3 beads were incubated in the presence of doxycycline as described in Example 3 and either (a) anti-PD-1 antibody nivolumab and anti- CTLA-4 antibody ipilimumab (b) small molecule compound 1 or small molecule compound 2, or (c) nivolumab, ipilimumab, and either compound 1 or compound 2.
- the small molecules compound 1 and compound 2 displayed a synergistic effect on interleukin-2 (IL2) secretion in combination with both nivolumab and ipilimumab ( Figure 5, experiments "3,” “6,” and “7").
- IL2 interleukin-2
- Example 7 The effect of small molecules on T-cell mediated interleukin-2 secretion disappears in T-cells comprising a gene knockout
- Inducible T-cells comprising or lacking a gene knockout were incubated with Raji cells, anti-CD3 beads, doxycycline, and either compound 1, compound 2, or vehicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides, among other things, an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors; a B- cell engineered to constitutively express one or more checkpoint receptor ligands; and an anti-CD3 antibody to stimulate T-cell receptor signaling. The inducible T-cell system may be used in (1) the discovery and validation of novel drug targets, for example, by knocking out a gene of the T-cell, (2) screening small molecule compounds, (3) testing interactions between small molecule compounds and checkpoint inhibitory antibodies, and (4) testing whether small molecule compounds affect T-cells through the specific inhibition of a target gene.
Description
INDUCIBLE T-CELL SYSTEM AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority to United States Provisional Patent Application serial number 62/408,547 filed on October 14, 2016, the entirety of which is hereby incorporated by reference.
BACKGROUND
The testing of therapeutic combinations between pharmaceuticals that act on checkpoint inhibitor pathways and intracellular targets currently requires complicated and time consuming mouse experiments. Mouse experiments are further limited as they cannot precisely replicate human physiology. Improved methods of testing therapeutic combination treatments in human- like systems are therefore desirable. SUMMARY OF THE INVENTION
In some aspects, the invention relates to an inducible T-cell system. An inducible T- cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors. The T-cell may express the T-cell receptor (TCR) and a costimulatory receptor. The inducible T-cell system may comprise a ligand-presenting cell (e.g. , a B-cell) engineered to constitutively express one or more checkpoint receptor ligands. The ligand-presenting cell may express a costimulatory ligand. The inducible T-cell system may comprise an anti-CD3 antibody, e.g. , to stimulate TCR signaling.
The T-cell may be a Jurkat cell. The ligand-presenting cell may be a B-cell or an antigen-presenting cell. The ligand-presenting cell may be a Raji cell. The T-cell and/or B- cell may be derived from a human cell line.
The ligand-presenting cell may be derived from a human or non-human cell, and the one or more checkpoint receptor ligands may be human checkpoint receptor ligands. The ligand-presenting cell may be derived from a human or non-human cell, and the
costimulatory ligand may be a human costimulatory ligand.
The two or more checkpoint receptors may comprise PD-1 and CTLA-4. The one or more checkpoint receptor ligands may comprise PD-L1 and/or PD-L2. The two or more checkpoint receptors may comprise PD-1, CTLA-4, PD-1H, LAG- 3, BTLA, KIR2D, TIM-3, ADORA2A, CD 160, 2B4, TIGIT, and/or interleukin-10 receptor. The one or more
checkpoint receptor ligands may comprise PD-L1, PD-L2, B7.1, B7.2, B7-H4, B7-H2, B7- H7, MHC class II, HVEM, CD155, galectin-9, and/or TIM-3 ligand.
The costimulatory receptor may be CD28. The costimulatory ligand expressed by the ligand-presenting cell may be B7.1 or B7.2.
The expression of the two or more checkpoint receptors may be controlled by a promoter inducible by doxycycline (dox).
The anti-CD3 antibody may be associated with a bead.
The inducible T-cell system may further comprise reagents to determine the expression of interleukin-2 or interferon γ by the T-cell. For example, the reagents may be selected from a primary antibody, an anti-interleukin-2 antibody, an anti-interferon γ antibody, a secondary antibody, an anti-IgG antibody, an antibody-fluorophore conjugate, an antibody-biotin conjugate, an antibody-enzyme conjugate, a colorimetric substrate for horseradish peroxidase, and a colorimetric substrate for alkaline phosphatase.
The T-cell may further comprise a gene knockout or knockdown. The gene knockout or knockdown may be a lymphoid lineage gene knockout or knockdown. A lymphoid lineage gene may be a T-cell gene. A knockout may be a CRISPR/Cas9-mediated knockout.
The inducible T-cell system may further comprise one or more pharmaceutical agents. The one or more pharmaceutical agents may comprise a small molecule compound and/or a large molecule (e.g. , an antibody).
In some aspects, the invention relates to a method of identifying small molecule T-cell activators. The method may comprise providing an inducible T-cell system comprising a T- cell engineered to inducibly express two or more checkpoint receptors. The T-cell may express the T-cell receptor (TCR) and a costimulatory receptor. The method may comprise providing a B-cell engineered to constitutively express one or more checkpoint receptor ligands. The B-cell may express a costimulatory ligand to provide a costimulatory signal. The method may comprise providing an anti-CD3 antibody to stimulate TCR signaling. The TCR signaling may be measurable by IL-2 expression of the T-cell (or interferon γ expression).
The method may comprise inducing the expression of the two or more checkpoint receptors in the T-cell. The method may comprise contacting the T-cell of the inducible T- cell system with one or more candidate compounds. The method may comprise determining the level of IL-2 expression (or interferon γ expression) of the T-cell as compared to a control level of IL-2 expression (or interferon γ expression) of a non-induced control T-cell, thereby identifying if the one or more candidate compounds are T-cell activators.
In some aspects, the invention relates to a method of assessing interactions between T-cell activators and checkpoint inhibitory antibodies. The method may comprise providing an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors. The T-cell may express the T-cell receptor (TCR) and a costimulatory receptor. The method may comprise providing a B-cell engineered to constitutively express one or more checkpoint receptor ligands. The B-cell may express a costimulatory ligand to provide a costimulatory signal. The method may comprise providing an anti-CD3 antibody to stimulate TCR signaling. The TCR signaling may be measurable by IL-2 expression of the T-cell (or interferon γ expression).
The method may comprise inducing the expression of the two or more checkpoint receptors in the T-cell. The method may further comprise contacting the T-cell of the inducible T-cell system with one or more candidate compounds. The method may further comprise contacting the T-cell of the inducible T-cell system with one, two, or more checkpoint inhibitory antibodies. The method may further comprise determining the level of IL-2 expression (or interferon γ expression) of the T-cell as compared to the level of IL-2 expression (or interferon γ expression) of an otherwise identical inducible T-cell system but contacted with only one or more candidate compounds, thereby assessing the interaction between one or more candidate compounds and the one, two, or more checkpoint inhibitory antibodies.
The one, two, or more checkpoint inhibitory antibodies may comprise an FDA approved checkpoint inhibitory drug. The FDA approved checkpoint inhibitory drug may be a monoclonal antibody. The one or more candidate compounds may comprise a small molecule compound.
In some aspects, the invention relates to a method of validating a T-cell target gene. The method may comprise providing an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors. The T-cell may further comprise a candidate T-cell gene knockout. The T-cell may express the T-cell receptor (TCR) and a costimulatory receptor. The method may comprise providing a B-cell engineered to constitutively express one or more checkpoint receptor ligands. The B-cell may express a costimulatory ligand to provide a costimulatory signal. The method may comprise providing an anti-CD3 antibody to stimulate TCR signaling. The TCR signaling may be measurable by IL-2 expression of the T-cell (or interferon γ expression).
The method may comprise inducing the expression of the two or more checkpoint receptors in the T-cell. The method may comprise determining the level of IL-2 expression
(or interferon γ expression) of the T-cell as compared to a control level of IL-2 expression (or interferon γ expression) of a non-induced control T-cell, thereby determining if the candidate T-cell gene is a T-cell checkpoint-independent target gene.
In some aspects, the invention relates to a method of interrogating ON or OFF target activity of a small molecule compound. The method may comprise providing an inducible T- cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors. The T-cell may further comprise a candidate T-cell gene knockout. The T-cell may express the T-cell receptor (TCR) and a costimulatory receptor. The method may comprise providing a B-cell engineered to constitutively express one or more checkpoint receptor ligands. The B-cell may express a costimulatory ligand to provide a costimulatory signal. The method may comprise providing an anti-CD3 antibody to stimulate TCR signaling. The TCR signaling may be measurable by IL-2 expression of the T-cell (or interferon γ expression).
The method may comprise inducing the expression of the two or more checkpoint receptors in the T-cell. The method may comprise contacting the T-cell of the inducible T- cell system with a small molecule compound. The method may comprise determining the level of IL-2 expression (or interferon γ expression) of the T-cell with the T-cell target gene knockout as compared to a control level of IL-2 expression (or interferon γ expression) of a control wild-type T-cell under otherwise identical conditions, thereby interrogating ON vs. OFF target activity of the small molecule compound.
In any of the foregoing methods, the T-cell may be a Jurkat cell line, the B-cell may be a Raji cell line, or the T-cell and/or the B-cell may be derived from a human cell line.
In any of the foregoing methods, the two or more checkpoint receptors may comprise PD-1 and CTLA-4. In any of the foregoing methods, the one or more checkpoint receptor ligands may comprise PD-L1 and/or PD-L2.
In any of the foregoing methods, the expression of the two or more checkpoint receptors may be controlled by a promoter inducible by doxycycline (dox). The inducing step may comprise introducing the dox to the T-cell.
In any of the foregoing methods, the costimulatory receptor may be CD28.
In any of the foregoing methods, the costimulatory ligand expressed by the B-cell may be B7.1 or B7.2.
In any of the foregoing methods, the anti-CD3 antibody may be associated with a bead.
In some aspects, the invention relates to a plurality of inducible T-cell systems. Each system may comprise a T-cell (e.g. , a Jurkat cell) engineered to inducibly express two or more checkpoint receptors (e.g. , PD-1 and CTLA-4). Each system may comprise a ligand- presenting cell (e.g. , a B cell such as a Raji cell) that expresses at least one checkpoint receptor ligand (e.g. , PD-L1 , PD-L2, B7.1, and/or B7.2). Each system may comprise a costimulatory ligand (e.g. , an anti-CD3 antibody associated with a solid support).
At least one system of a plurality of systems may comprise a transcription inducer (e.g. , doxycycline) that induces the transcription of the two or more checkpoint inhibitors. At least one system of a plurality of systems may lack the transcription inducer.
At least one system of a plurality of systems may comprise a pharmaceutical agent
(e.g. , anti-PD- 1 antibody, anti-CTLA-4 antibody, kinase inhibitor). At least one system of a plurality of systems may lack the pharmaceutical agent.
The T-cell of at least one system of the plurality may comprise a gene knockout or gene knockdown (e.g. , a random knockout or a knockout/knockdown of a T-cell signaling protein). The T-cell of at least one system of the plurality may lack the gene knockout or gene knockdown.
The plurality of systems may comprise a system that comprises a transcription inducer, comprises a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown. The plurality of systems may comprise a system that lacks a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown. The plurality of systems may comprise a system that comprises a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown. The plurality of systems may comprise a system that lacks a transcription inducer, comprises a pharmaceutical agent, and lacks a T- cell comprising a gene knockout or gene knockdown. The plurality of systems may comprise a system that lacks a transcription inducer, lacks a pharmaceutical agent, and comprises a T- cell comprising a gene knockout or gene knockdown. The plurality of systems may comprise a system that comprises a transcription inducer, comprises a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown. The plurality of systems may comprise a system that comprises a transcription inducer, lacks a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown. The plurality of systems may comprise a system that lacks a transcription inducer, comprises a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown.
The plurality of systems may comprise a system that comprises one small molecule compound and at least two large molecules. The plurality of systems may comprise a system that lacks a small molecule compound and lacks a large molecule. The plurality of systems may comprise a system that comprises one small molecule compound and lacks a large molecule. The plurality of systems may comprise a system that comprises both one small molecule compound and one large molecule. The plurality of systems may comprise a system that comprises at least two small molecule compounds and lacks a large molecule. The plurality of systems may comprise a system that comprises at least two small molecule compounds and one large molecule. The plurality of systems may comprise a system that lacks a small molecule compound and comprises at least two large molecules.
The at least one large molecule may comprise an antibody such as an anti-CTLA-4 antibody and/or an anti-PD- 1 antibody. The at least one large molecule may comprise avelumab, atezolizumab, durvalumab, ipilimumab, lambrolizumab, nivolumab,
pembrolizumab, pidilizumab, tremelimumab, and/or ticilimumab. The at least one large molecule may comprise
ipilimumab and/or nivolumab.
In some aspects, the invention relates to a multi-well plate comprising a plurality of inducible T-cell systems as described herein. The multi-well plate may be a 6 well, 12 well, 24 well, 96 well, 384 well, 1536 well, or 3,456 well plate.
In some aspects, the invention relates to a method of preparing the multi-well plate, comprising adding a T-cell to each well of a plurality of wells of the multi-well plate. The T- cell may be engineered to inducibly express the two or more checkpoint receptors. The method may comprise adding a transcription inducer to a first group of wells of the plurality of wells. The method may comprise adding a costimulatory ligand to the plurality of wells. The method may comprise adding a ligand-presenting cell to the plurality of wells, wherein the ligand-presenting cell expresses a checkpoint receptor ligand.
Adding a T-cell to each well of a plurality of wells may comprise adding a knockout or knockdown T-cell to a first group of wells of a plurality of wells and adding a wild type T- cell to a second group of wells of the plurality of wells. The knockout or knockdown T-cell may be engineered to inducibly express two or more checkpoint receptors, and the knockout or knockdown T-cell may comprise a gene knockout or knockdown. The wild type T-cell may be engineered to inducibly express the two or more checkpoint receptors, and the wild type T-cell may lack the gene knockout or knockdown.
The plurality of wells may consist of the first group of wells and the second group of wells. In some embodiments, no well of the plurality of wells is included in both the first group of wells and the second group of wells. The group of wells to which the transcription inducer is added may include both wells of the first group of wells and wells of the second group of wells.
The costimulatory ligand may be added to the plurality of wells at least 24 hours after adding the transcription inducer to a group of wells. The method may further comprise washing the cells of each well of the plurality prior to adding the costimulatory ligand, e.g., to reduce the concentration of the transcription inducer in each well.
The ligand-presenting cell may be added to the plurality of wells at least 5 minutes after adding the costimulatory ligand to the plurality of wells.
The method may further comprise adding a first antibody to each well of a fourth group of wells of the plurality of wells. The method may further comprise adding a second antibody to each well of a fifth group of wells of the plurality of wells, wherein the fifth group of wells includes at least one well of the fourth group of wells. The first antibody and second antibody may be selected from antibodies that bind checkpoint receptors and antibodies that bind checkpoint receptor ligands such as anti-CTLA-4 antibodies and anti- PD-1 antibodies.
The method may further comprise adding a first small molecule compound to each well of a sixth group of wells of the plurality of wells. The first small molecule compound may be, for example, a kinase inhibitor. The method may further comprise adding a second small molecule compound to each well of a seventh group of wells of the plurality of wells, wherein the seventh group of wells includes at least one well of the sixth group of wells.
In some aspects, the invention relates to a method of discovering or validating a drug target. The method may comprise providing a plurality of inducible T-cell systems as described herein. The method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising a T-cell having a knockout or knockdown of a gene encoding the drug target.
In some aspects, the invention relates to a method of determining whether a small molecule compound affects T-cell activation. The method may comprise providing a plurality of inducible T-cell systems as described herein. The method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two
systems of the plurality, wherein the at least two systems include both a system comprising the small molecule compound and a system lacking the small molecule compound.
In some aspects, the invention relates to a method of assessing an interaction between a small molecule compound and an antibody that binds a checkpoint receptor. The method may comprise providing a plurality of inducible T-cell systems as described herein. The method may further comprise measuring the concentration of a biomarker associated with T- cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the small molecule compound and the antibody.
In some aspects, the invention relates to a method of assessing an interaction between a first small molecule compound and a second small molecule compound. The method may comprise providing a plurality of inducible T-cell systems as described herein. The method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the first small molecule compound and the second small molecule compound.
In some aspects, the invention relates to a method of assessing whether a protein (e.g. , a signaling protein such as a kinase or phosphatase) affects T-cell activation through a signaling pathway mediated by a checkpoint receptor. The method may comprise providing a plurality of inducible T-cell systems as described herein. The method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both an antibody that specifically binds the checkpoint receptor and a T-cell comprising a knockout or knockdown of a gene encoding the protein.
In some aspects, the invention relates to a method of assessing whether a
pharmaceutical agent displays an ON target or OFF target affect. The method may comprise providing a plurality of inducible T-cell systems as described herein. The method may further comprise measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the pharmaceutical agent and a T-cell comprising a knockout or knockdown of a gene encoding the target. The pharmaceutical agent may be a small molecule compound or a large molecule (e.g. , antibody).
Various embodiments of the foregoing methods may further comprise comparing the relative concentration of the biomarker in at least one system of the plurality of systems to the
relative concentration of the biomarker in at least one other system of the plurality of systems.
BRIEF DESCRIPTION OF THE DRAWINGS
The drawings are for illustration purposes only and are not intended to limit the scope of the claims or invention.
Figure 1 depicts an exemplary embodiment of an inducible T-cell system. The drawing depicts a T-cell that inducibly expresses checkpoint receptors PD-1 and CTLA-4. The T-cell also expresses CD28 and the T-cell receptor (TCR). The drawing depicts a B-cell that expresses either PD-Ll, PD-L2, or both and either B7.1, B7.2, or both. The drawing also depicts beads coated with anti-CD3 antibodies.
Figures 2A-2B depict exemplary embodiments of an inducible T-cell system, similar to the embodiment depicted in Figure 1. Figure 2A shows two states of the inducible T-cell system. In a first state (2A, left), the transcription inducer doxycycline (dox) is not present, and thus, the T-cell does not express the PD-1 or CTLA-4 constructs. The T-cell may receive costimulatory signals from B7.1 or B7.2, which interact with CD28, and anti-CD3 antibodies, which interact with the T-cell receptor. The costimulatory signals result in interleukin-2 (IL2) production by the T-cell. In a second state (2 A, right), the transcription inducer doxycycline (dox) is added, and thus, the T-cell may express PD-1 and CTLA-4. The T-cell may receive costimulatory signals from B7.1 or B7.2 and the anti-CD3 antibodies. The T- cell may also receive inhibitory signals from PD-Ll or PD-L2, which interact with PD-1, and B7.1 or B7.2, which interact with CTLA-4. The inhibitory signals result in decreased interleukin-2 (IL2) production by the T-cell relative to the first state (2B).
Figures 3A-3B depict exemplary embodiments of an inducible T-cell system that demonstrate how the system may be utilized to analyze combinations of therapeutic antibodies targeting immune checkpoint receptors. Experiments "1" and "2" of Figures 3A and 3B are identical to Figures 2A and 2B. Experiment "3" depicts the addition of the anti- PD-1 antibody nivolumab (Nivo; N) to the system in addition to doxycycline. Experiment "4" depicts the addition of the anti-CTLA-4 antibody ipilimumab (Ipi; I) to the system in addition to doxycycline. Experiment "5" depicts the addition of nivolumab, ipilimumab, and doxycycline to the system. Nivolumab and ipilimumab both increased interleukin-2 (IL2) production relative to an IgG control, and the combination of nivolumab and ipilimumab displayed an additive effect (3B).
Figures 4A-4B depict exemplary embodiments of an inducible T-cell system that demonstrate how the system may be utilized to probe molecular pathways and identify drug targets related to checkpoint receptors. The figures depict a T-cell system that is similar to Figures 1 and 2A-2B except that the T-cell of the system comprises a knockout of a gene encoding an intracellular protein. The gene knockout resulted in elevated interleukin-2 (IL2) production in the presence of doxycycline thereby suggesting that the gene product inhibits T-cell activation. The protein product of the knockout gene may therefore be a viable drug target, e.g. , small molecule inhibitors of the protein product may increase T-cell activation.
Figures 5A-5B depict exemplary embodiments of an inducible T-cell system that demonstrate how the system may be utilized to analyze combination therapies that affect immune checkpoint receptors and the molecular pathways that the therapies might act upon. Experiments "1," "2," and "3" are described above (e.g. , in Figures 3A-3B). Experiment "4" is described in Figures 4A-4B. Experiment "5" shows that a knockout may be used in combination with a drug or drug cocktail, for example, to assess whether the drug or drug cocktail acts on a molecular pathway associated with the knockout gene. In this case, nivolumab (Nivo; N) and ipilimumab (Ipi; I) increase the activation of knockout T-cells, which suggests that a drug that inhibits the product of the knockout gene will display an additive effect when used in combination with nivolumab and/or ipilimumab. Experiments "6" and "7" show that the inducible T-cell system may be used to probe the effect of small molecule therapeutics either alone (Experiment "6") or in combination with other therapies (Experiment "7"). Experiment "6" shows that the small molecule compounds "compound 1" and "compound 2" activate T-cells despite checkpoint receptor-mediated T-cell inhibition (5B). Experiment "7" shows that the combination of nivolumab (Nivo; N), ipilimumab (Ipi; I), and either small molecule compound 1 or compound 2 displays a synergistic effect (5B).
Figures 6A-6C depict exemplary embodiments of an inducible T-cell system that demonstrate how the system may be utilized to analyze whether a small molecule compound affects T-cell signaling through a target protein. Figure 6A is identical to experiment "6" of Figure 5A, and it depicts an inducible T-cell system that is contacted with a small molecule compound. Figure 6B is similar to Figure 6A except that the T-cell of figure 6B comprises a gene knockout. Figure 6C depicts experiments with T-cells comprising or lacking a gene knockout that were incubated with Raji cells, anti-CD3 beads, doxycycline, and either small molecule "compound 1" or small molecule "compound 2." Control experiments were performed with either compound 1, compound 2, or vehicle (DMSO) and T-cells that did not include the knockout. The dashed line indicates the level of T-cell activation in DMSO
control samples either comprising (KO) or lacking (WT) the gene knockout (set at 100%). Both compound 1 and compound 2 increased T-cell activation relative to the vehicle control in T-cells that did not include the knockout. Neither compound 1 nor compound 2 increased T-cell activation relative to the vehicle control in T-cells that included the knockout. These results suggest that both compound 1 and compound 2, which are designed to target the protein encoded by the knockout gene, display an "ON" target effect.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a system comprising a T-cell engineered to inducibly express two or more checkpoint receptors, a B-cell engineered to constitutively express one or more checkpoint receptor ligands, and an anti-CD3 antibody (e.g. , anti-CD3 coated beads). This system allows for the analysis of pharmaceutical agents that target checkpoint receptors to determine whether the agents display an additive or synergistic effect. The system also allows for the analysis of molecular pathways related to checkpoint inhibition, e.g. , by selectively knocking out T-cell genes. Knockouts may provide insights into whether pharmaceutical agents that target checkpoint receptors target the same or different molecular pathways. Knockouts may also provide insights into whether a pharmaceutical agent displays an ON target or OFF target effect, e.g. , wherein the gene encoding the target is knocked out of a T-cell. Knockouts may also identify proteins that may be suitable drug targets that modulate T-cell activation. Importantly, the inducible T-cell system provides a useful control because baseline readouts (e.g. interleukin-2 expression) may be obtained for the system by simply performing an experiment in the absence of conditions that allow for expression of the checkpoint receptors. Additionally, the expression of two or more checkpoint receptors allows for the analysis of additive or synergistic effects among combinations of pharmaceutical agents that target different checkpoint receptor pathways.
I. T-CELLS THAT EXPRESS CHECKPOINT RECEPTORS
Various aspects of the invention relate to a T-cell. The T-cell may be a mammalian T-cell, such as a human T-cell. The T-cell may be immortalized. For example, the T-cell may be immortalized because the T-cell has been transformed with an Epstein-Barr virus. The T-cell may be derived from a T-cell leukemia or lymphoma. The T-cell may be derived from a cell line, such as a human cell line. The T-cell may be a Jurkat, HuT-78, CEM, Molt- 4, DND-41, T-ALL1, or HPB-ALL cell. The T-cell may be a ARR, CCRF-CEM, CML-T1, DEL, DND-41, DU.528, H-SB2, HUT 102, JB6, Karpas 299, Karpas 45, KE-37/SKW-3, K-
Tl, Loucy, MOLT 13, MOLT 16/17, MOLT 3/4, MT-1, P12-Ichikawa, Peer/Bel3, PF-382, RPMI 8402, SU-DHL-1, SUP-T1, SUP-T3, or TALL-104 cell. The T-cell may be derived from a Jurkat cell line. The T-cell may be a Jurkat cell. The T-cell may express one or more of CD3, TCRa, TCR , TCRy, TCR5, CD4, CD8, CD28, CTLA-4, CD40L, CD2, and LFA-1. The T-cell may be a suspension cell or an adherent cell.
T-cells express the T-cell receptor (TCR). A TCR may transduce a costimulatory signal upon binding to an antigen presented by a B-cell or an antigen presenting cell (APC). Alternatively, a TCR may transduce a costimulatory signal upon binding an anti-CD3 antibody. An anti-CD3 antibody may be associated with a bead, multi-well plate, or tissue culture plate, or an anti-CD3 antibody may be crosslinked as an oligomer, such as a tetramer. An anti-CD3 antibody may be a bi-specific antibody, such as a bi-specific T-cell engager (BiTE®). An example of an anti-CD3 bi-specific antibody that may bind CD3 and thereby transduce a costimulatory signal is blinatumomab (BLINCYTO®), which is bi-specific for CD3 and CD19 (present on B-cells).
A T-cell may express a costimulatory receptor such as CD28. CD28 is a cell surface receptor protein capable of transducing a costimulatory signal that enables T-cell activation and survival. CD28 may transduce an intracellular signal upon binding B7.1 (CD80) or B7.2 (CD86), which may be present on a B-cell. Alternatively, CD28 may transduce a costimulatory signal upon binding an anti-CD28 antibody. An anti-CD28 antibody may be associated with a bead, multi-well plate, or tissue culture plate, or an anti-CD28 antibody may be crosslinked as an oligomer, such as a tetramer.
A T-cell may express 4-1BB (CD137), CD27, OX40 (CD134; TNFRSF4), B-cell activating factor receptor (BAFFR), transmembrane activator and CAML interactor (TACI), B-cell Maturation Antigen (BMCA), CD40 ligand (CD40L; CD154), CD28, inducible T-cell costimulator (ICOS; CD278), and/or glucocorticoid-induced TNFR-related protein (GITR; AITR; TNFRSF18). 4- IBB, CD27, OX40, BAFFR, CAML, BMCA, CD40L, or GITR may transduce a costimulatory signal that enables T-cell activation and survival independent of CD28. A. Checkpoint receptors
A T-cell may be engineered to express two or more checkpoint receptors. A T-cell may comprise a recombinant gene encoding a checkpoint receptor. A T-cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene encodes a different checkpoint receptor. Each checkpoint receptor may be selected from cytotoxic T- lymphocyte
antigen 4 (CTLA-4; CD152), programmed cell death 1 (PD-1; CD279), programmed death- 1 homolog (PD-1H), lymphocyte-activation gene 3 (LAG-3; CD223), B- and T-lymphocyte attenuator (BTLA; CD272), a killer-cell immunoglobulin-like receptor (KIR), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), adenosine A2a receptor (A2aR; ADORA2A), CD 160, 2B4 (CD244), T cell immunoreceptor with Ig and ITIM domains (TIGIT), and interleukin-10 receptor. The two or more checkpoint receptors may be inhibitory checkpoint receptors. Nevertheless, a checkpoint receptor may be selected from stimulatory checkpoint receptors, such as 4-1BB (CD137), CD27, OX40 (CD134;
TNFRSF4), B-cell activating factor receptor (BAFFR), transmembrane activator and CAML interactor (TACI), B-cell Maturation Antigen (BMCA), CD40 ligand (CD40L; CD154), CD28, inducible T-cell costimulator (ICOS; CD278), and glucocorticoid-induced TNFR- related protein (GITR; AITR; TNFRSF18). A T-cell may be engineered to express two or more checkpoint receptors wherein the two or more checkpoint receptors comprise PD- 1 and CTLA-4.
A checkpoint receptor may be a human checkpoint receptor, e.g., the checkpoint receptor may have a human amino acid sequence. A checkpoint receptor may be encoded by a human nucleotide sequence. Nevertheless, the amino acid sequence of a checkpoint receptor or the nucleotide sequence encoding the checkpoint receptor may have slight variations from human sequences, which may be introduced, for example, to assist with the cloning or expression of a recombinant gene. For example, tyrosine 165 of CTLA-4 may be replaced with phenylalanine (Tyrl65Phe) to increase surface localization of CTLA-4. A nucleotide sequence encoding a checkpoint receptor may contain introns or lack introns. A nucleotide sequence encoding a checkpoint receptor may be a cDNA nucleotide sequence or a reverse complement thereof.
Each checkpoint receptor may be the target of an agent that specifically binds a checkpoint receptor, such as a therapeutic antibody. For example, lambrolizumab, nivolumab, pembrolizumab, and pidilizumab are therapeutic antibodies that specifically bind the checkpoint receptor PD-1. Ipilimumab, ticilimumab, and tremelimumab are therapeutic antibodies that specifically bind the checkpoint receptor CTLA-4. Lirilumab is a therapeutic antibody that specifically binds the checkpoint receptor KIR2D. In some embodiments, one or more checkpoint receptors are not targets of a therapeutic antibody or an agent that specifically binds a checkpoint receptor. For example, a stimulatory checkpoint receptor might not the target of a therapeutic antibody.
A T-cell may comprise a first recombinant gene and a second recombinant gene, e.g. , wherein the two or more checkpoint receptors are encoded by the first recombinant gene and the second recombinant gene. The first recombinant gene may encode the checkpoint receptor PD-1 and the second recombinant gene may encode the checkpoint receptor CTLA- 4. A gene may be recombinant because the mRNA-encoding nucleotide sequence of the gene may be operably-linked to an inducible promoter, such as a promoter that is inducible by doxycycline. A gene may be recombinant because the gene was introduced into a T-cell by transfection and then integrated into the genome of the cell.
The nucleotide sequence encoding a checkpoint receptor may be operably-linked to a promoter, such as an inducible promoter. A recombinant gene may therefore comprise a nucleotide sequence encoding a checkpoint receptor and a promoter (e.g. , inducible promoter) operably-linked to the nucleotide sequence. Each nucleotide sequence encoding a checkpoint receptor may be operably-linked to a promoter (e.g. , an inducible promoter). A T-cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene comprises both a nucleotide sequence encoding a checkpoint receptor and a promoter (e.g. , an inducible promoter) operably-linked to the nucleotide sequence. For example, a T- cell may comprise a first recombinant gene encoding the checkpoint receptor PD- 1 and a first inducible promoter, wherein the nucleotide sequence encoding PD- 1 is operably-linked to the first inducible promoter. The T-cell may comprise a second recombinant gene encoding the checkpoint receptor CTLA-4 and a second inducible promoter, wherein the nucleotide sequence encoding CTLA-4 is operably-linked to the second inducible promoter. The first inducible promoter and the second inducible promoter may comprise the same nucleotide sequence.
Each recombinant gene encoding a checkpoint receptor may comprise a promoter with the same nucleotide sequence, or each recombinant gene may have at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with one another. Each recombinant gene encoding a checkpoint receptor may comprise a promoter that is subject to control by the same stimulus.
The T-cell may be engineered to inducibly express two or more checkpoint receptors, wherein the two or more checkpoint receptors are controlled by an inducible promoter. The expression of a checkpoint receptor may be controlled by a promoter inducible by a transcription inducer such as doxycycline, tetracycline, a streptogramin, or a macrolide. The expression of a checkpoint receptor may be controlled by a promoter inducible by a dimerization (e.g. , ARGENT® or iDIMERIZE®). The expression of a checkpoint receptor
may be controlled by a promoter inducible by a transcription inducer such as AP20187, AP21967, AP21998, or AP1510 (e.g., which induce dimerization of a transcription factor). The expression of a checkpoint receptor may be controlled by a hormone response element, such as an estrogen response element. The expression of a checkpoint receptor may be controlled by a promoter inducible by a transcription inducer such as estrogen. The two or more checkpoint receptors may be controlled by a promoter inducible by doxycycline (dox).
The expression of a checkpoint receptor may be controlled by a promoter inducible by doxycycline. Each nucleotide sequence encoding a checkpoint receptor may be operably- linked to a promoter that is inducible by doxycycline. A T-cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene comprises a promoter that is inducible by doxycycline and operably-linked to a nucleotide sequence encoding a checkpoint receptor (e.g. , PD-1 and/or CTLA-4).
B. Genetic modifications
A T-cell may comprise one or more genetic modifications in addition to a
recombinant gene encoding a checkpoint receptor. A genetic modification may be a gene knockout, gene knockdown, expression cassette, or the modification of a regulatory element of a gene. For example, a T-cell may comprise a T-cell gene knockout or an antigen presenting cell gene knockout. Any gene may be knocked or knocked down, such as genes of the lymphoid lineage or T-cell specific genes.
Gene knockouts may be useful to determine whether the knockout gene affects a signaling pathway that is mediated by a checkpoint receptor. For example, PD- 1 may transduce signals through multiple different signaling pathways that implicate myriad signaling proteins, which may include SHP2, phosphoinositide 3-kinase (PI3K), protein kinase B (PKB; AKT), p27kip, and/or ZAP70. A T-cell may comprise a gene knockout of SHP2, PI3K, AKT, p27kip, and/or ZAP70.
A knockout of an individual signaling protein may enable the elucidation of whether a checkpoint receptor signals through the protein. For example, a knockout may be introduced into the T-cell of an inducible T-cell system as described herein, T-cell receptor signaling may be assessed in the absence of the checkpoint receptor (e.g. , IL2 production may be assessed in the absence of doxycycline-induced PD-l/CTLA-4 expression), and T-cell receptor signaling may be assessed in the presence of the checkpoint receptor (e.g. , IL2 production may be assessed in the presence of doxycycline-induced PD- l/CTLA-4 expression). If T-cell receptor signaling is similar in the absence and presence of the
checkpoint receptor, then the knockout gene might be critical for downstream signaling through the checkpoint receptor. Such systems may be further probed, for example, by adding an antibody to the system that blocks T-cell receptor signaling (e.g. , nivolumab or pembrolizumab for PD-1; ipilimumab or tremelimumab for CTLA-4). If T-cell receptor signaling is similar in the presence of the checkpoint receptor, regardless of whether an antibody is present that blocks the checkpoint receptor, then the knockout gene is likely critical for signaling downstream of the checkpoint receptor. Polypeptides encoded by genes that are determined to be critical for T-cell receptor signaling may be viable drug targets, particularly if the polypeptide exists on the cell membrane or if the protein is secreted.
Intracellular polypeptides may also be viable drug targets (e.g. , for small molecule drugs). A genetic knockout identified using the above strategy might also be introduced into a lymphocyte used in an adoptive cell transfer therapy, for example, to suppress checkpoint inhibition of the lymphocyte.
Methods for knocking out a gene in a T-cell include homologous recombination and CRISPR/Cas9-mediated knockout. Other methods of generating specific knockouts include TALEN (transcription activator-like effector nucleases) and zinc finger nuclease strategies. A T-cell gene may thus be knocked out by CRISPR/Cas9, a zinc finger nuclease, or a TALEN. A T-cell may comprise a T-cell gene knockout, wherein the T-cell gene is knocked out by CRISPR/Cas9. A knockout may or may not replace the coding regions of the knockout gene with the coding regions of a reporter gene, e.g. , a T-cell may comprise a reporter gene. Additionally, a knockout may replace the promoter of a knockout gene with a different promoter, e.g. , a promoter that is operably-linked to a reporter gene.
A T-cell may comprise a gene for luciferase. A T-cell may comprise two gene fragments of β-galactosidase which may encode polypeptide products that may combine in the T-cell to form a protein with β-galactosidase activity. A T-cell may comprise a luciferase protein or a β-galactosidase protein.
A T-cell may be homozygous for a knockout (e.g. , wherein both copies of a gene are knocked out) or heterozygous for a knockout (e.g. , wherein a single copy of a gene is knocked out).
A T-cell may comprise a random gene knockout. Random knockouts may be generated by insertion mutagenesis such as by transfecting a T-cell with a retrovirus or transposable element (transposon). Random knockouts may be useful to identify genes or other genetic features that may be involved in checkpoint inhibition or T-cell activation.
A T-cell may comprise a gene knockdown. A gene knockdown may be a transient knockdown (e.g. , wherein a T-cell is transfected with antisense RNA, short hairpin RNA, microRNA, or small interfering RNA) or a knockdown may be a stable knockdown (e.g. , wherein a T-cell is transfected with a vector encoding an antisense RNA, short hairpin RNA, microRNA, or small interfering RNA). A gene knockdown may be a conditional knockdown (e.g. , wherein the expression of an antisense RNA, microRNA, or small interfering RNA is controlled by an inducible promoter).
A T-cell may comprise a genetic modification that increases the expression of a gene, e.g. , in addition to the two or more checkpoint receptors. A T-cell may comprise a recombinant gene that does not encode a checkpoint receptor. A recombinant gene that does not encode a checkpoint receptor may instead encode a signaling protein, for example, such as a kinase or phosphatase. A recombinant gene that does not encode a checkpoint receptor may encode a human protein, such as a protein expressed by T-cells. The protein encoded by a recombinant gene may contain one or more mutations relative to the wild type protein. The one or more mutations may affect the expression, cellular localization, function, and/or activity of the protein. The one or more mutations may or may not be naturally-occurring mutations or mutations that are associated with disease, such as cancer or an autoimmune disease. The one or more mutations may or may not be associated with the efficacy of a drug that targets the protein, e.g. , a mutation may be associated with drug resistance or sensitivity.
A genetic modification that increases the expression of a gene may be introduced into a T-cell, for example, as an expression cassette comprising a promoter operably-linked to an open reading frame encoding a protein product. A T-cell may comprise a recombinant gene encoding a protein other than a checkpoint receptor, such as a signaling protein (e.g. , kinase or phosphatase). A nucleotide sequence encoding a protein other than a checkpoint receptor may be operably-linked to a promoter, such as a constitutive or inducible promoter.
A genetic modification may increase the expression of an endogenous gene of a T- cell. For example, the regulatory region of an endogenous gene of a T-cell may be modified to increase the expression of a gene. Modifications that increase expression include the replacement of an endogenous promoter with a strong promoter (or a promoter that is stronger than the endogenous promoter). An endogenous promoter may be replaced with an inducible promoter (e.g. , a doxycycline-inducible promoter) or a constitutive promoter (e.g. , cytomegalovirus promoter or SV40 promoter). Other modifications that increase gene expression include the mutation or deletion of a silencer nucleotide sequence. The modification of an endogenous gene may be accomplished using known techniques, such as
homologous recombination, CRISPR/Cas9-mediated gene editing, TALEN strategies, and zinc-finger strategies.
II. CELLS EXPRESSING A CHECKPOINT RECEPTOR LIGAND
Various aspects of the invention relate to a checkpoint receptor ligand-presenting cell
(also referred to as a ligand-presenting cell). A checkpoint receptor ligand-presenting cell may be a B-cell. A B-cell may be a mammalian B-cell, such as a human B-cell. A B-cell may be immortalized. For example, a B-cell may be immortalized because the B-cell has been transformed with an Epstein-Barr virus. A B-cell may be derived from a B-cell leukemia or lymphoma. A B-cell may be derived from a cell line, such as a human cell line. A B-cell may be derived from a Raji cell line. A B-cell may be a Raji cell or a BLCL cell. A B-cell may be an Epstein-Barr virus-immortalized lymphoblast.
A B-cell may endogenously express B7.1 and/or B7.2. B7.1 and/or B7.2 may bind to CD28 present on a T-cell thereby transducing a costimulatory signal. B7.1 and/or B7.2 may bind to CTLA-4 present on a T-cell thereby suppressing the activation and proliferation of the T-cell. A B-cell may endogenously express PD-L1. PD-L1 may bind PD-1 present on a T- cell thereby suppressing the activation and proliferation of the T-cell. A B-cell may endogenously express major histocompatibility complex class II (MHC class II). MHC class II may bind LAG-3 present on a T-cell thereby suppressing the activation and proliferation of the T-cell.
A checkpoint receptor ligand-presenting cell may be a human or non-human cell. In some embodiments, the ligand-presenting cell is not a B-cell. For example, a ligand- presenting cell may be a HEK293 cell or a Chinese hamster ovary (CHO) cell. A ligand- presenting cell may be a 3T3-L1, 4T1, 9L, A172, A20, A253, A2780, A2780ADR, A2780cis, A431, A549, AHL-1, ALC, B16, B35, BCP-1, BEAS-2B, bEnd.3, BHK-21, BOSC23, BT- 20, BxPC3, C2C12, C3H-10T1/2, C6, Caco-2, Cal-27, CGR8, CHO, CML Tl, CMT12, COR-L23, COS-7, COV-434, CT26, D17, DH82, DU145, DuCaP, E14Tg2a, EL4, EM-2, EM-3, EMT6/AR1, FM3, GL261, H1299, HaCaT, HCA2, HEK293, HeLa, Hep G2, Hepalclc7, HL-60, HT-1080, HT-29, J558L, Jurkat, JY, K562, KBM-7, KCL-22, KG1, Ku812, KYO-1, L1210, L243, LNCaP, MA2.1, Ma-Mel, MC-38, MCF-IOA, MCF-7, MDA- MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-468, MDCK II, MG63, Mono-Mac-6, MOR/0.2R, MRC-5, MTD-1A, MyEnd, NALM-1, NCI-H69, Neuro2a, NIH-3T3, NK-92, NTERA-2, NW-145, OK, OPCN, OPCT, P3X63Ag8, PC12, PC-3, Peer, PNT1A, PNT2, Pt K2, Raji, RBL-1, RenCa, RIN-5F, RMA-S, SaOS-2, SH-SY5Y, SiHa, SK-BR-3, SK-OV-3,
T2, T-47D, T84, T98G, THP-1, U373, U87, U937, VCaP, Vera, VG-1, WM39, WT-49, YAC-1, or YAR cell. A checkpoint receptor ligand-presenting cell may be an adherent cell or a suspension cell.
A checkpoint receptor ligand-presenting cell may be derived from a human or non- human cell, and the ligand-presenting cell may be engineered to express a human checkpoint receptor ligand, such as B7.1, B7.2, PD-L1, or PD-L2. A ligand-presenting cell may be derived from a human or non-human cell, and the ligand-presenting cell may be engineered to express a human costimulatory ligand such as B7.1 or B7.2. A. Checkpoint receptor ligands
A checkpoint receptor ligand-presenting cell may be engineered to constitutively express one or more checkpoint receptor ligands. A ligand-presenting cell may comprise a recombinant gene encoding a checkpoint receptor ligand. A ligand-presenting cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene encodes a different checkpoint receptor ligand. Each checkpoint receptor ligand may be selected from B7.1 (CD80), B7.2 (CD86), V-set domain-containing T-cell activation inhibitor 1 (VTCN1; B7-H4), programmed cell death-ligand 1 (PD-L1; B7-H1; CD274), B7-H2 (ICOS ligand; CD275), B7-H7, programmed cell death-ligand 2 (PD-L2; B7-DC; CD273), major histocompatibility complex class II (MHC class II), herpesvirus entry mediator (HVEM; TNFRSF14), CD155, galectin-9, and T-cell immunoglobulin and mucin-domain containing-3 ligand (TIM-3 ligand). The one or more checkpoint receptor ligands may comprise PD-L1 and/or PD-L2. A checkpoint receptor ligand may be a human checkpoint receptor ligand, e.g. , the checkpoint receptor ligand may have a human amino acid sequence. A checkpoint receptor ligand may be encoded by a human nucleotide sequence. Nevertheless, the amino acid sequence of a checkpoint receptor ligand or the nucleotide sequence encoding the checkpoint receptor ligand may have slight variations from human sequences, which may be introduced, for example, to assist with the cloning or expression of a recombinant gene. A nucleotide sequence encoding a checkpoint receptor ligand may contain introns or lack introns. A nucleotide sequence encoding a checkpoint receptor ligand may be a cDNA nucleotide sequence or a reverse complement thereof.
A checkpoint receptor ligand-presenting cell may comprise 1, 2, 3, 4, or more recombinant genes, wherein each recombinant gene encodes a checkpoint receptor ligand. A checkpoint receptor ligand may be selected from PD-L1, PD-L2, B7.1, and B7.2. A ligand- presenting cell may comprise a first recombinant gene wherein the first recombinant gene
encodes the checkpoint receptor ligand PD-L1 or PD-L2. A ligand-presenting cell may comprise a second recombinant gene, wherein the second recombinant gene encodes the checkpoint receptor ligand B7.1 or B7.2. A gene may be recombinant because the mRNA- encoding nucleotide sequence of the gene is operably-linked to an inducible promoter, such as a promoter that is inducible by doxycycline. A gene may be recombinant because the gene was introduced into a ligand-presenting cell by transfection and then integrated into the genome of the cell.
The nucleotide sequence encoding a checkpoint receptor ligand may be operably- linked to a promoter such as a constitutive promoter. A recombinant gene may therefore comprise a nucleotide sequence encoding a checkpoint receptor ligand and a promoter (e.g. , constitutive promoter) operably-linked to the nucleotide sequence. Each nucleotide sequence encoding a checkpoint receptor ligand may be operably-linked to a promoter (e.g. , a constitutive promoter). A checkpoint receptor ligand-presenting cell may comprise 1, 2, 3, 4, 5, or more recombinant genes, wherein each recombinant gene comprises both a nucleotide sequence encoding a checkpoint receptor ligand and a promoter (e.g. , a constitutive promoter) operably-linked to the nucleotide sequence. For example, a ligand-presenting cell may comprise a recombinant gene encoding the checkpoint receptor ligand PD-L1 or PD-L2 and a constitutive promoter, e.g. , wherein the nucleotide sequence encoding PD-L1 or PD-L2 is operably-linked to the constitutive promoter. A ligand-presenting cell may comprise a recombinant gene encoding the checkpoint receptor ligand B7.1 or B7.2 and a constitutive promoter, e.g. , wherein the nucleotide sequence encoding B7.1 or B7.2 is operably-linked to the constitutive promoter.
A checkpoint receptor ligand-presenting cell may comprise a first recombinant gene encoding the checkpoint receptor ligand PD-L1 or PD-L2 and a first constitutive promoter, e.g. , wherein the nucleotide sequence encoding PD-L1 or PD-L2 is operably-linked to the first constitutive promoter. The ligand-presenting cell may comprise a second recombinant gene encoding the checkpoint receptor ligand B7.1 or B7.2 and a second constitutive promoter, e.g. , wherein the nucleotide sequence encoding B7.1 or B7.2 is operably-linked to the second constitutive promoter. The first constitutive promoter and the second constitutive promoter may comprise the same nucleotide sequence. Each recombinant gene encoding a checkpoint receptor ligand may comprise a promoter with the same nucleotide sequence or with at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity.
In some embodiments, a checkpoint receptor ligand-presenting cell is not engineered to constitutively express one or more checkpoint receptor ligands. For example, a ligand- presenting cell may endogenously express one or more of the checkpoint receptor ligands, e.g. , wherein the checkpoint receptor ligands are selected from B7.1, PD-L1, and MHC class II.
B. Costimulatory ligands
A checkpoint receptor ligand-presenting cell may express a costimulatory ligand. For example, a ligand-presenting cell may express B7.1 and/or B7.2, which are costimulatory ligands for CD28. A B-cell may endogenously express a costimulatory ligand, such as B7.1. A ligand-presenting cell may be engineered to constitutively or inducibly express a costimulatory ligand. For example, the ligand-presenting cell may be a HEK293 cell or a CHO cell, and the ligand-presenting cell may be engineered to express human B7.1 and/or human B7.2. Similarly, a ligand-presenting cell (e.g. , either a B-cell or non-B-cell) may be engineered to express an anti-CD28 antibody (e.g. , an anti-CD28 scFv antibody), which may optionally comprise a transmembrane domain that anchors the antibody to the ligand- presenting cell.
In some embodiments, the checkpoint receptor ligand-presenting cell does not comprise a costimulatory ligand or the inducible T-cell system does not comprise a ligand- presenting cell or B-cell. A costimulatory ligand may instead be provided as a reagent optionally associated with a solid support, such as a bead. For example, a costimulatory ligand may be an anti-human CD28 antibody, which may optionally be associated with a bead. III. SYSTEMS COMPRISING T-CELLS
Various aspects of the invention relate to a system comprising a T-cell as described in section I, supra. A system may be an inducible T cell system, e.g. , the system may comprise a T cell engineered to inducibly express two or more checkpoint receptors. A system may further comprise a checkpoint receptor ligand-presenting cell as described in section II, supra. A ligand-presenting cell may or may not be a B-cell. For example, the system may comprise an antigen presenting cell (APC) instead of a B-cell, e.g. , wherein the T-cell receptor costimulatory signal is provided by a MHC-peptide complex on the surface of the APC.
A system may further comprise a second costimulatory ligand that is different from the costimulatory ligand expressed by a ligand-presenting cell, which may simulate T-cell receptor signaling. A second costimulatory ligand may be associated with a bead, multi-well plate, or tissue culture plate, or the second costimulatory ligand antibody may be crosslinked as an oligomer, such as a tetramer. A second costimulatory ligand may be, for example, an anti-CD3 antibody. An anti-CD3 antibody may be associated with a bead, e.g. , a system may further comprise an anti-CD3 antibody coated bead. An anti-CD3 antibody may be a bi- specific antibody, such as a bi-specific T-cell engager (BiTE®). An example of an anti-CD3 bi-specific antibody that may bind CD3 and thereby transduce a costimulatory signal is blinatumomab (BLINCYTO®), which is bi-specific for CD3 and CD19. C19 may be present on a B-cell, such as a B-cell of an inducible T-cell system.
A system may further comprise a transcription inducer. A transcription inducer may control the transcription of an inducible gene of a T-cell of a system. The transcription inducer may be doxycycline, tetracycline, a streptogramin, or a macrolide. The transcription inducer may be AP20187, AP21967, AP21998, or AP1510, which may mediate FKBPF36v- dimer mediated transcription (e.g. , in ARGENT® or iDIMERIZE®). The transcription inducer may be an estrogen, e.g. , which binds to a hormone response element.
A system may further comprise media, such as Roswell Park Memorial Institute (RPMI) media. A system may further comprise serum, such as fetal bovine serum (FBS). A system may further comprise an antibiotic such as a penicillin (e.g. , penicillin G), an aminoglycoside (e.g. , streptomycin, gentamicin), and/or an aminonucleoside (e.g. , puromycin).
A system may further comprise reagents to determine the expression level of a biomarker that is associated with T-cell activation. For example, a system may comprise an antibody that specifically binds the biomarker. The biomarker may be, for example, interleukin-2 or interferon γ. A system may further comprise reagents to determine the expression of interleukin-2 by the T-cell. For example, a system may comprise an anti- interleukin-2 antibody and/or a secondary antibody, such as an anti-IgG antibody. A system may further comprise reagents to determine the expression of interferon γ by the T-cell. For example, a system may comprise an anti-interferon γ antibody and/or a secondary antibody, such as an anti-IgG antibody. An anti-interleukin-2 antibody, anti-interferon γ antibody, or a secondary antibody may be conjugated to an enzyme (e.g. , alkaline phosphatase or horseradish peroxidase), a fluorophore (e.g. , fluorescein or Texas red), or a crosslinker (e.g. , biotin). A system may comprise a colorimetric alkaline phosphatase substrate or a
colorimetric horseradish peroxidase substrate. A system may comprise a luciferase substrate such as BIO-GLO®.
A system may comprise one or more pharmaceutical agents such as two or more pharmaceutical agents. A pharmaceutical agent may or may not be an FDA approved pharmaceutical agent.
A pharmaceutical agent may be a small molecule compound or a large molecule. The one or more pharmaceutical agents may be selected from small molecule compounds and large molecules.
A pharmaceutical agent may be a candidate compound. Candidate compounds are typically small molecule compounds that are drug-like, including compounds of a drug screen (such as compounds used in high-throughput screening), rationally designed compounds, pre-lead compounds, lead compounds, clinical candidates, and repurposed drugs.
A small molecule compound may have a molecular weight of less than about 900 amu, such as less than about 800, 700, or 600 amu. A small molecule compound may have a molecular weight of about 3 amu to about 899.9 amu, such as about 100 to 800, 100 to 700, 100 to 600, 100 to 500, 200 to 800, 200 to 700, 200 to 600, 200 to 500, 300 to 800, 300 to 700, 300 to 600, 300 to 500, 400 to 800, 400 to 700, 400 to 600, 500 to 800, 500 to 700, or 600 to 800 amu. In certain embodiments, the small molecule compound has a molecular weight of about 400 amu to about 700 amu.
A small molecule compound may be an immunomodulatory imide drug (IMiD). A small molecule compound may be thalidomide, lenalidomide, pomalidomide, or apremilast.
A small molecule compound may be a kinase inhibitor such as a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, or a lipid kinase inhibitor.
A large molecule may have a molecular weight of at least about 900 amu, such as at least about 1 kDa, 10 kDa, 50 kDa, 100 kDa, or 150 kDa. A large molecule may have a molecular weight of about 900 amu to 5 kDa, 1 kDa to 50 kDa, 1 kDa to 30 kDa, 1 kDa to 25 kDa, 1 kDa to 20 kDa, 1 kDa to 10 kDa, 5 kDa to 30 kDa, 5 kDa to 25 kDa, 5 kDa to 20 kDa, 5 kDa to 15 kDa, 10 kDa to 30 kDa, 10 kDa to 25 kDa, 10 kDa to 20 kDa, 20 kDa to 80 kDa, 20 kDa to 40 kDa, 40 kDa to 60 kDa, 50 kDa to 100 kDa, 100 kDa to 200 kDa, 120 kDa to 180 kDa, 140 kDa to 160 kDa, 150 kDa to 300 kDa, or 150 kDa to 250 kDa. A cytokine, for example, may have a molecular weight of about 5 kDa to about 20 kDa. An antibody may have a molecular weight of about 120 kDa to about 180 kDa, such as about 140 kDa to about 160 kDa. A fragment antigen-binding (Fab) fragment of an antibody may have a molecular weight of about 20 kDa to about 80 kDa, such as about 40 kDa to about 60 kDa.
A large molecule may be a hormone, cytokine, chemokine, lymphokine, interferon, or interleukin. A large molecule may be selected from interferon alfa, interferon alfacon-1, pegylated interferon alpfa-2a, pegylated interferon alfa- 2b, interferon βΐ, interferon jib, interleukin-2, interleukin-7, interleukin- 12, pifonakin, mobenakin, adargileukin alfa, aldesleukin, celmoleukin, denileukin diftitox, pegaldesleukin, teceleukin, tucotuzumab celmoleukin, daniplestim, muplestim, binetrakin, atexakin alfa, emoctakin, ilodecakin, oprelvekin, edodekin alfa, cintredekin besudotox, and iboctadekin.
A T-cell and/or ligand-presenting cell may produce a molecule with the same chemical structure as a large molecule or pharmaceutical agent, and the terms
"pharmaceutical agent" and "large molecule" are limited to molecules that are not produced by a cell of an inducible T-cell system. For example, a pharmaceutical agent (e.g. , large molecule) may be interleukin-2 or interferon γ, in which case the interleukin-2 or interferon γ pharmaceutical agent refers to interleukin-2 or interferon γ that is added to a T-cell system rather than interleukin-2 or interferon γ that is produced by a cell of the system. In some embodiments, the pharmaceutical agent does not have the same chemical structure as any molecule produced by a cell of a T-cell system, e.g. in some embodiments the pharmaceutical agent does not have the same chemical structure as interleukin-2, interferon γ, or any other molecule produced by a cell of an inducible T-cell system.
A large molecule may be interleukin-2 or interferon γ.
A large molecule may be selected from brain-derived neurotrophic factor (BDNF),
CCL11 (Eotaxin), CCL3 (MIP-1 alpha), CCL4 (MIP-1 beta), CCL5 (RANTES), CD31 (PECAM-1), CD62P (P-selectin), CXCL1 (GRO alpha), CXCL10 (IP-10), granulocyte- macrophage colony- stimulating factor (GM-CSF), hepatocyte growth factor (HGF), interferon a (IFNa), interferon γ (IFNy), interleukin- la, interleukin- 1β, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8 (cxcl8), interleukin-9, interleukin- 10, interleukin- 12, interleukin- 13, interleukin- 15, interleukin- 16, interleukin- 17a, interleukin-20, interleukin-21, interleukin- 1 receptor antagonist, leukemia inhibitory factor (LIF), monocyte chemoattractant protein 2 (MCP-2; CCL8), osteoprotegerin (OPG), platelet- derived growth factor subunit B dimer (PDGF-BB), sCD120b (sTNF Receptor II), stem cell factor (SCF), tumor necrosis factor a (TNFa), tissue plasminogen activator (t-PA), thymic stromal lymphopoietin (TSLP), vascular endothelial growth factor A (VEGF-A), and vascular endothelial growth factor A (VEGF-D).
A large molecule may be an antibody such as a therapeutic antibody. A therapeutic antibody is typically a monoclonal antibody, or an antigen-binding fragment thereof, which is
either chimeric (e.g. , comprising human sequences), humanized, or fully human. An antibody may be a checkpoint inhibitory antibody. One or more pharmaceutical agents may comprise a small molecule compound, an antibody, and/or an FDA approved checkpoint inhibitory antibody. Two or more pharmaceutical agents may comprise a small molecule compound, an antibody, and/or an FDA approved checkpoint inhibitory antibody.
The term "antibody" encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. , bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen- binding activity. An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments are well known in the art (see, e.g. , Nelson, MAbs (2010) 2(l):77-83) and include but are not limited to Fab, Fab', Fab'-SH, F(ab')2, and Fv; diabodies; linear antibodies; single-chain antibody molecules including but not limited to single-chain variable fragments (scFv), fusions of light and/or heavy-chain antigen-binding domains with or without a linker (and optionally in tandem); and monospecific or multispecific antigen-binding molecules formed from antibody fragments (including, but not limited to multispecific antibodies constructed from multiple variable domains which lack Fc regions).
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. , the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variants, e.g. , containing naturally occurring mutations or that may arise during production of the monoclonal antibody, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method (see, e.g. , Kohler et al, Nature, 256:495 (1975)), recombinant DNA methods (see, e.g. , U.S. Patent No. 4,816,567), phage-display methods (e.g. , using the techniques described in Clackson et al, Nature, 352:624-628 (1991) and Marks et al, J. Mol. Biol, 222:581-597 (1991)), and methods utilizing transgenic animals
containing all or part of the human immunoglobulin loci. Specific examples of monoclonal antibodies herein include chimeric antibodies, humanized antibodies, and human antibodies, including antigen-binding fragments thereof. Two or more checkpoint inhibitory drugs may comprise an FDA approved checkpoint inhibitory drug wherein the FDA approved checkpoint inhibitory drug is a monoclonal antibody.
A "bi-specific antibody" is a multispecific antibody comprising an antigen-binding domain that is capable of specifically binding to two different epitopes on one biological molecule or is capable of specifically binding to epitopes on two different biological molecules.
A large molecule may be an antibody that specifically binds 2B4, 4- IBB, BAFF,
CCL2, CCR5, CD19, CD2, CD20, CD22, CD23, CD27, CD274, CD28, CD3, CD3, CD30, CD37, CD38, CD4, CD40, CD44, CD5, CD52, CD6, CD70, CD79B, CD80, CD134, CD152, CD154, CD160, CSF2, CTGF, CTLA-4, CXCR4, ICOSL, IFN-a, IFN-γ, interleukin-ΐβ, interleukin-4, interleukin-5, interleukin-6, interleukin-9, interleukin-12, interleukin-13, interleukin-17, interleukin-17A, interleukin-17F, interleukin-20, interleukin-22, interleukin- 23, interleukin-23A, KIR2D, LFA-1, L-selectin, MIF, OX40, PD-1, PD-IH, TIGIT, RANKL, T-cell receptor, TGF-β, TGF-βΙ, TGF- 2, or thymic stromal lymphopoietin.
A large molecule may be an antibody that specifically binds brain-derived
neurotrophic factor (BDNF), CCL11 (Eotaxin), CCL3 (MIP-1 alpha), CCL4 (MIP-1 beta), CCL5 (RANTES), CD31 (PECAM-1), CD62P (P-selectin), CXCL1 (GRO alpha), CXCL10 (IP- 10), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), interferon a (IFNa), interferon γ (IFNy), interleukin-la, interleukin-ΐβ, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8 (cxcl8), interleukin-9, interleukin-10, interleukin-12, interleukin-13, interleukin-15, interleukin-16, interleukin-17a, interleukin-20, interleukin-21, interleukin-1 receptor antagonist, leukemia inhibitory factor (LIF), monocyte chemoattractant protein 2 (MCP-2; CCL8), osteoprotegerin (OPG), platelet-derived growth factor subunit B dimer (PDGF-BB), sCD120b (sTNF Receptor II), stem cell factor (SCF), tumor necrosis factor a (TNFa), tissue plasminogen activator (t-PA), thymic stromal lymphopoietin (TSLP), vascular endothelial growth factor A (VEGF-A), or vascular endothelial growth factor A (VEGF-D).
A large molecule may be selected from Afasevikumab (which binds interleukin-17 A and interleukin-17F), Afutuzumab (which binds CD20), ALD518 (which binds interleukin- 6), Alemtuzumab (which binds CD52), Anrukinzumab (which binds interleukin-13), Aselizumab (which binds L-selectin), Atezolizumab (which binds CD274), Avelumab (which
binds CD274), Basiliximab (which binds CD23), Bectumomab (which binds CD22), Belimumab (which binds BAFF), Bimekizumab (which binds interleukin-17A and interleukin-17F), Bivatuzumab (which binds CD44), Bleselumab (which binds CD40), Blinatumomab (which binds CD 19), Blontuvetmab (which binds CD20), Brazikumab (which binds interleukin-23), Brentuximab (which binds CD30), Briakinumab (which binds interleukin-12 and interleukin-23), Brodalumab (which binds interleukin-17), Canakinumab (which binds interleukin-ΐβ), Carlumab (which binds CCL2), Cedelizumab (which binds CD4), Clenoliximab (which binds CD4), Coltuximab (which binds CD 19), Dacetuzumab (which binds CD40), Daclizumab (which binds CD23), Dapirolizumab pegol (which binds CD154), Daratumumab (which binds CD38), Dectrekumab (which binds interleukin-13),
Denintuzumab (which binds CD19), Denosumab (which binds RANKL), Dupilumab (which binds interleukin-4), Durvalumab (which binds CD274), Efalizumab (which binds LFA-1), Elsilimomab (which binds interleukin-6), Enokizumab (which binds interleukin-9),
Epratuzumab (which binds CD22), FBTA05 (which binds CD20), Fezakinumab (which binds interleukin-22), Fletikumab (which binds interleukin-20), Fontolizumab (which binds IFN-γ), Foralumab (which binds CD3), Fresolimumab (which binds TGF-β), Galiximab (which binds CD80), Gevokizumab (which binds interleukin-ΐβ), Gomiliximab (which binds CD23), GSK3174998 (which binds OX40), Guselkumab (which binds interleukin-23), Ibalizumab (which binds CD4), Ibritumomab (which binds CD20), Imalumab (which binds MIF), Inebilizumab (which binds CD 19), Inolimomab (which binds CD23), Inotuzumab (which binds CD22), Ipilimumab (which binds CD152), Iratumumab (which binds CD30),
Isatuximab (which binds CD38), Itolizumab (which binds CD6), Ixekizumab (which binds interleukin-17 A), Keliximab (which binds CD4), Lambrolizumab (which binds PD-1), Lebrikizumab (which binds interleukin-13), Lenzilumab (which binds CSF2), Lerdelimumab (which binds TGF- 2), Lilotomab (which binds CD37), Lirilumab (which binds KIR2D), Lucatumumab (which binds CD40), Lulizumab pegol (which binds CD28), Lumiliximab (which binds CD23), Maslimomab (which binds T-cell receptor), MEDI6383 (which binds OX40), Mepolizumab (which binds interleukin-5), Metelimumab (which binds TGF-βΙ), Moxetumomab (which binds CD22), Muromonab-CD3 (which binds CD3), Namilumab (which binds CSF2), Naratuximab (which binds CD37), Nivolumab (which binds PD-1), Obinutuzumab (which binds CD20), Ocaratuzumab (which binds CD20), Ocrelizumab (which binds CD20), Odulimomab (which binds LFA-1), Ofatumumab (which binds CD20), Olokizumab (which binds interleukin-6), Otelixizumab (which binds CD3), Otlertuzumab (which binds CD37), Oxelumab (which binds OX-40), Pamrevlumab (which binds CTGF),
Pascolizumab (which binds interleukin-4), Pembrolizumab (which binds PD-1), Perakizumab (which binds interleukin-17A), Pidilizumab (which binds PD- 1), Pinatuzumab (which binds CD22), Pogalizumab (which binds CD134), Polatuzumab (which binds CD79B),
Prezalizumab (which binds ICOSL), Priliximab (which binds CD4), PRO 140 (which binds CCR5), Reslizumab (which binds interleukin-5), Risankizumab (which binds interleukin- 23A), Rituximab (which binds CD20), Rontalizumab (which binds IFN-a), Ruplizumab (which binds CD 154), Sarilumab (which binds interleukin-6), Secukinumab (which binds interleukin-17A), SGN-CD19A (which binds CD19), Sifalimumab (which binds IFN-a), Siltuximab (which binds interleukin-6), Siplizumab (which binds CD2), Sirukumab (which binds interleukin-6), Tabalumab (which binds BAFF), Tamtuvetmab (which binds CD52), Taplitumomab (which binds CD 19), Teneliximab (which binds CD40), Teplizumab (which binds CD3), Tetulomab (which binds CD37), Tezepelumab (which binds thymic stromal lymphopoietin), TGN1412 (which binds CD28), Ticilimumab (which binds CTLA-4), Tildrakizumab (which binds interleukin-23), TNX-650 (which binds interleukin- 13), Toralizumab (which binds CD154), Tositumomab (which binds CD20), Tralokinumab
(which binds interleukin-13), Tregalizumab (which binds CD4), Tremelimumab (which binds CTLA-4), Ublituximab (which binds CD20), Ulocuplumab (which binds CXCR4), Urelumab (which binds 4- IBB), Ustekinumab (which binds interleukin- 12 and interleukin-23), Utomilumab (which binds 4-1BB), Varlilumab (which binds CD27), Veltuzumab (which binds CD20), Visilizumab (which binds CD3), Vorsetuzumab (which binds CD70),
Zanolimumab (which binds CD4), and Zolimomab (which binds CD5) or an antigen-binding fragment of any one of the foregoing. The large molecule may be selected from
YW243.55.S70, MED 14736, and MDX-1105 or an antigen-binding fragment of any one of the foregoing.
A system may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more pharmaceutical agents as described herein. A system may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
pharmaceutical agents.
IV. PLURALITY OF SAMPLES
Various aspects of the invention relate to a plurality of systems. A system of the plurality may comprise an inducible T-cell, a checkpoint receptor ligand-presenting cell (e.g. , a B-cell), and second costimulatory ligand. A system may or may not further comprise a transcription inducer such as doxycycline. A system may further comprise 0, 1, 2, 3, or 4 of a first large molecule, a second large molecule, a first small molecule compound, and a second
small molecule compound. A system may comprise an inducible T-cell, modified inducible T-cell, transcription inducer, checkpoint receptor ligand-presenting cell (e.g. , a B-cell), second costimulatory ligand, first large molecule, second large molecule, first small molecule compound, and second small molecule.
A plurality of systems may be arranged, for example, in a plate configured for high- throughput screening, e.g. , a multi-well plate, such as a 6 well, 12 well, 24 well, 96 well, 384 well, 1536 well, or 3,456 well plate. A plurality of systems may comprise 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 or more systems.
Each system of a plurality of systems may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a ligand-presenting cell that expresses at least one checkpoint receptor ligand; and a costimulatory ligand. The T-cell may be any T-cell described herein, such as a human T-cell (e.g. , a Jurkat cell). The ligand-presenting cell may be any ligand-presenting cell described herein, such as a human B-cell (e.g. , a Raji cell). The costimulatory ligand may be an anti-CD3 antibody or other ligand that specifically binds the T-cell receptor thereby activating T-cell receptor mediated signaling. An anti-CD3 antibody may be associated with a solid support, such as a bead.
At least one system of a plurality of systems may comprise a transcription inducer that induces the transcription of the two or more checkpoint inhibitors. At least one system of a plurality of systems may lack the transcription inducer. The transcription inducer may be a small molecule such as doxycycline, tetracycline, a streptogramin, a macrolide, a steroid (e.g. , an estrogen), AP20187, AP21967, AP21998, or AP1510.
At least one system of a plurality of systems may comprise a pharmaceutical agent. At least one system of a plurality of systems may lack the pharmaceutical agent. For example, at least one system may lack both a transcription inducer and a pharmaceutical agent; at least one system may comprise the transcription inducer and lack the pharmaceutical agent; at least one system may lack the transcription inducer and comprise the pharmaceutical agent; and/or at least one system may comprise both the transcription inducer and the pharmaceutical agent.
At least one system of a plurality of systems may comprise a T-cell comprising a gene knockout or gene knockdown (i.e. , wherein a T-cell comprising the gene knockout or gene knockdown is a T-cell engineered to inducibly express two or more checkpoint inhibitors). At least one system of a plurality of systems may comprise a T-cell lacking the gene knockout or gene knockdown (i.e. , wherein the T-cell lacking the gene knockout or gene
knockdown is a T-cell engineered to inducibly express two or more checkpoint inhibitors). For example, at least one system may lack a transcription inducer and comprise a T-cell lacking the gene knockout or gene knockdown; at least one system may comprise the transcription inducer and comprise a T-cell lacking the gene knockout or gene knockdown; at least one system may lack the transcription inducer and comprise a T-cell comprising the gene knockout or gene knockdown; and/or at least one system may comprise the transcription inducer and comprise a T-cell comprising the gene knockout or gene knockdown. Similarly, at least one system may lack a pharmaceutical agent and comprise a T-cell lacking the gene knockout or gene knockdown; at least one system may comprise the pharmaceutical agent and comprise a T-cell lacking the gene knockout or gene knockdown; at least one system may lack the pharmaceutical agent and comprise a T-cell comprising the gene knockout or gene knockdown; and/or at least one system may comprise the pharmaceutical agent and comprise a T-cell comprising the gene knockout or gene knockdown
At least one system of a plurality of systems may comprise a T-cell engineered to express a recombinant gene in addition to the two or more checkpoint receptors. At least one system of a plurality of systems may comprise a T-cell lacking the recombinant gene. For example, at least one system may lack a transcription inducer and comprise a T-cell engineered to express the recombinant gene; at least one system may comprise the transcription inducer and comprise a T-cell engineered to express the recombinant gene; at least one system may lack the transcription inducer and comprise a T-cell lacking the recombinant gene; and/or at least one system may comprise the transcription inducer and comprise a T-cell lacking the recombinant gene. Similarly, at least one system may lack a pharmaceutical agent and comprise a T-cell engineered to express the recombinant gene; at least one system may comprise the pharmaceutical agent and comprise a T-cell engineered to express the recombinant gene; at least one system may lack the pharmaceutical agent and comprise a T-cell lacking the recombinant gene; and/or at least one system may comprise the pharmaceutical agent and comprise a T-cell lacking the recombinant gene.
A T-cell may be engineered to inducibly express two or more checkpoint receptors as described herein, such as two or more checkpoint receptors are selected from PD-1, CTLA-4, PD-1H, LAG-3, BTLA, KIR2D, TIM-3, ADORA2A, CD160, 2B4, TIGIT, and interleukin- 10 receptor. A T-cell may be engineered to inducibly express two or more checkpoint receptors selected from PD-1 and CTLA-4.
A ligand-presenting cell may express at least one checkpoint receptor ligand that is a ligand of the two or more checkpoint receptors of the T-cell. The ligand-presenting cell may
endogenously express the at least one checkpoint receptor ligand or the ligand-presenting cell may be engineered to express the at least one checkpoint receptor ligand. The at least one checkpoint receptor ligand(s) may be selected from PD-L1, PD-L2, B7.1, B7.2, B7-H4, B7- H2, B7-H7, MHC class II, HVEM, CD 155, galectin-9, and TIM-3 ligand. For example, a ligand-presenting cell may express either PD-L1 or PD-L2 and either B7.1 or B7.2.
A ligand-presenting cell may express a second costimulatory ligand in addition to the costimulatory ligand of a system. The second costimulatory ligand may be a ligand of a costimulatory receptor, e.g. , wherein the costimulatory receptor is expressed by the T-cell of a system. The second costimulatory ligand may be a ligand of 4- IBB, CD27, OX40, BAFFR, TACI, BMCA, CD40L, CD28, ICOS, or GITR. For example, a ligand-presenting cell may express B7.1 and/or B7.2, which are ligands of CD28.
The costimulatory ligand may be, for example, an anti-CD3 antibody as described herein, which may be associated with a solid support, such as a bead, the surface of a tissue culture plate, or the surface of a multi-well plate.
A plurality of systems may be useful to determine whether a protein may be a suitable drug target or whether a pharmaceutical agent has an ON target or OFF target affect. For example, a plurality of systems may comprise an inducible T-cell system comprising a gene knockout or knockdown to determine whether a protein encoded by the gene is a suitable drug target. Similarly, a plurality of systems may comprise (1) a system comprising a pharmaceutical agent and a T-cell comprising a gene knockout or knockdown, (2) a system comprising the pharmaceutical agent and a T-cell lacking the gene knockout or knockdown, (3) a system lacking the pharmaceutical agent and a T-cell lacking the gene knockout or knockdown, and/or (4) a system lacking the pharmaceutical agent and a T-cell comprising the gene knockout or knockdown, which may be useful to determine whether the pharmaceutical agent affects T-cell activation through a pathway mediated by the protein product of the gene.
Each system of a plurality of systems may be selected from: a system that lacks a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown; a system that comprises a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown; a system that lacks a transcription inducer, comprises a pharmaceutical agent, and lacks a T- cell comprising a gene knockout or gene knockdown; a system that comprises a transcription inducer, comprises a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown; a system that lacks a transcription inducer, lacks a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown; a system that
comprises a transcription inducer, lacks a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown; a system that lacks a transcription inducer, comprises a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown; and/or a system that comprises a transcription inducer, comprises a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown.
A plurality of systems may comprise a system comprising two pharmaceutical agents. The two pharmaceutical agents may be selected from at least one small molecule compound and at least one large molecule. For example, the two pharmaceutical agents may be two small molecule compounds, two large molecules (e.g. , two antibodies), or a small molecule compound (e.g. , a kinase inhibitor) and a large molecule (e.g. , an antibody). Each system of a plurality of systems may be selected from: a system that lacks a small molecule compound and lacks a large molecule; a system that comprises one small molecule compound and lacks a large molecule; a system that comprises one small molecule compound and one large molecule; a system that comprises at least two small molecule compounds and lacks a large molecule; a system that comprises at least two small molecule compounds and one large molecule; a system that lacks a small molecule compound and comprises at least two large molecules; and/or a system that comprises one small molecule compound and at least two large molecules.
The at least one large molecule may comprise an antibody such as an anti-CTLA-4 antibody and an anti-PD- 1 antibody. The plurality of systems may comprise a system comprising two pharmaceutical agents wherein the two pharmaceutical agents are an anti- CTLA-4 antibody and an anti-PD- 1 antibody. The at least one large molecule may comprise 1 or 2 of avelumab, atezolizumab, durvalumab, ipilimumab, lambrolizumab, nivolumab, pembrolizumab, pidilizumab, tremelimumab, and ticilimumab. The plurality of systems may comprise a system comprising two pharmaceutical agents wherein the two pharmaceutical agents are selected from avelumab, atezolizumab, durvalumab, ipilimumab, lambrolizumab, nivolumab, pembrolizumab, pidilizumab, tremelimumab, and ticilimumab. For example, the at least one large molecule may comprise ipilimumab and/or nivolumab. The plurality of systems may comprise a system comprising two pharmaceutical agents wherein the two pharmaceutical agents are ipilimumab and nivolumab.
Each system of a plurality of inducible T-cell systems may comprise tissue culture media, such as RPMI media. A system may further comprise blood serum (e.g. , FBS), which may be present at a concentration of about 1% to about 20% serum, such as about 5% to
about 15%, such as about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15%. Each system may further comprise an antibiotic such as a penicillin (e.g. , penicillin G), an aminoglycoside (e.g. , streptomycin, gentamicin), and/or an aminonucleoside (e.g. , puromycin).
Various aspects of the invention relate to a plurality of samples corresponding to a plurality of systems as described herein. A plurality of samples may comprise the supernatants of each system of a plurality of systems. A plurality of samples may or may not comprise the cells of an inducible T-cell system. A plurality of samples may be substantially free of the cells of a plurality of inducible T-cell systems (i.e. , T-cells and ligand-presenting cells).
A plurality of samples may comprise the supernatant of a plurality of inducible T-cell systems as described herein and reagents for an enzyme-linked immunosorbent assay (ELISA) or other colorimetric immunoassay. Each sample of a plurality of samples may consist essentially of the supernatant of an inducible T-cell system (e.g. , of a plurality of systems) as described herein and reagents for an (ELISA) or other colorimetric immunoassay.
Reagents for an ELISA or other colorimetric immunoassay may include one or more a primary antibody (e.g. , an anti-interleukin-2 antibody or an anti-interferon γ antibody), a secondary antibody (e.g. , an anti-IgG antibody, anti-IgA antibody, anti-IgY antibody, anti- IgM antibody, anti-IgE antibody, anti-IgD antibody, an anti-Rabbit IgG antibody, an anti-Rat IgG antibody, an anti-Mouse IgG antibody, an anti-Human IgG antibody), an antibody- fluorophore conjugate (e.g. , an antibody- Alexa Fluor 488 conjugate, an antibody-Texas Red conjugate, an antibody-fluorescein conjugate), an antibody-biotin conjugate, an antibody- enzyme conjugate (e.g. , an antibody- horseradish peroxidase conjugate or an antibody- alkaline phosphatase conjugate), a colorimetric substrate for horseradish peroxidase (e.g. , ABTS, OPD, AmplexRed, DAB, AEC, TMB, homovanillic acid, luminol), and a colorimetric substrate for alkaline phosphatase (e.g. , nitroblue tetrazolium, 5-bromo-4-chloro-3-indolyl phosphate).
A plurality of systems or plurality of samples may be arranged in a multi-well plate such as a 6 well, 12 well, 24 well, 96 well, 384 well, 1536 well, or 3,456 well plate. A multi- well plate may comprise, for example, U-bottom wells.
V. APPLICATIONS
Various aspects of the invention relate to methods of preparing an inducible T-cell system as described herein or a plurality of inducible T-cell systems. A method may utilize a
multi-well plate, although a method may be adapted to other formats including individual tissue culture plates, tissue culture flasks, test tubes, microfluidics platforms, or lab-on-chip platforms. A method may be a method of preparing a multi-well plate.
The following methods generally describe the addition of cells, beads, transcription inducers, pharmaceutical agents, etc. to "systems." The addition of a composition (e.g. , cell, bead, transcription inducer, pharmaceutical agent) to a "system" may comprise the addition of the composition to a well of a multi-well plate. A plurality of systems may be arranged, for example, in a plurality of wells of a multi-well plate (or a plurality of wells on multiple multi-well plates). A group of systems may correspond to a group of wells of a plurality of wells.
A method may comprise adding a T-cell as described herein to each well of a plurality of wells of a multi-well plate. A method may comprise adding a T-cell as described herein to each system of a plurality of systems. The cells may be added in tissue culture media such as RPMI media, which may comprise serum (e.g. FBS). The tissue culture media may optionally comprise L-glutamine. The tissue culture media may optionally comprise an antibiotic, such as a penicillin (e.g. , penicillin G), an aminoglycoside (e.g. , streptomycin, gentamicin), and/or an aminonucleoside (e.g. , puromycin).
A T-cell may or may not comprise a genetic modification such as a gene knockout, gene knockdown, or a recombinant gene (i.e. , in addition to the two or more recombinant genes encoding checkpoint receptors). Each T-cell added to a system may be from the same species or cell line. For example, each T-cell may be a Jurkat cell. Each T-cell added to a system of a plurality of systems may comprise recombinant gene(s) encoding the same checkpoint receptors, e.g. , each T-cell may be descendant from the same parent cell, wherein the cell lineage defined by the parent cell is engineered to inducibly express two or more checkpoint receptors. The T-cells of individual systems may nevertheless vary. For example, a T-cell may further comprise a gene knockout, gene knockdown, or additional recombinant gene that has been engineered into the T-cell on top of the genes encoding the two or more checkpoint receptors.
A method may comprise adding a knockout T-cell to a first group of systems of a plurality of systems. The knockout T-cell may be engineered to inducibly express two or more checkpoint receptors and the knockout T-cell may comprise a gene knockout. The method may further comprise adding a wild type T-cell to a second group of systems of the plurality of systems. The wild type T-cell may be engineered to inducibly express the two or more checkpoint receptors and the wild type T-cell may lack the gene knockout. A wild type
T-cell and knockout T-cell may be descendent from the same parent cell, e.g. , wherein the parent cell comprised genes encoding the two or more checkpoint receptors and wherein the parent cell lacked the gene knockout. A plurality of systems may consist of the first group of systems and the second group of systems. In some embodiments, the first group and second group do not overlap.
A method may further comprise adding a transcription inducer to a group of systems (e.g. , a third group of systems). The transcription inducer may be doxycycline, which may be added at a concentration of about 50 ng/mL to about 1000 ng/mL, such as about 100 ng/mL to about 500 ng/mL or about 200 ng/mL to about 300 ng/mL. The group of systems may be a subset of a plurality of systems. Systems that do not comprise the transcription inducer may serve as relevant controls.
A method may further comprise incubating the T-cells of a plurality of systems (e.g. , after adding the T-cells to a plurality of systems and after adding the transcription inducer to a group of systems). The T-cells may be incubated at about 37°C. The T-cells may be incubated for about 6 hours to about 7 days, such as about 12 hours to about 96 hours, about 24 hours to about 72 hours, or about 36 hours to about 50 hours. The T-cells may be incubated for at least about 6 hours, 12 hours, 24 hours, 30 hours, 36 hours, 42 hours, or 48 hours.
A method may further comprise washing the T-cells of a plurality of systems (e.g. , after adding a transcription inducer to a group of systems and/or prior to adding a costimulatory ligand). The T-cells may be washed in tissue culture media. Washing the T- cells may reduce the concentration of a transcription inducer in the tissue culture media.
A method may further comprise adding a costimulatory ligand as described herein (e.g. , anti-CD3 antibody-coated beads) to each system of a plurality of systems. The costimulatory ligand may be added to each system of a plurality of systems about 6 hours to about 7 days after adding the transcription inducer, such as about 12 hours to about 96 hours, about 24 hours to about 72 hours, or about 36 hours to about 50 hours. The costimulatory ligand may be added to each system of a plurality of systems at least about 6 hours, 12 hours, 24 hours, 30 hours, 36 hours, 42 hours, or 48 hours after adding the transcription inducer to a group of systems. The costimulatory ligand may be added to each system of a plurality of systems after washing the T-cells of a plurality of systems to reduce the concentration of a transcription inducer.
A method may comprise adding one or more pharmaceutical agents to systems of the plurality. For example, a method may comprise adding a first pharmaceutical agent to each
system of a group of systems (e.g. , a fourth group of systems). A first pharmaceutical agent may be a large molecule (e.g. , antibody, such as an anti-PD-1 or anti-CTLA-4 antibody) or a small molecule compound (e.g. , kinase inhibitor). A first pharmaceutical agent may be added to a system that was contacted with a transcription inducer, e.g. , to determine whether the first pharmaceutical agent can increase the activation state of a T-cell expressing two or more checkpoint receptors in the presence of checkpoint receptor ligands. A first pharmaceutical agent may be added to a system that was not contacted with a transcription inducer, e.g. , as a control. A first pharmaceutical agent may be added to a system comprising a knockout T- cell, e.g. , to determine whether the first pharmaceutical agent increases T-cell activation through a signaling pathway mediated by the knockout gene. A first pharmaceutical agent may be added to a system comprising a wild type T-cell, e.g. , as a control.
A method may comprise adding a second pharmaceutical agent to a group of systems (e.g. , a fifth group of systems). A second pharmaceutical agent may be a large molecule or a small molecule compound. For example, the first pharmaceutical agent and the second pharmaceutical agent may be antibodies, e.g. , the first pharmaceutical agent may be an anti- PD- 1 antibody and the second pharmaceutical agent may be an anti-CTLA-4 antibody. The first pharmaceutical agent and the second pharmaceutical agent may both be small molecule compounds, or the first pharmaceutical agent may be a large molecule and the second pharmaceutical agent may be a small molecule compound. The first pharmaceutical agent and the second pharmaceutical agent may both be added to at least one discrete system, e.g. , to assess whether the two pharmaceutical agents display an additive or synergistic effect. The at least one system may comprise a system that was contacted with the transcription inducer. The at least one system may comprise a system that was not contacted with the transcription inducer, e.g. , to serve as a control. The first pharmaceutical agent may be added to at least one system to which the second pharmaceutical agent is not added, e.g. to serve as a control. The second pharmaceutical agent may be added to at least one system to which the first pharmaceutical agent is not added, e.g. to serve as a control. A plurality of systems may comprise a system to which neither the first pharmaceutical agent nor the second
pharmaceutical agent is added, e.g. , to serve as a control.
A method may comprise adding a third pharmaceutical agent to a group of systems
(e.g. , a sixth group of systems). A third pharmaceutical agent may be a large molecule or a small molecule compound. For example, the first pharmaceutical agent and the second pharmaceutical agent may be antibodies (e.g. , anti-PD-1 and anti-CTLA-4 antibodies, respectively), and the third pharmaceutical agent may be a small molecule compound (e.g. , a
kinase inhibitor). The first pharmaceutical agent, second pharmaceutical agent, and third pharmaceutical agent may each be added to at least one discrete system, e.g. , to assess whether the three pharmaceutical agents display an additive or synergistic effect. The at least one system may comprise a system that was contacted with the transcription inducer. The at least one system may comprise a system that was not contacted with the transcription inducer, e.g. , to serve as a control. The first pharmaceutical agent may be added to at least one system to which the second pharmaceutical agent and third pharmaceutical agent are not added, e.g. to serve as a control. The second pharmaceutical agent may be added to at least one system to which the first pharmaceutical agent and third pharmaceutical agent are not added, e.g. to serve as a control. The third pharmaceutical agent may be added to at least one system to which the second pharmaceutical agent and first pharmaceutical agent are not added, e.g. to serve as a control. A plurality of systems may comprise a system to which neither the first pharmaceutical agent, second pharmaceutical agent, nor third pharmaceutical agent is added, e.g. , to serve as a control. Each permutation of the three pharmaceutical agents may be added to systems that were contacted with the transcription inducer. Various permutations of the three pharmaceutical agents may be added to systems that were not contacted with the transcription inducer, e.g. , to serve as controls.
A method may comprise adding a fourth pharmaceutical agent to a group of systems (e.g. , a seventh group of systems). A fourth pharmaceutical agent may be a large molecule or a small molecule compound. For example, the third pharmaceutical agent may be a small molecule compound and the fourth pharmaceutical agent may be a small molecule compound.
A pharmaceutical agent may be added at a concentration of about 0.1 μg/mL to about 100 μg/mL, such as about 1 μg/mL to about 50 μg/mL, about 0.1 μg/mL to about 10 μg/mL, about 0.1 μg/mL to about 1 μg/mL, about 1 μg/mL to about 10 μg/mL, about 5 μg/mL to about 20 μg/mL, about 10 μg/mL to about 30 μg/mL, or about 20 μg/mL to about 50 μg/mL (e.g. , wherein the pharmaceutical agent is a large molecule, such as an antibody).
A pharmaceutical agent may be added at a concentration of about 100 pM to about 10 μΜ, such as about 100 pM to about 10 nM, about 500 pM to about 50 nM, about 1 nM to about 100 nM, about 5 nM to about 500 nM, about 10 nM to about 1 μΜ, about 50 nM to about 5 μΜ, about 100 pM to about 10 nM, about 500 pM to about 100 nM, about 1 nM to about 500 nM, about 1 nM to about 1 μΜ, or about 1 nM to about 5 μΜ (e.g. , for small molecule compounds).
A method may further comprise adding a ligand-presenting cell to each system of a plurality of systems. The same ligand-presenting cell (e.g., different cells from the same cell line) may be added to each system. The ligand-presenting cell may be a B-cell, such as a Raji cell. The ligand-presenting cell may be a cell that is engineered to express a ligand of a checkpoint receptor (e.g. , PD-L1, PD-L2, B7.1, B7.2). The ligand-presenting cell may be added at a ratio of about 1: 10 to 10: 1 relative to the T-cell, such as about 1 :5 to about 5: 1, about 1 :4 to about 4: 1, about 1 :3 to about 3: 1, or about 1 :2 to about 2: 1. The ligand- presenting cell may be added after adding the costimulatory ligand. The ligand-presenting cell may be added after adding the one or more pharmaceutical agents.
A method may comprise measuring a concentration of a biomarker. Measuring the concentration of the biomarker may comprise measuring the concentration of the biomarker in the supernatant of a system. Measuring may comprise performing an enzyme-linked immunosorbent assay (ELISA) or other colorimetric immunoassay. The biomarker may be interleukin-2 or interferon γ. A method may comprise contacting a system or supernatant thereof with one or more of a primary antibody, an anti-interleukin-2 antibody, an anti- interferon γ antibody, a secondary antibody, an anti-IgG antibody, an antibody-fluorophore conjugate, an antibody-biotin conjugate, an antibody-enzyme conjugate, a colorimetric substrate for horseradish peroxidase, and a colorimetric substrate for alkaline phosphatase. A method may comprise contacting each system of a plurality of systems (or the supernatants thereof) with one or more of a primary antibody, an anti-interleukin-2 antibody, an anti- interferon γ antibody, a secondary antibody, an anti-IgG antibody, an antibody-fluorophore conjugate, an antibody-biotin conjugate, an antibody-enzyme conjugate, a colorimetric substrate for horseradish peroxidase, and a colorimetric substrate for alkaline phosphatase. A method may further comprise comparing the relative concentration of the biomarker in at least one system of the plurality of systems to the relative concentration of the biomarker in at least one other system of the plurality of systems.
A. Discovery and validation of novel targets
Various aspects of the invention relate to methods of validating a T-cell target gene. A method may comprise providing an inducible T-cell system as described herein. The inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a checkpoint receptor ligand-presenting cell engineered to
constitutively express one or more checkpoint receptor ligands; and/or an anti-CD3 antibody to stimulate TCR signaling. The T-cell may express the T-cell receptor (TCR) and a
costimulatory receptor such as CD28. The T-cell may be a Jurkat cell. The ligand-presenting cell may express a costimulatory ligand (e.g. , B7.1 and/or B7.2). The costimulatory ligand may be useful to provide a costimulatory signal. The ligand-presenting cell may be a B-cell, such as a Raji cell.
The T-cell may comprise a gene knockout or knockdown, as described herein, supra.
A gene knockout may be made, for example, using a CRISPR/Cas9 strategy. The T-cell engineered to inducibly express two or more checkpoint receptors may therefore be a T-cell comprising a gene knockout or knockdown, such as a gene knockout generated using a CRISPR/Cas9 strategy. A method may comprise providing a CRISPR/Cas9 system to knockout a candidate T-cell gene.
A method may further comprise inducing the expression of the two or more checkpoint receptors in the T-cell. For example, the two or more checkpoint receptors may be operably-linked to a promoter that is inducible by doxycycline, and inducing the expression of two or more checkpoint receptors may comprise contacting the T-cell (or the inducible T-cell system) with doxycycline.
TCR signaling (e.g. , T-cell activation) is measurable by monitoring the interleukin-2 (IL2) expression of a T-cell. A method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in a non-induced control T-cell. A method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in an induced control T-cell that does not comprise the gene knockout or gene knockdown.
TCR signaling is measurable by monitoring other molecules, such as interferon γ (INFy), and thus, a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in a non-induced control T-cell. A method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in an induced control T-cell that does not comprise the gene knockout or gene knockdown.
A method may thereby identify if the candidate T-cell gene is a T-cell checkpoint target gene.
Various aspects of the invention relate to a method of discovering or validating a drug target, comprising providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon γ) in at least two systems of the plurality. For example, a plurality of inducible T-cell systems may include a system comprising a T-cell having a knockout or
knockdown of a gene encoding the drug target. The plurality may further include a system comprising a T-cell lacking the knockout or knockdown of the gene. The method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising the knockout or knockdown and the T-cell system lacking the knockout or knockdown. The drug target is validated if the system comprising the T-cell having the knockout or knockdown displays increased T-cell activation relative to the system
comprising the T-cell lacking the knockout or knockdown.
B. Small molecule screening and validation
Various aspects of the invention relate to methods of identifying checkpoint inhibitors. A method may comprise providing an inducible T-cell system as described herein. The inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a checkpoint receptor ligand-presenting cell engineered to constitutively express one or more checkpoint receptor ligands; and/or an anti-CD3 antibody to stimulate TCR signaling. The T-cell may express the T-cell receptor (TCR) and a costimulatory receptor such as CD28. The T-cell may be a Jurkat cell. The ligand-presenting cell may express a costimulatory ligand (e.g. , B7.1 and/or B7.2). The costimulatory ligand may be useful to provide a costimulatory signal. The ligand-presenting cell may be a B-cell, such as a Raji cell.
A method may further comprise inducing the expression of the two or more checkpoint receptors in the T-cell. For example, the two or more checkpoint receptors may be operably-linked to a promoter that is inducible by doxycycline, and inducing the expression of two or more checkpoint receptors may comprise contacting the T-cell (or the inducible T-cell system) with doxycycline.
A method may further comprise contacting the T-cell (or inducible T-cell system) with one or more candidate compounds. A candidate compound may be, for example, a pharmaceutical agent, such as a small molecule compound or a large molecule as described herein, supra.
TCR signaling (e.g. , T-cell activation) is measurable by monitoring the interleukin-2 (IL2) expression of a T-cell. A method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in a non-induced control T-cell. A method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in an induced control T-cell that is not contacted with the one or more candidate compounds.
TCR signaling is measurable by monitoring other molecules, such as interferon γ (INFy), and thus, a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in a non-induced control T-cell. A method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in an induced control T-cell that is not contacted with the one or more candidate compounds.
A method may thereby identify if the one or more candidate compounds are checkpoint inhibitors.
Various aspects of the invention relate to a method of determining whether a small molecule compound affects T-cell activation, comprising providing a plurality of inducible T- cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon γ) in at least two systems of the plurality. For example, a plurality of inducible T-cell systems may include a system comprising the small molecule compound. The plurality may further include a system lacking the small molecule compound. The method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising the small molecule compound and the T-cell system lacking the small molecule compound. The small molecule compound affects T-cell activation if the system comprising the small molecule compound displays different T-cell activation relative to the system lacking small molecule compound. A small molecule compound may be a viable drug candidate for use in treating cancer or infection, for example, if the system comprising the small molecule compound displays increased T-cell activation relative to the system lacking small molecule compound. A small molecule compound may be a viable drug candidate for use in autoimmune disease, for example, if the system comprising the small molecule compound displays attenuated T-cell activation relative to the system lacking small molecule compound.
C. Drug interaction screening
Various aspects of the invention relate to methods of assessing interactions between checkpoint inhibitors. A method may comprise providing an inducible T-cell system as described herein. The inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a checkpoint receptor ligand-presenting cell engineered to constitutively express one or more checkpoint receptor ligands; and/or an anti- CD3 antibody to stimulate TCR signaling. The T-cell may express the T-cell receptor (TCR) and a costimulatory receptor such as CD28. The T-cell may be a Jurkat cell. The ligand-
presenting cell may express a costimulatory ligand (e.g. , B7.1 and/or B7.2). The
costimulatory ligand may be useful to provide a costimulatory signal. The ligand-presenting cell may be a B-cell, such as a Raji cell.
A method may further comprise inducing the expression of the two or more checkpoint receptors in the T-cell. For example, the two or more checkpoint receptors may be operably-linked to a promoter that is inducible by doxycycline, and inducing the expression of two or more checkpoint receptors may comprise contacting the T-cell (or the inducible T-cell system) with doxycycline.
A method may further comprise contacting the T-cell (or inducible T-cell system) with two or more checkpoint inhibitors. A checkpoint inhibitory drug may be, for example, an FDA-approved checkpoint inhibitory drug. A checkpoint inhibitory drug may be a monoclonal antibody, such as an anti-CTLA or anti-PD-1 antibody. The two or more checkpoint inhibitors may comprise a small molecule compound as described herein, supra.
TCR signaling (e.g. , T-cell activation) is measurable by monitoring the interleukin-2 (IL2) expression of a T-cell. A method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in a non-induced control T-cell. A method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in an induced control T-cell that is contacted with less than two or more checkpoint inhibitors, such as a single individual checkpoint inhibitor.
TCR signaling is also measurable by monitoring other molecules, such as interferon γ (INFy), and thus, a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in a non-induced control T-cell. A method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in an induced control T-cell that is contacted with less than two or more checkpoint inhibitors, such as a single individual checkpoint inhibitor.
A method may thereby assess the interaction between the one or more checkpoint inhibitors.
Various aspects of the invention relate to a method of assessing an interaction between a small molecule compound and an antibody that binds a checkpoint receptor. The method may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon γ) in at least two systems of the plurality. For example, a plurality
of inducible T-cell systems may include a system comprising both the small molecule compound and the antibody. The plurality may further include a system comprising the small molecule compound and lacking the antibody, a system lacking the small molecule compound and comprising the antibody, and/or a system lacking the small molecule compound and lacking the antibody. The method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising both the small molecule compound and the antibody with a T-cell system lacking either the small molecule compound, the antibody, or both. Assessing an interaction between the small molecule compound and the antibody may comprise determining whether the two pharmaceutical agents display an additive or synergistic effect, e.g., based on one or more comparisons.
Various aspects of the invention relate to a method of assessing an interaction between a first small molecule compound and a second small molecule compound. The method may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon γ) in at least two systems of the plurality. For example, a plurality of inducible T-cell systems may include a system comprising the first small molecule compound and the second small molecule compound. The plurality may further include a system comprising the first small molecule compound and lacking the second small molecule compound, a system lacking the first small molecule compound and comprising the second small molecule compound, and/or a system lacking both the first small molecule compound and the second small molecule compound. The method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising both the first small molecule compound and the second small molecule compound with a T-cell system lacking either the first small molecule compound, the second small molecule compound, or both. Assessing an interaction between the first small molecule compound and the second small molecule compound may comprise determining whether the two small molecule compounds display an additive or synergistic effect, e.g. , based on one or more comparisons.
Various aspects of the invention relate to a method of assessing an interaction between a first large molecule and a second large molecule. The method may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon γ) in at least two systems of the plurality. For example, a plurality of inducible T- cell systems may include a system comprising both the first large molecule and the second large molecule. The plurality may further include a system comprising the first large
molecule and lacking the second large molecule, a system lacking the first large molecule and comprising the second large molecule, and/or a system lacking both the first large molecule and the second large molecule. The method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising both the first large molecule and the second large molecule with a T-cell system lacking either the first large molecule, the second large molecule, or both. Assessing an interaction between the first large molecule and the second large molecule may comprise determining whether the two large molecules display an additive or synergistic effect, e.g. , based on one or more comparisons. D. Analysis of mechanism of action
Various aspects of the invention relate to methods of interrogating ON or OFF target activity of a small molecule compound. A method may comprise providing an inducible T- cell system as described herein. The inducible T-cell system may comprise a T-cell engineered to inducibly express two or more checkpoint receptors; a checkpoint receptor ligand-presenting cell engineered to constitutively express one or more checkpoint receptor ligands; and/or an anti-CD3 antibody to stimulate TCR signaling. The T-cell may express the T-cell receptor (TCR) and a costimulatory receptor such as CD28. The T-cell may be a Jurkat cell. The ligand-presenting cell may express a costimulatory ligand (e.g. , B7.1 and/or B7.2). The costimulatory ligand may be useful to provide a costimulatory signal. The ligand-presenting cell may be a B-cell, such as a Raji cell.
The T-cell may comprise a gene knockout or knockdown, as described herein, supra. A gene knockout may be made, for example, using a CRISPR/Cas9 strategy. The T-cell engineered to inducibly express two or more checkpoint receptors may therefore be a T-cell comprising a gene knockout or knockdown, such as a gene knockout generated using a CRISPR/Cas9 strategy. A method may comprise providing a CRISPR/Cas9 system to knockout a candidate T-cell gene.
A method may further comprise inducing the expression of the two or more checkpoint receptors in the T-cell. For example, the two or more checkpoint receptors may be operably-linked to a promoter that is inducible by doxycycline, and inducing the expression of two or more checkpoint receptors may comprise contacting the T-cell (or the inducible T-cell system) with doxycycline.
A method may further comprise contacting the T-cell (or the inducible T-cell system) with a pharmaceutical agent, such as a small molecule compound. The pharmaceutical agent may specifically bind and/or inhibit the product encoded by the knockout gene or knockdown
gene, or the pharmaceutical agent may specifically bind and/or inhibit a molecule upstream or downstream of the product in a signaling pathway that includes the product. For example, the gene knockout or gene knockdown may be a kinase and the pharmaceutical agent may be a kinase inhibitor. Similarly, the gene knockout or gene knockdown may be a substrate of a kinase and the pharmaceutical agent may be a kinase inhibitor.
TCR signaling (e.g. , T-cell activation) is measurable by monitoring the interleukin-2 (IL2) expression of a T-cell. A method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in a non-induced control T-cell. A method may further comprise determining the level of IL2 expression of the T-cell as compared to a control level of IL2 expression in an induced control T-cell that does not comprise the gene knockout or gene knockdown.
TCR signaling is measurable by monitoring other molecules, such as interferon γ (INFy), and thus, a method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in a non-induced control T-cell. A method may further comprise determining the level of INFy expression of the T-cell as compared to a control level of INFy expression in an induced control T-cell that does not comprise the gene knockout or gene knockdown.
A method may thereby identify if the candidate T-cell gene is a T-cell checkpoint target gene.
Various aspects of the invention relate to a method of assessing whether a protein affects T-cell activation through a signaling pathway mediated by a checkpoint receptor. The protein may be, for example, a kinase or phosphatase. The method may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g., interleukin-2 or interferon γ) in at least two systems of the plurality. For example, a plurality of inducible T- cell systems may include a system comprising a checkpoint inhibitory antibody and a T-cell having a knockout or knockdown of a gene encoding the protein. The plurality may further include a system comprising the checkpoint inhibitory antibody and comprising a T-cell lacking the knockout or knockdown of the gene, a system lacking the checkpoint inhibitory antibody and comprising a T-cell having the knockout or knockdown of the gene, and/or a system lacking the checkpoint inhibitory antibody and comprising a T-cell lacking the knockout or knockdown of the gene. The method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising the checkpoint inhibitor antibody and T-cell comprising the knockout or knockdown with a T-cell system
lacking either the checkpoint inhibitor antibody, the knockout/knockdown, or both. A protein affects T-cell activation through a signaling pathway mediated by the checkpoint receptor targeted by the checkpoint inhibitory antibody if T-cell activation in the system comprising the checkpoint inhibitory antibody and knockout/knockdown is different from the system comprising the checkpoint inhibitory antibody and lacking the knockout/knockdown.
Various aspects of the invention relate to a method of assessing whether a pharmaceutical agent displays an ON target or OFF target effect. The method may comprise providing a plurality of inducible T-cell systems as described herein, supra, and measuring the concentration of a biomarker associated with T-cell activation (e.g. , interleukin-2 or interferon γ) in at least two systems of the plurality. For example, a plurality of inducible T- cell systems may include a system comprising both a pharmaceutical agent and a T-cell having a knockout or knockdown of a gene encoding the target. The plurality may further include a system comprising the pharmaceutical agent and a T-cell lacking the knockout or knockdown of the gene, a system lacking the pharmaceutical agent and comprising a T-cell having the knockout or knockdown of the gene, and/or a system lacking the pharmaceutical agent and comprising a T-cell lacking the knockout or knockdown of the gene. The method may further comprise comparing the relative concentration of the biomarker in the T-cell system comprising both the pharmaceutical agent and the T-cell comprising the knockout or knockdown with a T-cell system lacking either the pharmaceutical agent, the
knockout/knockdown, or both. The pharmaceutical agent may display an ON target effect, for example, if the system comprising the pharmaceutical agent and knockout/knockdown displays similar T-cell activation as the system comprising the pharmaceutical agent and lacking the knockout/knockdown and/or similar T-cell activation as the system lacking the pharmaceutical agent and comprising the knockout/knockdown.
EXEMPLIFICATION
While certain cells, compositions, and methods of the present invention have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds of the invention and are not intended to limit the same.
Example 1. T-cells expressing doxy cycline -inducible PD-1 and CTLA-4
Jurkat cells, which are immortalized human T-cells, were transfected with a gene for checkpoint receptor PD- 1 operably-linked to a doxycycline-inducible promoter and a gene for checkpoint receptor CTLA-4 operably-linked to a doxycycline-inducible promoter.
Briefly, human checkpoint receptor cDNAs for PD- 1 and CTLA-4 were cloned into a pLVX- TetOne vector (Clontech) under the control of the doxycycline inducible TRE3G promoter. Jurkat cells were infected with lenti viral vectors pLVX-TetOne-PD-1 and pLVX-TetOne- CTLA-4 thereby generating a T-cell line configured to inducibly express PD-1 and CTLA-4.
Jurkat cells endogenously express CD28 and the T-cell receptor (TCR). Figure 1 includes a drawing of a T-cell expressing PD-1 and CTLA-4 transgenes as well as CD28 and the T-cell receptor (TCR). CD28 is a costimulatory receptor required for T-cell activation and survival. T-cell stimulation through CD28 in addition to the T-cell receptor can provide a potent signal for the production of various cytokines including interleukin-2 (IL2). CD28 may be activated by ligands B7.1 (CD80) and B7.2 (CD86) as well as certain anti-CD28 antibodies. The T-cell receptor may be activated by engaging an antigen bound to a major histocompatibility complex (MHC) molecule or by engaging an anti-TCR antibody such as an anti-CD3 antibody.
Example 2. B-cells constitutively expressing PD-L1 or PD-L2
Raji cells, which are immortalized human B-cells, were transfected with a gene for either PD-L1 or PD-L2. Briefly, human checkpoint ligand cDNAs for PD-L1 and PD-L2 were each cloned into a pLVX-IRES-Puro vector (Clontech) under expression of a constitutive CMV promoter. Raji cells were infected with a lentiviral vector pLVX-IRES- Puro-PD-Ll or pLVX-IRES-Puro-PD-L2, thereby generating B-cells that constitutively express either PD-L1 or PD-L2.
PD-L1 and PD-L2 are checkpoint receptor ligands, which bind to checkpoint receptor PD-1, thereby inhibiting T-cell activation. Raji cells also endogenously express checkpoint receptor ligands B7.1 (CD80) and B7.2 (CD86), which bind to checkpoint receptor CTLA-4. B7.1 and B7.2 may also activate T-cells by binding CD28. Figure 1 includes a drawing of a B-cell expressing either a PD-L1 transgene or a PD-L2 transgene (PD-L1/PD-L2) as well as B7.1 and B7.2 (B-7.1/B-7.2).
Example 3. Expression of PD-1 and CTLA-4 checkpoint receptors in the presence of a PD-1 checkpoint ligand (PD-L1 or PD-L2) and a CTLA-4 checkpoint ligand (B7.1 or B7.2) decreases Ί -cell-mediated interleukin-2 production
The Jurkat cells expressing inducible PD-1 and CTLA-4 transgenes described in Example 1 were combined with (a) the Raji cells constitutively expressing either a PD-L1 or PD-L2 transgene as well as B7.1 and B7.2 as described in Example 2 and (b) anti-CD3 beads
(CD3 Ab). The anti-CD3 beads were prepared by coating anti-human CD3 antibodies from eBioscience to Dynabeads M-450 Epoxy beads from Invitrogen using Invitrogen' s coating protocol. Briefly, 700 of Dynabeads M-450 Epoxy beads were separated from
supernatant using a magnet. 616 of phosphate-buffered saline (PBS, pH 7.4) was added to the beads followed by 140 of anti-human CD3 antibodies from eBioscience. The mixture was incubated at room temperature for 15 minutes on a rotary mixer. 84 μΐ^ οί 1% bovine serum albumin (BSA) in PBS (pH 7.4) was added to a final concentration of 0.1% BSA. The mixture was incubated at room temperature for 16-24 hours on a rotary mixer. The beads were then washed 3 times with 1 mL of 0.1% BSA in PBS (pH 7.4). The beads were resuspended in 1120 μΐ, of 0.1% BSA in PBS (pH 7.4) resulting in a lOx stock solution of 200,000 beads per 10 μΐ,. Prior to adding the beads to cells, the PBS is removed and the beads were diluted with RPMI media containing 10% fetal bovine serum (FBS).
The inducible Jurkat cells described in Example 1 were induced with 250 ng/niL doxycycline for 2 days. Control samples without doxycycline were cultured in parallel. After the 2 days, the cell media was changed to wash out the doxycycline, and the cells were diluted to 1,000,000 cells in 900 μΐ, of RPMI media containing 10% fetal bovine serum (FBS). Raji cells constitutively expressing either PD-Ll or PD-L2 as described in Example 2 were diluted to 1,000,000 cells in 1000 μΐ, of RPMI media containing 10% FBS. 2,000,000 anti-CD3 beads in 50 μΐ, were added to 450 μΐ, of the Jurkat cells (500,000 cells), i.e. , at a ratio of four anti-CD3 beads to one Jurkat cell (4: 1). The Jurkat cells and beads were incubated at room temperature for 30 minutes. 500 μΐ, of the Raji cells (500,000 cells) were then added to the Jurkat cells (500,000 cells), and beads (2,000,000 beads), i.e. , at a ratio of one Raji cell to one Jurkat cell to 4 beads (1: 1 :4), thereby resulting in 1000 μΐ, total volume. 200 μΐ, of each sample was then transferred into a 96-well U-bottom plate, and the plate was incubated at 37°C for 22 hours.
After 22 hours, the 96-well plates were centrifuged at 1000 rpm for 5 minutes. 150 μΐ^ of supernatant was transferred into a new 96-well U-bottomed plate. The new 96-well plate was optionally frozen. 100 μΐ, of supernatant was then used in an interleukin-2 (IL2) ELISA to determine the concentration of IL2 secreted by the Jurkat cells.
The Jurkat cells secreted IL2 in the absence of doxycycline (- dox), and interleukin-2 secretion decreased upon the addition of doxycycline (+ dox). This finding suggests that the doxycycline-inducible expression of checkpoint receptors PD-1 and CTLA-4 decreases T-cell activation in the presence of PD- 1 and CTLA-4 checkpoint ligands, which is consistent with canonical checkpoint inhibition (Figure 2).
Example 4. T-cells expressing inducible PD-1 and CTLA-4 display increased interleukin-2 secretion in the presence of anti-PD-1 antibody nivolumab and anti-CTLA-4 antibody ipilimumab
The anti-PD-1 antibody nivolumab (Nivo; N) and/or the anti-CTLA-4 antibody ipilimumab (Ipi; I) were added to the Jurkat/Raji/anti-CD3 bead system described in Example 3. Briefly, 5-25 μg of nivolumab and/or ipilimumab was added to Jurkat cells in a protocol similar to that described in Example 3. The antibodies were added to the system after adding the anti-CD3 beads to the Jurkat cells and before incubating the Jurkat cells for 30 minutes at room temperature. A control IgG antibody (IgG) was added to a different sample as a negative control. Individually, the anti-PD-1 antibody and the anti-CTLA-4 antibody partially restored interleukin-2 (IL2) secretion in the presence of doxycycline-induced PD-1 and CTLA-4 expression (Figure 3B, experiments "3" and "4"). The combination of the anti- PD-1 antibody and the anti-CTLA-4 antibody displayed an additive effect (Figure 3B, experiment "5").
Example 5. T-cells expressing inducible PD-1 and CTLA-4 and comprising a gene knockout display increased interleukin-2 expression
A gene involved in the negative regulation of T-cells was knocked out of the Jurkat cells described in Example 1 using a CRISPR/Cas9 knockout strategy. Briefly, single guide RNAs (sgRNAs) and Cas9 were co-delivered to the Jurkat cells described in Example 1 using a single lentiviral vector. The knockout cells were incubated with Raji cells, anti-CD3 beads, and doxycycline as described in Example 3. The knockout cells displayed high interleukin-2 (IL2) secretion, suggesting that the knockout gene could be targeted to activate T-cells in the context of immune checkpoint inhibition (Figure 4).
The knockout cells were incubated with Raji cells, anti-CD3 beads, doxycycline, anti- PD-1 antibody nivolumab (Nivo; N), and anti-CTLA-4 antibody ipilimumab (Ipi; I) as described in Example 4. The gene knockout and the anti-PD- 1 and anti-CTLA-4 antibodies displayed an additive effect on interleukin-2 (IL2) secretion (Figure 5, experiments "3," "4," and "5"). This finding suggests that a drug that inhibits the product of the knockout gene will display an additive effect when used in combination with nivolumab and/or ipilimumab.
Example 6. Small molecules "compound 1 " and "compound 2 " display an additive effect in combination with anti-PD-1 antibody nivolumab and anti-CTLA-4 antibody ipilimumab on T- cell mediated interleukin-2 secretion in the presence of checkpoint inhibitors
Jurkat cells, Raji cells, and anti-CD3 beads were incubated in the presence of doxycycline as described in Example 3 and either (a) anti-PD-1 antibody nivolumab and anti- CTLA-4 antibody ipilimumab (b) small molecule compound 1 or small molecule compound 2, or (c) nivolumab, ipilimumab, and either compound 1 or compound 2. The small molecules compound 1 and compound 2 displayed a synergistic effect on interleukin-2 (IL2) secretion in combination with both nivolumab and ipilimumab (Figure 5, experiments "3," "6," and "7").
Example 7. The effect of small molecules on T-cell mediated interleukin-2 secretion disappears in T-cells comprising a gene knockout
Inducible T-cells comprising or lacking a gene knockout were incubated with Raji cells, anti-CD3 beads, doxycycline, and either compound 1, compound 2, or vehicle
(DMSO). Control experiments were performed with either compound 1, compound 2, or vehicle and T-cells that did not include the knockout. Both compound 1 and compound 2 increased T-cell activation relative to the vehicle control in T-cells that did not include the knockout (Figure 6C). Neither compound 1 nor compound 2 increased T-cell activation relative to the vehicle control in T-cells that included the knockout (Figure 6C). These results suggest that both compound 1 and compound 2, which are designed to target the protein encoded by the knockout gene, display an "ON" target effect, i. e. , that compound 1 and compound 2 specifically target the protein product of the knockout gene. EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the following claims:
Claims
1. An inducible T-cell system comprising:
a T-cell engineered to inducibly express two or more checkpoint receptors, wherein the T-cell expresses the T-cell receptor (TCR) and a costimulatory receptor;
a ligand-presenting cell engineered to constitutively express one or more checkpoint receptor ligands, wherein the ligand-presenting cell expresses a costimulatory ligand; and an anti-CD3 antibody to stimulate TCR signaling.
2. The inducible T-cell system of claim 1, wherein the T-cell is a Jurkat cell.
3. The inducible T-cell system of claim 1 or 2, wherein the ligand-presenting cell is a B- cell or an antigen-presenting cell.
4. The inducible T-cell system of claim 3, wherein the ligand-presenting cell is a B-cell, and the B-cell is a Raji cell.
5. The inducible T-cell system of any one of the preceding claims, wherein the ligand- presenting cell is derived from a human or non-human cell, and the one or more checkpoint receptor ligands are human checkpoint receptor ligands.
6. The inducible T-cell system of any one of the preceding claims, wherein the ligand- presenting cell is derived from a human or non-human cell, and the costimulatory ligand is a human costimulatory ligand.
7. The inducible T-cell system of any one of the preceding claims, wherein the T-cell and/or B-cell is derived from a human cell line.
8. The inducible T-cell system of any one of the preceding claims, wherein the two or more checkpoint receptors comprise PD-1 and CTLA-4.
9. The inducible T-cell system of claim 8, wherein the one or more checkpoint receptor ligands comprise PD-L1 and/or PD-L2.
10. The inducible T-cell system of any one of the preceding claims, wherein the two or more checkpoint receptors comprise PD-1, CTLA-4, PD-1H, LAG- 3, BTLA, KIR2D, TIM-3, ADORA2A, CD 160, 2B4, TIGIT, and/or interleukin-10 receptor.
11. The inducible T-cell system of any one of the preceding claims, wherein the one or more checkpoint receptor ligands comprise PD-L1, PD-L2, B7.1, B7.2, B7-H4, B7-H2, B7- H7, MHC class II, HVEM, CD155, galectin-9, and/or TIM-3 ligand.
12. The inducible T-cell system of any one of the preceding claims, wherein the expression of the two or more checkpoint receptors is controlled by a promoter inducible by doxycycline (dox).
13. The inducible T-cell system of any one of the preceding claims, wherein the costimulatory receptor is CD28.
14. The inducible T-cell system of any one of the preceding claims, wherein the costimulatory ligand expressed by the ligand-presenting cell is B7.1 or B7.2.
15. The inducible T-cell system of any one of the preceding claims, wherein the anti-CD3 antibody is associated with a bead.
16. The inducible T-cell system of any one of the preceding claims, wherein the system further comprises reagents to determine the expression of interleukin-2 or interferon γ by the T-cell.
17. The inducible T-cell system of claim 16, wherein the reagents are selected from a primary antibody, an anti-interleukin-2 antibody, an anti-interferon γ antibody, a secondary antibody, an anti-IgG antibody, an antibody-fluorophore conjugate, an antibody-biotin conjugate, an antibody-enzyme conjugate, a colorimetric substrate for horseradish peroxidase, and a colorimetric substrate for alkaline phosphatase.
18. The inducible T-cell system of any one of the preceding claims, wherein the T-cell further comprises a gene knockout or knockdown.
19. The inducible T-cell system of claim 18, wherein the gene knockout or knockdown is a lymphoid lineage gene knockout or knockdown.
20 The inducible T-cell system of claim 19, wherein the lymphoid lineage gene is a T- cell gene.
21. The inducible T-cell system of any one of claims 18-20, wherein the T-cell comprises a gene knockout, and the knockout is a CRISPR/Cas9-mediated knockout.
22. The inducible T-cell system of any one of the preceding claims, wherein the system further comprises one or more pharmaceutical agents.
23. The inducible T-cell system of claim 22, wherein the one or more pharmaceutical agents comprise a small molecule compound and/or an antibody.
24. A method of identifying small molecule T-cell activators, comprising
providing an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors, wherein the T-cell expresses the T-cell receptor (TCR) and a costimulatory receptor; a B-cell engineered to constitutively express one or more checkpoint receptor ligands, wherein the B-cell expresses a costimulatory ligand to provide a costimulatory signal; and an anti-CD3 antibody to stimulate TCR signaling, wherein the TCR signaling is measurable by IL-2 expression of the T-cell;
inducing the expression of the two or more checkpoint receptors in the T-cell;
contacting the T-cell of the inducible T-cell system with one or more candidate compounds;
determining the level of IL-2 expression of the T-cell as compared to a control level of IL-2 expression of a non-induced control T-cell, thereby identifying if the one or more candidate compounds are T-cell activators.
25. A method of assessing interactions between T-cell activators and checkpoint inhibitory antibodies, comprising
providing an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors, wherein the T-cell expresses the T-cell receptor (TCR) and a costimulatory receptor; a B-cell engineered to constitutively express one or
more checkpoint receptor ligands, wherein the B-cell expresses a costimulatory ligand to provide a costimulatory signal; and an anti-CD3 antibody to stimulate TCR signaling, wherein the TCR signaling is measurable by IL-2 expression of the T-cell;
inducing the expression of the two or more checkpoint receptors in the T-cell;
contacting the T-cell of the inducible T-cell system with one or more candidate compounds;
contacting the T-cell of the inducible T-cell system with one, two, or more checkpoint inhibitory antibodies; and
determining the level of IL-2 expression of the T-cell as compared to the level of IL-2 expression of an otherwise identical inducible T-cell system but contacted with only one or more candidate compounds, thereby assessing the interaction between one or more candidate compounds and the one, two, or more checkpoint inhibitory antibodies.
26. The method of claim 25, wherein the one, two, or more checkpoint inhibitory antibodies comprise an FDA approved checkpoint inhibitory drug.
27. The method of claim 26, wherein the FDA approved checkpoint inhibitory drug is a monoclonal antibody.
28. The method of any one of claims 25-27, wherein the one or more candidate compounds is a small molecule compound.
29. A method of validating a T-cell target gene, comprising
providing an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors, wherein the T-cell expresses the T-cell receptor (TCR) and a costimulatory receptor; a B-cell engineered to constitutively express one or more checkpoint receptor ligands, wherein the B-cell expresses a costimulatory ligand to provide a costimulatory signal; and an anti-CD3 antibody to stimulate TCR signaling, wherein the TCR signaling is measurable by IL-2 expression of the T-cell; and wherein the T-cell further comprises a candidate T-cell gene knockout;
inducing the expression of the two or more checkpoint receptors in the T-cell;
determining the level of IL-2 expression of the T-cell as compared to a control level of IL-2 expression of a non-induced control T-cell, thereby determining if the candidate T- cell gene is a T-cell checkpoint-independent target gene.
30. A method of interrogating ON or OFF target activity of a small molecule compound, comprising:
providing an inducible T-cell system comprising a T-cell engineered to inducibly express two or more checkpoint receptors, wherein the T-cell expresses the T-cell receptor (TCR) and a costimulatory receptor; a B-cell engineered to constitutively express one or more checkpoint receptor ligands, wherein the B-cell expresses a costimulatory ligand to provide a costimulatory signal; and an anti-CD3 antibody to stimulate TCR signaling, wherein the TCR signaling is measurable by IL-2 expression of the T-cell; and wherein the T-cell further comprises a T-cell target gene knockout;
inducing the expression of the two or more checkpoint receptors in the T-cell;
contacting the T-cell of the inducible T-cell system with a small molecule compound; determining the level of IL-2 expression of the T-cell with the T-cell target gene knockout as compared to a control level of IL-2 expression of a control wild-type T-cell under otherwise identical conditions, thereby interrogating ON vs. OFF target activity of the small molecule compound.
31. The method of any one of claims 24-30, wherein the T-cell is a Jurkat cell line.
32. The method of any one of claims 24-31, wherein the B-cell is a Raji cell line.
33. The method of any one of claims 24-32, wherein the T-cell and/or the B-cell is derived from a human cell line.
34. The method of any one of claims 24-33, wherein the two or more checkpoint receptors comprise PD-1 and CTLA-4.
35. The method of claim 34, wherein the one or more checkpoint receptor ligands comprise PD-L1 and/or PD-L2.
36. The method of any one of claims 24-35, wherein the expression of the two or more checkpoint receptors is controlled by a promoter inducible by doxycycline (dox), and the inducing step comprises introducing the dox to the T-cell.
37. The method of any one of claims 24-36, wherein the costimulatory receptor is CD28.
38. The method of claim 37, wherein the costimulatory ligand expressed by the B-cell is B7.1 or B7.2.
39. The method of any one of claims 24-38, wherein the anti-CD3 antibody is associated with a bead.
40. A plurality of inducible T-cell systems, each system comprising:
a T-cell engineered to inducibly express two or more checkpoint receptors;
a ligand-presenting cell that expresses at least one checkpoint receptor ligand; and a costimulatory ligand,
wherein:
at least one system of the plurality comprises a transcription inducer that induces the transcription of the two or more checkpoint inhibitors; and
at least one system of the plurality lacks the transcription inducer.
41. The plurality of inducible T-cell systems of claim 40, wherein:
at least one system of the plurality comprises a pharmaceutical agent; and at least one system of the plurality lacks the pharmaceutical agent.
42. The plurality of inducible T-cell systems of claim 40 or 41, wherein:
the T-cell of at least one system of the plurality comprises a gene knockout or gene knockdown; and
the T-cell of at least one system of the plurality lacks the gene knockout or gene knockdown.
43. A plurality of inducible T-cell systems, each system comprising:
a T-cell engineered to inducibly express two or more checkpoint receptors;
a ligand-presenting cell that expresses at least one checkpoint receptor ligand; and a costimulatory ligand,
wherein:
at least one system of the plurality comprises a pharmaceutical agent; and at least one system of the plurality lacks the pharmaceutical agent.
44. A plurality of inducible T-cell systems, each system comprising:
a T-cell engineered to inducibly express two or more checkpoint receptors;
a ligand-presenting cell that expresses at least one checkpoint receptor ligand; and a costimulatory ligand,
wherein:
the T-cell of at least one system of the plurality comprises a gene knockout or gene knockdown; and
the T-cell of at least one system of the plurality lacks the gene knockout or gene knockdown.
45. The plurality of inducible T-cell systems of any one of claims 40-44, wherein the two or more checkpoint receptors are selected from PD-1, CTLA-4, PD-1H, LAG-3, BTLA, KIR2D, TIM-3, ADORA2A, CD160, 2B4, TIGIT, and interleukin-10 receptor.
46. The plurality of inducible T-cell systems of claim 45, wherein the two or more checkpoint receptors comprise PD- 1 and CTLA-4.
47. The plurality of inducible T-cell systems of any one of claims 40-46, wherein the at least one checkpoint receptor ligand comprises a ligand of the two or more checkpoint receptors.
48. The plurality of inducible T-cell systems of claim 47, wherein the at least one checkpoint receptor ligand(s) are selected from PD-Ll, PD-L2, B7.1, B7.2, B7-H4, B7-H2, B7-H7, MHC class II, HVEM, CD155, galectin-9, and TIM-3 ligand.
49. The plurality of inducible T-cell systems of claim 48, wherein the at least one checkpoint receptor ligand includes either PD-Ll or PD-L2 and either B7.1 or B7.2.
50. The plurality of inducible T-cell systems of any one of claims 40-49, wherein the costimulatory ligand is an anti-CD3 antibody.
51. The plurality of inducible T-cell systems of claim 50, wherein the anti-CD3 antibody is associated with a solid support.
52. The plurality of inducible T-cell systems of claim 51, wherein the solid support is a bead, the surface of a tissue culture plate, or the surface of a multi-well plate.
53. The plurality of inducible T-cell systems of any one of claims 40-52, wherein the ligand-presenting cell expresses a second costimulatory ligand, and the second costimulatory ligand is a ligand of a costimulatory receptor.
54. The plurality of inducible T-cell systems of any one of claims 40-53, wherein the T- cell of each system is a human T-cell.
55. The plurality of inducible T-cell systems of claim 54, wherein the T-cell of each system is a Jurkat cell.
56. The plurality of inducible T-cell systems of any one of claims 40-55, wherein the ligand-presenting cell of each system is a human B-cell.
57. The plurality of inducible T-cell systems of claim 56, wherein the human B-cell of each system is a Raji cell.
58. The plurality of inducible T-cell systems of any one of claims 40-57, wherein each system of the plurality is selected from:
a system that lacks a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown;
a system that comprises a transcription inducer, lacks a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown;
a system that lacks a transcription inducer, comprises a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown;
a system that lacks a transcription inducer, lacks a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown;
a system that comprises a transcription inducer, comprises a pharmaceutical agent, and lacks a T-cell comprising a gene knockout or gene knockdown;
a system that comprises a transcription inducer, lacks a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown;
a system that lacks a transcription inducer, comprises a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown; and
a system that comprises a transcription inducer, comprises a pharmaceutical agent, and comprises a T-cell comprising a gene knockout or gene knockdown.
59. The plurality of inducible T-cell systems of any one of claims 40-58, wherein at least one system comprises two pharmaceutical agents selected from at least one small molecule compound and at least one large molecule, and each system of the plurality is selected from: a system that lacks a small molecule compound and lacks a large molecule;
a system that comprises one small molecule compound and lacks a large molecule; a system that comprises both one small molecule compound and one large molecule; a system that comprises at least two small molecule compounds and lacks a large molecule;
a system that comprises at least two small molecule compounds and one large molecule;
a system that lacks a small molecule compound and comprises at least two large molecules; and
a system that comprises one small molecule compound and at least two large molecules.
60. The plurality of inducible T-cell systems of claim 59, wherein the at least one large molecule comprises an antibody.
61. The plurality of inducible T-cell systems of claim 60, wherein the at least one large molecule comprises an anti-CTLA-4 antibody and/or an anti-PD- 1 antibody.
62. The plurality of inducible T-cell systems of claim 61, wherein the at least one large molecule comprises avelumab, atezolizumab, durvalumab, ipilimumab, lambrolizumab, nivolumab, pembrolizumab, pidilizumab, tremelimumab, and/or ticilimumab.
63. The plurality of inducible T-cell systems of claim 62, wherein the at least one large molecule comprises ipilimumab and/or nivolumab.
64. The plurality of inducible T-cell systems of any one of claims 40-63, wherein each system comprises tissue culture media and blood serum.
65. A plurality of samples, each sample comprising:
the supernatant of each system of the plurality of systems of any one of claims 40-64; and
reagents for an enzyme-linked immunosorbent assay (ELISA) or other colorimetric immunoassay.
66. The plurality of samples of claim 65, wherein the reagents for an ELISA or other colorimetric immunoassay comprise an anti-interleukin-2 antibody or an anti-interferon γ antibody.
67. The plurality of samples of claim 65 or 66, wherein the supernatant of each system is substantially free of the T-cells and ligand-presenting cells of the system.
68. A multi-well plate comprising the plurality of inducible T-cell systems of any one of claims 40-64.
69. The multi-well plate of claim 68, wherein the multi-well plate is a 6 well, 12 well, 24 well, 96 well, 384 well, 1536 well, or 3,456 well plate.
70. A method of preparing the multi-well plate of claim 68 or 69, comprising:
adding a T-cell to each well of a plurality of wells of the multi-well plate;
adding a transcription inducer to each well of a first group of wells of the plurality of wells;
adding a costimulatory ligand to each well of the plurality of wells; and
adding a ligand-presenting cell to each well of the plurality of wells.
71. A method of preparing a multi-well plate, comprising:
adding a T-cell to each well of a plurality of wells, wherein the T-cell is engineered to inducibly express the two or more checkpoint receptors;
adding a transcription inducer to each well of a first group of wells of the plurality of wells;
adding a costimulatory ligand to each well of the plurality of wells; and
adding a ligand-presenting cell to each well of the plurality of wells, wherein the ligand-presenting cell expresses a checkpoint receptor ligand.
72. A method of preparing a multi-well plate, comprising:
adding a knockout T-cell to each well of a first group of wells of a plurality of wells, wherein the knockout T-cell is engineered to inducibly express two or more checkpoint receptors and the knockout T-cell comprises a gene knockout;
adding a wild type T-cell to each well of a second group of wells of the plurality of wells, wherein the wild type T-cell is engineered to inducibly express the two or more checkpoint receptors and the wild type T-cell lacks the gene knockout;
adding a transcription inducer to each well of a third group of wells of the plurality of wells, wherein the third group of wells consists of wells of the first group of wells and/or wells of the second group of wells;
adding a costimulatory ligand to each well of the plurality of wells; and
adding a ligand-presenting cell that expresses a checkpoint receptor ligand to each well of the plurality of wells,
wherein:
the plurality of wells consists of the first group of wells and the second group of wells; and
no well of the plurality of wells is included in both the first group of wells and the second group of wells.
73. The method of any one of claims 70-72, wherein the costimulatory ligand is added to the plurality of wells at least 24 hours after adding the transcription inducer to a group of wells.
74. The method of claim 73, further comprising washing the cells of each well of the plurality prior to adding the costimulatory ligand to reduce the concentration of the transcription inducer in each well.
75. The method of any one of claims 70-74, wherein the ligand-presenting cell is added to the plurality of wells at least 5 minutes after adding the costimulatory ligand to the plurality of wells.
76. The method of any one of claims 70-75, further comprising adding a first antibody to each well of a fourth group of wells of the plurality of wells.
77. The method of claim 76, further comprising adding a second antibody to each well of a fifth group of wells of the plurality of wells, wherein the fifth group of wells includes at least one well of the fourth group of wells.
78. The method of claim 77, wherein the first antibody and second antibody are selected from antibodies that bind checkpoint receptors and antibodies that bind checkpoint receptor ligands.
79. The method of claim 78, wherein the first antibody and second antibody are selected from anti-CTLA-4 antibodies and anti-PD-1 antibodies.
80. The method of any one of claims 70-79, further comprising adding a first small molecule compound to each well of a sixth group of wells of the plurality of wells.
81. The method of claim 80, further comprising adding a second small molecule compound to each well of a seventh group of wells of the plurality of wells, wherein the seventh group of wells includes at least one well of the sixth group of wells.
82. The method of claim 80 or 81, wherein the first small molecule compound is a kinase inhibitor.
83. A method of discovering or validating a drug target, comprising:
providing a plurality of inducible T-cell systems of any one of claims 40-64; and measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising a T-cell having a knockout or knockdown of a gene encoding the drug target.
84. A method of determining whether a small molecule compound affects T-cell activation, comprising:
providing a plurality of inducible T-cell systems of any one of claims 40-64; and
measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include both a system comprising the small molecule compound and a system lacking the small molecule compound.
85. A method of assessing an interaction between a small molecule compound and an antibody that binds a checkpoint receptor, comprising:
providing a plurality of inducible T-cell systems of any one of claims 40-64; and measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the small molecule compound and the antibody.
86. A method of assessing an interaction between a first small molecule compound and a second small molecule compound, comprising:
providing a plurality of inducible T-cell systems of any one of claims 40-64; and measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the first small molecule compound and the second small molecule compound.
87. A method of assessing whether a protein affects T-cell activation through a signaling pathway mediated by a checkpoint receptor, comprising:
providing a plurality of inducible T-cell systems of any one of claims 40-64; and measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both an antibody that specifically binds the checkpoint receptor and a T-cell comprising a knockout or knockdown of a gene encoding the protein.
88. The method of claim 87, wherein the protein is a kinase.
89. A method of assessing whether a pharmaceutical agent displays an ON target or OFF target effect, comprising:
providing a plurality of inducible T-cell systems of any one of claims 40-64; and
measuring the concentration of a biomarker associated with T-cell activation in at least two systems of the plurality, wherein the at least two systems include a system comprising both the pharmaceutical agent and a T-cell comprising a knockout or knockdown of a gene encoding the target.
90. The method of claim 89, wherein the pharmaceutical agent is a small molecule compound.
91. The method of claim 89, wherein the pharmaceutical agent is a large molecule.
92. The method of claim 91, wherein the pharmaceutical agent is an antibody.
93. The method of any one of claims 83-92, wherein measuring the concentration of a biomarker comprises performing an enzyme-linked immunosorbent assay (ELISA) or other colorimetric immunoassay.
94. The method of any one of claims 83-93, wherein the biomarker is interleukin-2 or interferon γ.
95. The method of any one of claims 83-94, wherein measuring the concentration of the biomarker comprises measuring the concentration of the biomarker in the supernatant of a system.
96. The method of any one of claims 83-95, further comprising contacting the system or supernatant thereof with one or more of a primary antibody, an anti-interleukin-2 antibody, an anti-interferon γ antibody, a secondary antibody, an anti-IgG antibody, an antibody- fluorophore conjugate, an antibody-biotin conjugate, an antibody-enzyme conjugate, a colorimetric substrate for horseradish peroxidase, and a colorimetric substrate for alkaline phosphatase.
97. The method of any one of claims 83-96, further comprising comparing the relative concentration of the biomarker in at least one system of the plurality of systems to the relative concentration of the biomarker in at least one other system of the plurality of systems.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662408547P | 2016-10-14 | 2016-10-14 | |
US62/408,547 | 2016-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018071809A1 true WO2018071809A1 (en) | 2018-04-19 |
Family
ID=60269918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/056576 WO2018071809A1 (en) | 2016-10-14 | 2017-10-13 | Inducible t-cell system and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018071809A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019237388A1 (en) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | Grna sequence for knocking out human btdc gene and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO2002079499A1 (en) * | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
WO2016081854A1 (en) * | 2014-11-20 | 2016-05-26 | Promega Corporation | Systems and methods for assessing modulators of immune checkpoints |
-
2017
- 2017-10-13 WO PCT/US2017/056576 patent/WO2018071809A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO2002079499A1 (en) * | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
WO2016081854A1 (en) * | 2014-11-20 | 2016-05-26 | Promega Corporation | Systems and methods for assessing modulators of immune checkpoints |
Non-Patent Citations (5)
Title |
---|
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
MARKS ET AL., J. MOL. BIOL, vol. 222, 1991, pages 581 - 597 |
NELSON, MABS, vol. 2, no. 1, 2010, pages 77 - 83 |
SIU ERIC ET AL: "TCR subunit specificity of CTLA-4-mediated signaling", 1 December 2003, JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, PAGE(S) 1102 - 1107, ISSN: 0741-5400, XP002530021 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019237388A1 (en) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | Grna sequence for knocking out human btdc gene and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6905163B2 (en) | Biomarkers that predict cytokine release syndrome | |
AU2018228501B2 (en) | Therapies based on control of regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis | |
Pardeo et al. | Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies | |
CA2921774C (en) | Immunoreceptor modulation for treating cancer and viral infections | |
Williams et al. | Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy | |
US10975155B2 (en) | CD40L-Fc fusion polypeptides and methods of use thereof | |
CN110582287A (en) | Compositions, articles of manufacture, and methods relating to administration in cell therapy | |
JP2022084710A (en) | Methods for determining car-t cell dosing | |
Li et al. | Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy | |
KR20200116081A (en) | Methods of administration and control of genetically engineered cells | |
KR20190115079A (en) | Co-use of anti-BCMA antibodies and antibody-coupled T cell receptors (ACTR) in cancer therapy and B cell disorders | |
CN110637031B (en) | Recombinant antibodies to programmed death protein 1 (PD-1) and uses thereof | |
US20200048321A1 (en) | Pantids for treatment of autoimmune disorders | |
US20160151486A1 (en) | CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis | |
JP2024016134A (en) | Articles of manufacture and methods related to toxicity associated with cell therapy | |
KR20200006526A (en) | Therapeutic Agents and Methods for Enhancing Immune Responses in Tumor Microenvironments | |
Yi et al. | Human and mouse CD137 have predominantly different binding CRDs to their respective ligands | |
WO2018071809A1 (en) | Inducible t-cell system and uses thereof | |
KR20190129062A (en) | Antibody Selection Method | |
Sasaki-Iwaoka et al. | Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor | |
JP2016540506A (en) | Identification of novel B cell cytokines | |
CN116178545A (en) | Anti-human PD-L1 humanized antibody or antigen binding fragment thereof and application thereof | |
CA2971508A1 (en) | Composition, kit and method for inhibition of il-21 mediated activation of human cells | |
US20230100000A1 (en) | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | |
Morita et al. | Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17795102 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17795102 Country of ref document: EP Kind code of ref document: A1 |